{"meta":{"query_hash":"abc7a7fb8bc6","filters":{"venue":"European Urology Oncology"},"cohort_total":180,"direct_labels_cover":0,"predictions_cover":180,"exported":180,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/abc7a7fb8bc6","api":"https://metacan.xera.ac/api/v1/cohort?venue=European+Urology+Oncology"},"results":[{"id":"W2793748657","doi":"10.1016/j.euo.2019.03.007","title":"Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; London Health Sciences Centre; Sunnybrook Hospital; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary","funders":"Janssen Biotech; National Cancer Institute; Foundation Medicine; Pfizer Canada; Novartis Pharmaceuticals Canada; Bristol-Myers Squibb Canada; Eisai; National Comprehensive Cancer Network; Ipsen; Astellas Pharma Canada; Genentech; AstraZeneca Canada; Novartis; GlaxoSmithKline; Merck; Exelixis; Bayer; Bristol-Myers Squibb; AstraZeneca; Astellas Pharma; Celldex Therapeutics; Pfizer","keywords":"Medicine; Renal cell carcinoma; Nephrectomy; Papillary renal cell carcinomas; Carcinoma; Oncology; Internal medicine; Kidney; Database; Pathology; Urology","score_opus":0.0301147906641542,"score_gpt":0.26762377117072317,"score_spread":0.23750898050656896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793748657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729398,0.0017022536,0.00015927343,0.00025548515,0.000012314689,0.00008343656,0.023715792,0.000012094493,0.0011195509],"genre_scores_gemma":[0.966013,0.0006100799,0.00019627322,0.00010210507,0.000022973192,0.00008575442,0.03282179,0.000008295928,0.00013985687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689317,0.0008266303,0.00041087772,0.00058060593,0.0010751783,0.00021362424],"domain_scores_gemma":[0.99167234,0.0019683405,0.0038452276,0.00062015373,0.0011493729,0.0007445553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034558547,0.00025828282,0.0007799081,0.001519912,0.00027264986,0.0010734857,0.00080554147,0.00039774645,0.00096659584],"category_scores_gemma":[0.010018403,0.00014753175,0.00077148067,0.0037953912,0.00022287149,0.00050410384,0.001138707,0.00035571234,0.00021071684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005031748,0.000031862488,0.9949661,0.00009742171,0.00030813715,0.00004420565,0.000067594636,0.00014389951,0.000069933,0.000039318405,0.0012099586,0.0025183985],"study_design_scores_gemma":[0.00008655771,0.00006798692,0.9975454,0.00004605901,0.00021564492,0.0001727746,0.00015744452,0.000526727,0.00008897347,0.000027207827,0.0010558005,0.000009545218],"about_ca_topic_score_codex":0.020386497,"about_ca_topic_score_gemma":0.023008613,"teacher_disagreement_score":0.020386497,"about_ca_system_score_codex":0.0011267618,"about_ca_system_score_gemma":0.0011529531,"threshold_uncertainty_score":0.04053563},"labels":[],"label_agreement":null},{"id":"W2793980325","doi":"10.1016/j.euo.2018.02.009","title":"Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer","year":2018,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Prostate Cancer UK; GlaxoSmithKline; Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Voting; Delphi method; Biomarker; Consensus conference; Clinical trial; MEDLINE; Intensive care medicine; Cancer; Medical physics; Oncology; Pathology; Internal medicine; Computer science; Political science","score_opus":0.11904081778682665,"score_gpt":0.4557216727429578,"score_spread":0.3366808549561311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793980325","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001939072,0.07695095,0.028915776,0.7829202,0.07642559,0.005794916,0.0044508986,0.0003334117,0.02226912],"genre_scores_gemma":[0.052458927,0.1428841,0.17395845,0.5044064,0.047740463,0.025115872,0.018162888,0.0005470651,0.03472589],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.8424262,0.081945054,0.031308506,0.007039518,0.032219462,0.0050612367],"domain_scores_gemma":[0.7342459,0.10667264,0.0158,0.006536623,0.12101315,0.0157317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.14664288,0.0023495906,0.004230571,0.0066952994,0.0039253416,0.0072794887,0.010023426,0.027095066,0.011121593],"category_scores_gemma":[0.20498738,0.0019406712,0.010546193,0.004183382,0.004513474,0.0061709713,0.01185259,0.023872228,0.009986601],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005195526,0.00015024265,0.0012727121,0.030029293,0.00071506476,0.00094881636,0.0021948623,0.0016695451,0.0020859684,0.022334516,0.7613057,0.17677365],"study_design_scores_gemma":[0.00034974693,0.00027346972,0.001750036,0.0541348,0.0007373086,0.0012254509,0.0010344872,0.0006579207,0.0011723114,0.025516093,0.9129506,0.00019784397],"about_ca_topic_score_codex":0.0039359513,"about_ca_topic_score_gemma":0.0025883461,"teacher_disagreement_score":0.14664288,"about_ca_system_score_codex":0.008702815,"about_ca_system_score_gemma":0.0508846,"threshold_uncertainty_score":0.77553093},"labels":[],"label_agreement":null},{"id":"W2801612425","doi":"10.1016/j.euo.2018.04.013","title":"Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Rochester Epidemiology Project; Epidemiology; Surveillance, Epidemiology, and End Results; Odds ratio; Confidence interval; Cohort; Incidence (geometry); Internal medicine; Population; Logistic regression; Cancer; Prostate; Cancer registry","score_opus":0.05876208115487862,"score_gpt":0.37008032226869425,"score_spread":0.3113182411138156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801612425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93927974,0.004087072,0.00025379998,0.0004253278,0.00003123501,0.0000212701,0.05428466,0.00003948517,0.0015774099],"genre_scores_gemma":[0.9662987,0.0012607375,0.00027410104,0.00019162585,0.000056711684,0.00002598672,0.03166261,0.000014189567,0.0002154456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783546,0.0004937964,0.0003777216,0.0006466364,0.0004308234,0.00021565886],"domain_scores_gemma":[0.99413115,0.0013339473,0.0029846309,0.00046650248,0.00069370854,0.0003900057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015610995,0.00022983296,0.0008951344,0.0025217,0.00031496843,0.0013245973,0.0007814446,0.00076716556,0.0015062677],"category_scores_gemma":[0.0069799293,0.00036270055,0.0012803528,0.0067182495,0.00017225395,0.0013031363,0.0009838224,0.0008668995,0.00027668817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017457717,0.000019867028,0.99656254,0.000056263958,0.00030685568,0.00003858783,0.00003592907,0.00009534454,0.000060012284,0.00005576779,0.0011664053,0.0014278793],"study_design_scores_gemma":[0.000010450964,0.000015930302,0.998811,0.000011033049,0.00009909076,0.00015588198,0.000071166985,0.00030973024,0.00002454999,0.000017041939,0.00046998405,0.0000041065514],"about_ca_topic_score_codex":0.024043972,"about_ca_topic_score_gemma":0.026472889,"teacher_disagreement_score":0.024043972,"about_ca_system_score_codex":0.0007110352,"about_ca_system_score_gemma":0.0008111321,"threshold_uncertainty_score":0.04780805},"labels":[],"label_agreement":null},{"id":"W2805171356","doi":"10.1016/j.euo.2018.05.008","title":"Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Leiomyosarcoma; Hazard ratio; Sarcoma; Liposarcoma; Confidence interval; Internal medicine; Epidemiology; Radiation therapy; Proportional hazards model; Surgery; Oncology; Gastroenterology; Pathology","score_opus":0.041686899165674945,"score_gpt":0.33368052075052274,"score_spread":0.29199362158484776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805171356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964121,0.0011190564,0.001116622,0.00016089305,0.000019724732,0.000030685365,0.0008089419,0.0000107103015,0.00032132346],"genre_scores_gemma":[0.9980563,0.00028582805,0.00035254078,0.000043365057,0.0000377967,0.000027868475,0.00096749817,0.000008505575,0.00022020112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967213,0.0017312142,0.0002610203,0.00064725964,0.00026661585,0.00037251657],"domain_scores_gemma":[0.9929269,0.0039573,0.0014983448,0.0008093601,0.00031682965,0.0004911128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004879984,0.0009007817,0.0014046918,0.0013801778,0.00065108645,0.0016089734,0.001361553,0.0014171988,0.003930272],"category_scores_gemma":[0.0088034915,0.00089822256,0.0059137736,0.0015898637,0.0006769352,0.0013612573,0.0016373277,0.0025020812,0.0003071296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008264396,0.0006477326,0.965984,0.00019043029,0.0123058325,0.0007580644,0.0002526138,0.0038088546,0.00041831128,0.00090320816,0.00089970964,0.0055668186],"study_design_scores_gemma":[0.0011853094,0.004237096,0.927286,0.00011045301,0.01630951,0.0036996948,0.0020151976,0.040460635,0.00025438,0.0025078335,0.001756662,0.00017718053],"about_ca_topic_score_codex":0.004196144,"about_ca_topic_score_gemma":0.0041197897,"teacher_disagreement_score":0.004879984,"about_ca_system_score_codex":0.0006636293,"about_ca_system_score_gemma":0.00067324215,"threshold_uncertainty_score":0.025808096},"labels":[],"label_agreement":null},{"id":"W2805215598","doi":"10.1016/j.euo.2018.02.001","title":"Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Cystectomy; Medicine; Bladder cancer; Cancer; Oncology; Bladder Neoplasm; General surgery; Urology; Internal medicine","score_opus":0.020059077603888316,"score_gpt":0.34007945176971327,"score_spread":0.32002037416582496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805215598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977679,0.00076981535,0.00015812751,0.00017110172,0.00003822896,0.0000031368306,0.00021650644,0.000008116448,0.0008671043],"genre_scores_gemma":[0.9994936,0.0001118592,0.00003446628,0.000021938542,0.00003610819,0.0000014878367,0.00012610272,0.0000035614912,0.00017080027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995116,0.00015784531,0.000055904395,0.000064148946,0.00005439014,0.00015614239],"domain_scores_gemma":[0.9956617,0.0012356425,0.0015742225,0.0002541924,0.00024879756,0.0010254979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005095544,0.00034265307,0.0004639516,0.000651434,0.00047201588,0.0010931945,0.00074216904,0.0008044971,0.0053616357],"category_scores_gemma":[0.00475015,0.0002554218,0.00096917886,0.00090552244,0.00039134538,0.00066759915,0.00084897137,0.0009651865,0.00050353183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026673055,0.000032381766,0.9972671,0.000017961103,0.0001132033,0.00024877864,0.00005082604,0.00013225494,0.00024929238,0.00002652088,0.00013854635,0.0014563376],"study_design_scores_gemma":[0.0000056753183,0.00010794876,0.998185,0.000020839114,0.00009890265,0.00048639174,0.0004029354,0.00039101244,0.00007729471,0.000059521855,0.00015457283,0.000009934662],"about_ca_topic_score_codex":0.0031204992,"about_ca_topic_score_gemma":0.0042533935,"teacher_disagreement_score":0.0053616357,"about_ca_system_score_codex":0.00035226948,"about_ca_system_score_gemma":0.0005955821,"threshold_uncertainty_score":0.017936468},"labels":[],"label_agreement":null},{"id":"W2805244703","doi":"10.1016/j.euo.2018.05.001","title":"Role of Active Surveillance for Localized Small Renal Masses","year":2018,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Interquartile range; Kidney cancer; MEDLINE; Cancer; Surgery; Internal medicine","score_opus":0.07044376850108269,"score_gpt":0.3449440507820464,"score_spread":0.2745002822809637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805244703","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000079784215,0.9989116,0.000060043756,0.00032039022,0.000124918,0.0000020201496,0.000012677842,0.0000029750486,0.0004855249],"genre_scores_gemma":[0.001658677,0.99689674,0.00016732332,0.00071664207,0.0003072541,0.000004662903,0.000031831412,0.0000017008686,0.0002151246],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996214,0.00010481836,0.00008213239,0.00007535813,0.00008850006,0.000027731807],"domain_scores_gemma":[0.9986191,0.00092923903,0.0002349835,0.000023203786,0.00014608305,0.00004740674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009201611,0.0005504133,0.0012047045,0.0017514386,0.00018817579,0.0010490833,0.00073542143,0.00085507525,0.003286127],"category_scores_gemma":[0.0027169953,0.0001922979,0.0008121182,0.0012251845,0.0004914538,0.0012535959,0.0006688378,0.001395297,0.0006363886],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007808911,0.000030176721,0.0008189005,0.024467843,0.00022451508,0.00018727887,0.00005325616,0.00027679346,0.00034118106,0.0015499284,0.01869493,0.953277],"study_design_scores_gemma":[0.000067498484,0.00016432686,0.0036692482,0.039358377,0.001378812,0.0030674313,0.00013675347,0.00020047261,0.00034429954,0.0015411765,0.9500349,0.00003650449],"about_ca_topic_score_codex":0.0014623418,"about_ca_topic_score_gemma":0.0038495685,"teacher_disagreement_score":0.003286127,"about_ca_system_score_codex":0.00068851386,"about_ca_system_score_gemma":0.001532547,"threshold_uncertainty_score":0.010993183},"labels":[],"label_agreement":null},{"id":"W2805258017","doi":"10.1016/j.euo.2018.03.005","title":"Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Institutes of Health; Institute of Clinical and Translational Sciences; University of Texas Medical Branch","keywords":"Comorbidity; Medicine; Cystectomy; Bladder cancer; MEDLINE; Perioperative; Intensive care medicine; Risk assessment; Systematic review; Internal medicine; Cancer; Surgery","score_opus":0.05377424198456397,"score_gpt":0.39814201089946516,"score_spread":0.3443677689149012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805258017","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010905311,0.9860815,0.0002869864,0.00020384452,0.00014423704,0.00018103854,0.0019713512,0.000011872611,0.00021392346],"genre_scores_gemma":[0.40994233,0.58275646,0.0023669493,0.0011991466,0.0002635786,0.0007071606,0.0025213566,0.000021711274,0.00022125804],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9822428,0.007925533,0.0064372276,0.0015610408,0.0014794741,0.00035387944],"domain_scores_gemma":[0.95832807,0.031026062,0.0075767115,0.0010874817,0.001627841,0.00035379146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010287078,0.0013394476,0.0077137584,0.004574446,0.00052890094,0.0016902988,0.0016320521,0.0016072608,0.003001906],"category_scores_gemma":[0.058374234,0.0011931185,0.021458441,0.0059121842,0.00058084825,0.001292442,0.0015764866,0.0016581921,0.00014650126],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018492047,0.000026550582,0.019454708,0.55132955,0.41005006,0.00011086316,0.000182795,0.00034538037,0.00012271095,0.00015608157,0.0013634146,0.015008622],"study_design_scores_gemma":[0.0018099225,0.00038653935,0.03996578,0.11022963,0.8409685,0.0003838829,0.00019694431,0.00030104604,0.00010061743,0.00041311095,0.0051520616,0.00009196221],"about_ca_topic_score_codex":0.017161164,"about_ca_topic_score_gemma":0.051075432,"teacher_disagreement_score":0.017161164,"about_ca_system_score_codex":0.0021732056,"about_ca_system_score_gemma":0.0049303435,"threshold_uncertainty_score":0.0544039},"labels":[],"label_agreement":null},{"id":"W2806535129","doi":"10.1016/j.euo.2018.04.010","title":"Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review","year":2018,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cystoscopy; Urinary system; Bladder cancer; Randomized controlled trial; Clinical trial; Urology; Cancer; Internal medicine; Oncology","score_opus":0.12933062305410345,"score_gpt":0.42197412263934186,"score_spread":0.2926434995852384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806535129","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003185574,0.99764,0.00086287415,0.00040944776,0.00026461852,0.00021195176,0.00007923352,0.000009017614,0.00020432245],"genre_scores_gemma":[0.018075287,0.970417,0.00636726,0.0029377767,0.00078239135,0.0010067243,0.00018710198,0.000023716946,0.0002027969],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9794372,0.013313586,0.004036113,0.0014395493,0.001492026,0.00028157185],"domain_scores_gemma":[0.9278252,0.0647918,0.0040579215,0.0012780319,0.0016961868,0.00035088393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.031406745,0.0012800345,0.010129918,0.001681518,0.00034209396,0.0033745447,0.0029378263,0.003275259,0.0050503835],"category_scores_gemma":[0.07258427,0.0007753954,0.009102474,0.001973531,0.00087657117,0.0019817369,0.0012288352,0.002912764,0.0004634786],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072596334,0.00017630743,0.001624963,0.4186994,0.059594594,0.00012450975,0.000148568,0.0016543448,0.00048679832,0.0041660448,0.008479297,0.4975855],"study_design_scores_gemma":[0.031205619,0.004215986,0.007986566,0.36761397,0.40726966,0.0009103447,0.00026335317,0.0025254143,0.0010635885,0.025226818,0.15143183,0.00028674005],"about_ca_topic_score_codex":0.0011848108,"about_ca_topic_score_gemma":0.0028329447,"teacher_disagreement_score":0.031406745,"about_ca_system_score_codex":0.0015133,"about_ca_system_score_gemma":0.0049084583,"threshold_uncertainty_score":0.16609675},"labels":[],"label_agreement":null},{"id":"W2806910229","doi":"10.1016/j.euo.2018.05.003","title":"Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Interquartile range; Androgen deprivation therapy; Biochemical recurrence; Radiation therapy; Urology; Stage (stratigraphy); Metastasis; Biopsy; Concomitant; Cancer; Prostate; Prostate-specific antigen; Internal medicine; Perineural invasion; Oncology","score_opus":0.02501038793937871,"score_gpt":0.30309944216885065,"score_spread":0.27808905422947194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806910229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802198,0.0069259615,0.0015973463,0.00023656715,0.00007744745,0.00007045419,0.00024389278,0.00009602076,0.010532511],"genre_scores_gemma":[0.99615556,0.001200089,0.0011781524,0.00011942697,0.00008814479,0.000010273724,0.00020085485,0.000021394806,0.0010261623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99946266,0.000115501105,0.000052231546,0.000067720466,0.00017082904,0.00013103],"domain_scores_gemma":[0.9989792,0.0002821828,0.00020331454,0.000084381034,0.0001566987,0.00029419476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078102737,0.0005202534,0.00046854556,0.0019786062,0.00057118473,0.0012479222,0.00044799712,0.0005819252,0.0031666772],"category_scores_gemma":[0.0022921795,0.0003838975,0.00034518872,0.00086659926,0.00057262543,0.00091650494,0.00096021325,0.0004634477,0.0005816593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021465523,0.00009615112,0.856077,0.00048273808,0.00011428011,0.019350866,0.00044360888,0.0005830512,0.0548709,0.00040446347,0.0011176091,0.0643128],"study_design_scores_gemma":[0.000028096983,0.00035861973,0.9294215,0.00011328409,0.00018841856,0.055827767,0.000687966,0.0009503533,0.008318052,0.00047914835,0.0036068435,0.000019926918],"about_ca_topic_score_codex":0.0019736746,"about_ca_topic_score_gemma":0.009047065,"teacher_disagreement_score":0.0031666772,"about_ca_system_score_codex":0.00034507073,"about_ca_system_score_gemma":0.0006094899,"threshold_uncertainty_score":0.010593593},"labels":[],"label_agreement":null},{"id":"W2807009771","doi":"10.1016/j.euo.2018.03.006","title":"Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Stage (stratigraphy); Adverse effect; Urology; Prostate; Oncology; Cancer; Internal medicine","score_opus":0.014382548418915408,"score_gpt":0.28928467068598257,"score_spread":0.2749021222670672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807009771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944864,0.001517274,0.00016094268,0.00023217578,0.0000660515,0.0000056405775,0.0018278339,0.000022367052,0.0016813595],"genre_scores_gemma":[0.99784625,0.0003773822,0.000061255814,0.00008821956,0.00004330708,0.0000049585256,0.0009994122,0.0000064161363,0.0005727883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997002,0.00004512546,0.000038987633,0.00007297184,0.000040808492,0.0001020497],"domain_scores_gemma":[0.99888784,0.00014206658,0.00051687995,0.00005526344,0.00016102767,0.00023694106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021092729,0.0001628946,0.0002516768,0.0005391776,0.00034715695,0.0005043756,0.00025815627,0.0003978509,0.0033251261],"category_scores_gemma":[0.0017378499,0.0001332048,0.00077944295,0.000798518,0.00016523362,0.00038969243,0.00038686086,0.0007322343,0.0003117937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028198198,0.000017597471,0.9955872,0.000035056277,0.000093619194,0.0000733491,0.0000677763,0.00009559485,0.00022615057,0.000042349588,0.0004615091,0.003017723],"study_design_scores_gemma":[0.0000041701383,0.00007116564,0.9986111,0.000013843471,0.00004943256,0.00024403367,0.0002022406,0.00014117148,0.000047146168,0.00003630223,0.00057284505,0.0000065273102],"about_ca_topic_score_codex":0.00645464,"about_ca_topic_score_gemma":0.009707582,"teacher_disagreement_score":0.00645464,"about_ca_system_score_codex":0.00029140562,"about_ca_system_score_gemma":0.00056178897,"threshold_uncertainty_score":0.012834132},"labels":[],"label_agreement":null},{"id":"W2807167984","doi":"10.1016/j.euo.2018.03.007","title":"The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Logistic regression; Brachytherapy; Radiation therapy; Internal medicine; Odds ratio; Proportional hazards model; Cancer; Epidemiology; Hazard ratio; Oncology; Urology; Surgery; Confidence interval","score_opus":0.037231248731797284,"score_gpt":0.3735573927117167,"score_spread":0.3363261439799194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807167984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99099123,0.0019228542,0.0007244602,0.0012228584,0.0002631499,0.000020568039,0.0025848094,0.000033978948,0.0022359532],"genre_scores_gemma":[0.9973435,0.00021594306,0.00020914893,0.00023064688,0.00010925817,0.0000096630465,0.000951374,0.000015310705,0.0009151984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978847,0.00080638315,0.00014759088,0.00046787327,0.00016405892,0.00052933296],"domain_scores_gemma":[0.99585116,0.0018120131,0.0010966836,0.00048372056,0.00022596863,0.00053050776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019469721,0.00059158093,0.00056837435,0.0006502099,0.0006214695,0.0011202125,0.001098119,0.0007577737,0.006194528],"category_scores_gemma":[0.008191519,0.00041053398,0.0038229635,0.0012252051,0.0003997975,0.0011079921,0.0010102855,0.0021258127,0.0003706881],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002130335,0.00012569652,0.987333,0.00006477501,0.0026747282,0.00012577458,0.00011571118,0.00048150594,0.00033729832,0.00032071385,0.0011460976,0.0051443083],"study_design_scores_gemma":[0.000073973184,0.0003056603,0.993294,0.000029029045,0.0014765833,0.00013280196,0.0003888424,0.0020540536,0.00020881627,0.00034035483,0.0016779171,0.000018058197],"about_ca_topic_score_codex":0.038928356,"about_ca_topic_score_gemma":0.03358097,"teacher_disagreement_score":0.038928356,"about_ca_system_score_codex":0.0005646478,"about_ca_system_score_gemma":0.0012731646,"threshold_uncertainty_score":0.077403545},"labels":[],"label_agreement":null},{"id":"W2807345550","doi":"10.1016/j.euo.2018.04.004","title":"Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Hazard ratio; Oncology; Internal medicine; Placebo; Androgen deprivation therapy; Randomized controlled trial; Confidence interval; Prostate-specific antigen; Cancer; Urology; Androgen receptor; Pathology","score_opus":0.03979434032370471,"score_gpt":0.3766406032830469,"score_spread":0.33684626295934217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807345550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97872514,0.017685553,0.00016944234,0.00012038844,0.000090469875,0.000081355785,0.00031712986,0.000016109068,0.002794541],"genre_scores_gemma":[0.9948579,0.004009193,0.00013654424,0.000053518997,0.00007926887,0.000018537805,0.00014056313,0.000005076453,0.0006993176],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9985055,0.0010956734,0.00006386668,0.000081059545,0.0001896052,0.00006424697],"domain_scores_gemma":[0.9980116,0.0011363324,0.0003756877,0.00011711926,0.000096095595,0.00026304356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013058281,0.0006873879,0.002202302,0.0006017097,0.00013941509,0.0006843702,0.00057719374,0.00063290464,0.003839023],"category_scores_gemma":[0.0026488537,0.00028096055,0.0011018573,0.00064046343,0.0005439548,0.0007909585,0.00046911175,0.0012725894,0.00027531481],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90057534,0.0025568851,0.014753728,0.0014903273,0.0067241136,0.00011972067,0.00013285162,0.001784254,0.006715965,0.000283006,0.00032467194,0.064539135],"study_design_scores_gemma":[0.14879112,0.6012802,0.19405405,0.00044568456,0.030209282,0.0009980128,0.0004947974,0.0043138093,0.010528001,0.0006816233,0.008051098,0.00015241654],"about_ca_topic_score_codex":0.003989528,"about_ca_topic_score_gemma":0.006138566,"teacher_disagreement_score":0.003989528,"about_ca_system_score_codex":0.00077262544,"about_ca_system_score_gemma":0.0006318487,"threshold_uncertainty_score":0.012842774},"labels":[],"label_agreement":null},{"id":"W2810579527","doi":"10.1016/j.euo.2018.08.009","title":"Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2–4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Cystectomy; Medicine; Bladder cancer; Perioperative; Oncology; Nomogram; Neoadjuvant therapy; Internal medicine; Stage (stratigraphy); Chemotherapy; Proportional hazards model; Confidence interval; Urology; Clinical trial; Surgery; Cancer; Breast cancer","score_opus":0.04498250182132508,"score_gpt":0.35564242784721484,"score_spread":0.31065992602588977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810579527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877389,0.0028170773,0.004598906,0.0010769357,0.00008551892,0.00037016417,0.0023705177,0.00007714366,0.000864853],"genre_scores_gemma":[0.9914396,0.00054971,0.0028110116,0.00024574588,0.000070971706,0.0005656504,0.0032805828,0.000034355136,0.0010024238],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99647564,0.0028060547,0.000096695614,0.00036818715,0.00009138471,0.00016203262],"domain_scores_gemma":[0.9845436,0.012628949,0.0015772011,0.0005539227,0.00030377973,0.00039259827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015403697,0.002252007,0.0021998421,0.00045890457,0.0003477081,0.0014961739,0.0019321698,0.0016082145,0.0017990206],"category_scores_gemma":[0.017463008,0.0007556155,0.005677591,0.00044623282,0.0006907666,0.0013077348,0.0008719317,0.002050314,0.00028676575],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06361257,0.0041433126,0.09356223,0.0008786233,0.006974528,0.00013401601,0.00026395736,0.78476816,0.0010676738,0.0014923892,0.0038087459,0.03929389],"study_design_scores_gemma":[0.006884879,0.020549897,0.039300896,0.00017090926,0.0043156124,0.00014429948,0.00012758466,0.92098117,0.0010456739,0.004831609,0.0015490741,0.00009824363],"about_ca_topic_score_codex":0.0050541777,"about_ca_topic_score_gemma":0.004232112,"teacher_disagreement_score":0.015403697,"about_ca_system_score_codex":0.0019945086,"about_ca_system_score_gemma":0.002294701,"threshold_uncertainty_score":0.081463516},"labels":[],"label_agreement":null},{"id":"W2846016134","doi":"10.1016/j.euo.2018.06.008","title":"“Reverse Stage Migration”: What Can Population-based Data Tell Us About Trends in Prostate Cancer Presentation?","year":2018,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Presentation (obstetrics); Stage (stratigraphy); Population; Cancer; Data presentation; Oncology; Internal medicine; Environmental health; Surgery; Statistics; Data collection","score_opus":0.04622336113204339,"score_gpt":0.3496175459854732,"score_spread":0.3033941848534298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2846016134","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019372687,0.0017527129,0.00008749914,0.99133086,0.003577908,0.000004091679,0.00010346293,0.000011012527,0.0011951734],"genre_scores_gemma":[0.02705464,0.0039235293,0.00037609274,0.92419875,0.043113578,0.000023007207,0.00016856068,0.00001874585,0.0011231895],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99552613,0.0022107202,0.0007694321,0.00040801225,0.0005797176,0.0005060075],"domain_scores_gemma":[0.9792991,0.012646057,0.0023634823,0.0006175946,0.0028757309,0.0021980393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005868787,0.00032357682,0.0011705607,0.0008286621,0.0016029625,0.0023847236,0.0013931912,0.017866258,0.0036185344],"category_scores_gemma":[0.04327535,0.00038137607,0.0007354249,0.0012402129,0.0017936792,0.005934888,0.0011612981,0.017254092,0.0020747613],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014159163,0.000094646544,0.055246033,0.00028598425,0.000087561886,0.004042711,0.0009498152,0.00016438394,0.00018854658,0.0045232843,0.8797212,0.054554276],"study_design_scores_gemma":[0.00034153962,0.0003339806,0.05815718,0.0040682005,0.00021964607,0.018067349,0.01096272,0.0023320508,0.00049779145,0.044117372,0.86061174,0.0002904822],"about_ca_topic_score_codex":0.006487882,"about_ca_topic_score_gemma":0.009709806,"teacher_disagreement_score":0.017866258,"about_ca_system_score_codex":0.002450904,"about_ca_system_score_gemma":0.002462467,"threshold_uncertainty_score":0.03103751},"labels":[],"label_agreement":null},{"id":"W2884540301","doi":"10.1016/j.euo.2018.06.007","title":"Systematic Review of the Management of Local Kidney Cancer Relapse","year":2018,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Nephrectomy; Kidney cancer; Renal cell carcinoma; Cancer; Radiation therapy; Meta-analysis; Surgery; Systematic review; Retrospective cohort study; CINAHL; MEDLINE; Kidney; General surgery; Oncology; Internal medicine; Psychological intervention","score_opus":0.04137451773879018,"score_gpt":0.3400570479144596,"score_spread":0.2986825301756694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884540301","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005841571,0.9987411,0.00006166569,0.000114712995,0.000063740685,0.00007025465,0.00020280118,0.0000035921717,0.0001579271],"genre_scores_gemma":[0.011564394,0.9871564,0.0003388108,0.0005173816,0.0000587488,0.00010551193,0.00016616889,0.000003298048,0.0000892656],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99612516,0.001234244,0.0015958182,0.0003868113,0.00051533367,0.00014255352],"domain_scores_gemma":[0.99182445,0.005632802,0.0017576917,0.00011953967,0.0005483857,0.00011721101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037568556,0.001249103,0.0070418897,0.0046580494,0.0004719565,0.0018143334,0.00183539,0.0015659917,0.0047554434],"category_scores_gemma":[0.018222742,0.0007934845,0.00810405,0.005411402,0.00065792137,0.0015739894,0.0014166395,0.0013972165,0.0003033561],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003029486,0.000021842148,0.0008443858,0.9407951,0.018014802,0.00009561134,0.00012768334,0.00011092359,0.00013090337,0.00014403039,0.0018466823,0.03756506],"study_design_scores_gemma":[0.0006783015,0.00032419045,0.006786367,0.7409123,0.21764891,0.0006578824,0.00031181402,0.00009469662,0.00018171723,0.00041278242,0.03192806,0.000062863546],"about_ca_topic_score_codex":0.010061868,"about_ca_topic_score_gemma":0.032558,"teacher_disagreement_score":0.010061868,"about_ca_system_score_codex":0.0022612023,"about_ca_system_score_gemma":0.0068778084,"threshold_uncertainty_score":0.020006597},"labels":[],"label_agreement":null},{"id":"W2885280442","doi":"10.1016/j.euo.2018.07.002","title":"Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Joseph Brant Hospital; McMaster University","funders":"National Institutes of Health; National Cancer Institute; Prostate Cancer Foundation","keywords":"Aspirin; Medicine; Hazard ratio; Prostate cancer; Proportional hazards model; Confidence interval; Internal medicine; Cancer; Surgery; Oncology","score_opus":0.039439900897022206,"score_gpt":0.3684279539946468,"score_spread":0.3289880530976246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885280442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984231,0.0006065234,0.000030249741,0.00007876091,0.00001349256,0.000014457524,0.00036197316,0.0000017029074,0.000469903],"genre_scores_gemma":[0.99886876,0.00029094703,0.00003107214,0.00005690014,0.000025606822,0.000009672621,0.00035311995,0.0000010522552,0.00036293163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99954057,0.00013607653,0.00003722407,0.00007151708,0.00009003523,0.00012457573],"domain_scores_gemma":[0.99924964,0.00008921375,0.00026893112,0.000056723176,0.000053396165,0.00028205093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045977224,0.000309874,0.00061171065,0.0008135123,0.0008862945,0.00097285066,0.00040363715,0.00090307626,0.001336525],"category_scores_gemma":[0.0012621267,0.0004633874,0.0010095639,0.0014190456,0.00028631472,0.000572444,0.00078033545,0.0009982169,0.00019414094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063194573,0.00016975054,0.9974421,0.000014293576,0.00025839693,0.00014746282,0.00010491241,0.000017578866,0.0001896122,0.000015946353,0.00012092425,0.00088704255],"study_design_scores_gemma":[0.000037886035,0.00016460099,0.9990434,0.000006953469,0.00019685831,0.0001282853,0.00016008771,0.000047355832,0.000034642402,0.00001289417,0.00016238759,0.0000045954102],"about_ca_topic_score_codex":0.017754426,"about_ca_topic_score_gemma":0.025612166,"teacher_disagreement_score":0.017754426,"about_ca_system_score_codex":0.00042608663,"about_ca_system_score_gemma":0.0006424421,"threshold_uncertainty_score":0.035302162},"labels":[],"label_agreement":null},{"id":"W2886065680","doi":"10.1016/j.euo.2018.07.003","title":"Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"F. Hoffmann-La Roche","keywords":"Atezolizumab; Carboplatin; Medicine; Gemcitabine; Oncology; Internal medicine; Cisplatin; Hazard ratio; Chemotherapy; Metastatic Urothelial Carcinoma; Cancer; Bladder cancer; Urothelial carcinoma; Nivolumab; Confidence interval; Immunotherapy","score_opus":0.07254437410222264,"score_gpt":0.41245632057114395,"score_spread":0.3399119464689213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886065680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972363,0.0012616318,0.00006902628,0.00018042019,0.000045992336,0.00016315625,0.00044233605,0.000014285666,0.0005867808],"genre_scores_gemma":[0.9966815,0.0009249593,0.00020374807,0.00022831543,0.00009413208,0.0001696282,0.00092572405,0.000011084654,0.0007609089],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9991341,0.0006035987,0.00002788006,0.00009150154,0.000037548216,0.00010543853],"domain_scores_gemma":[0.9990495,0.00026856922,0.00022134438,0.0000765818,0.000038503524,0.00034543645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015493311,0.0008417239,0.0019348531,0.0004086467,0.0002670929,0.00087153673,0.00095066696,0.0010870374,0.0035490708],"category_scores_gemma":[0.0015309404,0.00036826142,0.00213432,0.0005380764,0.00067215745,0.00096482557,0.00045323864,0.0021261324,0.00039213654],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9447488,0.012072243,0.0074827024,0.00024584992,0.0014906555,0.000040901705,0.00008862109,0.0010511993,0.0039638607,0.00011616395,0.0006886958,0.028010303],"study_design_scores_gemma":[0.43398458,0.5085406,0.049552668,0.00005326593,0.0025911396,0.00013245762,0.00017775765,0.0013780055,0.0018581824,0.00015863657,0.0015368488,0.0000359241],"about_ca_topic_score_codex":0.0015438859,"about_ca_topic_score_gemma":0.0035370523,"teacher_disagreement_score":0.0035490708,"about_ca_system_score_codex":0.0010965896,"about_ca_system_score_gemma":0.0010414802,"threshold_uncertainty_score":0.011872828},"labels":[],"label_agreement":null},{"id":"W2886529900","doi":"10.1016/j.euo.2018.07.006","title":"Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer","year":2018,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; University of British Columbia","funders":"National Center for Advancing Translational Sciences; DOD Peer Reviewed Cancer Research Program; National Cancer Institute; National Institutes of Health; Institute of Clinical and Translational Sciences; University of Texas Medical Branch; U.S. Department of Defense","keywords":"Medicine; Psychological intervention; Comorbidity; Cystectomy; Socioeconomic status; Corpectomy; Marital status; Receipt; Bladder cancer; MEDLINE; Systematic review; Cancer; Family medicine; Emergency medicine; Gerontology; Environmental health; Internal medicine; Surgery; Psychiatry; Population","score_opus":0.1034561736754374,"score_gpt":0.39005715634427907,"score_spread":0.28660098266884165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886529900","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015548635,0.997549,0.000059797097,0.000091315786,0.00006208108,0.00006378725,0.0004736687,0.0000035244223,0.00014196035],"genre_scores_gemma":[0.018099165,0.98085165,0.00026687415,0.00028279048,0.000057942078,0.000103954844,0.0002513488,0.0000027224391,0.000083619176],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9973953,0.0006804722,0.0011313867,0.00027855398,0.00039261996,0.00012169992],"domain_scores_gemma":[0.9921876,0.0052698217,0.001816003,0.000106210005,0.0005035808,0.000116633186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002459006,0.001044754,0.005046494,0.004618148,0.00041324066,0.0013590041,0.001159977,0.0012538341,0.0037549247],"category_scores_gemma":[0.015305326,0.0007417144,0.008482909,0.006844413,0.00047779168,0.0010248208,0.001081726,0.0010747346,0.0002350984],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035628007,0.000029703204,0.004060485,0.9184315,0.044448297,0.0001595251,0.0001482637,0.00015859827,0.00014671158,0.00015241282,0.0018324545,0.030075809],"study_design_scores_gemma":[0.00052199676,0.0003582954,0.028658194,0.53890413,0.40384674,0.00075306767,0.00038710775,0.00012539457,0.00019085247,0.00041991987,0.025737835,0.00009641229],"about_ca_topic_score_codex":0.015617984,"about_ca_topic_score_gemma":0.041945018,"teacher_disagreement_score":0.015617984,"about_ca_system_score_codex":0.0015602933,"about_ca_system_score_gemma":0.005902784,"threshold_uncertainty_score":0.031054199},"labels":[],"label_agreement":null},{"id":"W2888744124","doi":"10.1016/j.euo.2018.08.001","title":"Individual Comparison of Cholesterol Metabolism in Normal and Tumour Areas in Radical Prostatectomy Specimens from Patients with Prostate Cancer: Results of the CHOMECAP Study","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Association pour la Recherche sur les Tumeurs de la Prostate; Fonds pour la Formation de Chercheurs et l'Aide à la Recherche","keywords":"Prostate cancer; Prostatectomy; Prostate; Cholesterol; Medicine; Pathology; Cancer; Immunohistochemistry; Internal medicine; Endocrinology","score_opus":0.010232621292633848,"score_gpt":0.26050403909763997,"score_spread":0.2502714178050061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888744124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99945813,0.00019648753,0.000043332962,0.000006478819,0.000002514811,0.0000035764187,0.00013880017,0.0000025171937,0.00014812502],"genre_scores_gemma":[0.9995697,0.000058921476,0.000040975294,0.0000070896685,0.0000040397254,0.000002717806,0.00020758426,0.0000029370267,0.000106020736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995908,0.00012168979,0.00003674284,0.000117100055,0.000083990104,0.00004969979],"domain_scores_gemma":[0.9993235,0.00019782658,0.00012190195,0.00011716501,0.00011460161,0.0001250259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047811287,0.00037508784,0.00056840957,0.0012273992,0.00051175815,0.0006470818,0.00030930672,0.00051127764,0.0008059768],"category_scores_gemma":[0.0012135446,0.00029750288,0.0004371277,0.0009690099,0.0003299479,0.00032563633,0.0005970596,0.0003752518,0.00020867665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004300674,0.000069493435,0.9840681,0.000025756872,0.00041518532,0.0002210448,0.0003317695,0.00006946528,0.007447201,0.000020484078,0.000060316688,0.0029704703],"study_design_scores_gemma":[0.000013531577,0.00015868906,0.9986162,0.0000012645038,0.00008598745,0.00023809353,0.00019472736,0.00004960097,0.0005278831,0.00001015934,0.00009862516,0.0000052303826],"about_ca_topic_score_codex":0.0042398395,"about_ca_topic_score_gemma":0.004401876,"teacher_disagreement_score":0.0042398395,"about_ca_system_score_codex":0.00025920916,"about_ca_system_score_gemma":0.00017575864,"threshold_uncertainty_score":0.008430302},"labels":[],"label_agreement":null},{"id":"W2889240474","doi":"10.1016/j.euo.2018.08.003","title":"GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Prostate Cancer Canada","keywords":"Methylation; DNA methylation; Prostate cancer; Biochemical recurrence; Oncology; Epigenetics; Medicine; breakpoint cluster region; Cancer research; Cancer; Prostatectomy; Internal medicine; Biology; Genetics; Gene; Gene expression","score_opus":0.019729878792382964,"score_gpt":0.28836486595863975,"score_spread":0.2686349871662568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889240474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778026,0.0010976376,0.00016448196,0.0001676856,0.000016592787,0.000004792789,0.0002343613,0.000012215727,0.0005219502],"genre_scores_gemma":[0.99870753,0.00019957019,0.0001504643,0.000048128397,0.000021998481,0.0000031652369,0.0003501709,0.000004181214,0.00051485095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99976856,0.000054524833,0.000017606411,0.000061596285,0.00005321024,0.000044556695],"domain_scores_gemma":[0.9996182,0.000073137584,0.00015001635,0.000029149638,0.000043330478,0.000086140986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038527919,0.00034730608,0.00043835508,0.0005488552,0.00032597117,0.0006692306,0.0003436669,0.00043208105,0.0016565922],"category_scores_gemma":[0.0010769279,0.00021302298,0.00028504655,0.0006443501,0.00030573053,0.00041368723,0.00048575623,0.00050731417,0.00024352709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005721801,0.00003336973,0.9878814,0.000022014312,0.00011647014,0.00007078932,0.000050393373,0.00015316078,0.0035688519,0.00002400936,0.00021568382,0.007291648],"study_design_scores_gemma":[0.000018114444,0.00016022855,0.996289,0.000008425751,0.00010659973,0.00034391522,0.000112242036,0.00087406056,0.0013563975,0.00009971661,0.0006244973,0.000006812717],"about_ca_topic_score_codex":0.0030191042,"about_ca_topic_score_gemma":0.005593815,"teacher_disagreement_score":0.0030191042,"about_ca_system_score_codex":0.00027041265,"about_ca_system_score_gemma":0.00025772367,"threshold_uncertainty_score":0.006003022},"labels":[],"label_agreement":null},{"id":"W2890338448","doi":"10.1016/j.euo.2018.08.017","title":"Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia; University Health Network; University of Toronto; Sunnybrook Health Science Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Health Sciences Centre","funders":"National Cancer Institute; Movember Foundation","keywords":"Medicine; Prostate cancer; Histopathology; Grading (engineering); Biopsy; Concordance; Prostatectomy; International agency; Cancer; Pathology; Internal medicine","score_opus":0.13266953195984751,"score_gpt":0.4189207318701253,"score_spread":0.2862511999102778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890338448","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2671852,0.25171965,0.077325396,0.33675706,0.013636975,0.006263798,0.0122142965,0.00038780845,0.03450971],"genre_scores_gemma":[0.83087575,0.01957241,0.09297805,0.03826366,0.005601844,0.003682195,0.0074778628,0.0002617576,0.0012865141],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9233162,0.04282807,0.011406955,0.0050149127,0.014702982,0.0027309235],"domain_scores_gemma":[0.6069064,0.18450306,0.053636238,0.039674718,0.100866705,0.014412821],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.18972094,0.0009968798,0.003662628,0.0022405046,0.0022561958,0.007226135,0.0055141877,0.0040817843,0.0036002642],"category_scores_gemma":[0.32112825,0.0009269569,0.0026354452,0.003970335,0.0033132145,0.01191106,0.0048972913,0.008289019,0.00085098523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013237856,0.0010027565,0.7656124,0.0032916912,0.0027226454,0.00014081576,0.0019441844,0.0011481004,0.0003576905,0.010392922,0.025914907,0.18614797],"study_design_scores_gemma":[0.00037280045,0.0031096318,0.8403934,0.021777952,0.0032954935,0.00061989855,0.010041428,0.004492158,0.0014484222,0.036969107,0.07706325,0.00041645457],"about_ca_topic_score_codex":0.027282914,"about_ca_topic_score_gemma":0.03414052,"teacher_disagreement_score":0.18972094,"about_ca_system_score_codex":0.0042109266,"about_ca_system_score_gemma":0.025122406,"threshold_uncertainty_score":0.99921834},"labels":[],"label_agreement":null},{"id":"W2895225151","doi":"10.1016/j.euo.2018.08.031","title":"Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Toronto; University of British Columbia; University Health Network; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Stage (stratigraphy); Nuclear medicine; Computed tomography; Radiology","score_opus":0.006326498858319275,"score_gpt":0.23850046015535176,"score_spread":0.2321739612970325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895225151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980268,0.0009947862,0.0002196156,0.00006928823,0.000012064582,0.000008265747,0.000059633378,0.000013955655,0.0005956134],"genre_scores_gemma":[0.99938715,0.00018495503,0.00017818512,0.000027828779,0.000019903282,0.0000031140946,0.0000923274,0.0000046481505,0.000101847625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99963915,0.000118620206,0.00004273273,0.000049002472,0.000063698666,0.00008662745],"domain_scores_gemma":[0.9986952,0.0005268656,0.00036632526,0.00006957866,0.00013324106,0.00020885876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006238608,0.00032235536,0.00042570237,0.0013891278,0.00030446434,0.00088488206,0.0004992573,0.0007102567,0.00094747375],"category_scores_gemma":[0.0038966136,0.00027654917,0.00038171123,0.000636311,0.00047458685,0.00063735823,0.00033374268,0.0005216087,0.00018176335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012374194,0.000075936034,0.9827979,0.00003499588,0.000029997771,0.0016973831,0.00021813264,0.00023691128,0.004553121,0.00002600209,0.00017441559,0.008917665],"study_design_scores_gemma":[0.00002214911,0.000854315,0.98437184,0.000029875433,0.00011726907,0.007983946,0.0004855935,0.0020278343,0.0035079126,0.00007647892,0.0005053514,0.000017499447],"about_ca_topic_score_codex":0.004075037,"about_ca_topic_score_gemma":0.0044127773,"teacher_disagreement_score":0.004075037,"about_ca_system_score_codex":0.00048414755,"about_ca_system_score_gemma":0.00039022943,"threshold_uncertainty_score":0.008102655},"labels":[],"label_agreement":null},{"id":"W2900345444","doi":"10.1016/j.euo.2018.10.003","title":"Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis","year":2018,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Nephrectomy; Renal cell carcinoma; Radiation therapy; Hazard ratio; Internal medicine; Oncology; Meta-analysis; Adjuvant therapy; Adjuvant; Proportional hazards model; Randomized controlled trial; Kidney cancer; Surgery; Cancer; Kidney; Confidence interval","score_opus":0.03927091721695056,"score_gpt":0.29670798988080344,"score_spread":0.25743707266385285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900345444","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007268614,0.9917686,0.00019503514,0.00009723763,0.00009281762,0.000054190918,0.0003378703,0.000009704913,0.00017590373],"genre_scores_gemma":[0.26060984,0.7353994,0.0011726676,0.0012972711,0.00020913166,0.00019654834,0.0007111042,0.000021464273,0.00038246438],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9973405,0.00096807844,0.0008513336,0.00044021444,0.00026200846,0.00013773315],"domain_scores_gemma":[0.99576795,0.002766928,0.0009785761,0.00015603568,0.00024352253,0.00008702436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032586681,0.0014844219,0.008081092,0.0022052755,0.00038139804,0.0015980904,0.0014709712,0.0017509469,0.0031342383],"category_scores_gemma":[0.009451143,0.0009937854,0.018076643,0.003733694,0.00046568358,0.0012810829,0.0010775186,0.001547259,0.00024065342],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027646185,0.00006550773,0.016024673,0.37791032,0.57924837,0.00019260439,0.00019065736,0.00060478126,0.0003943451,0.00014500172,0.001182442,0.021276575],"study_design_scores_gemma":[0.0006933218,0.00024155313,0.010645447,0.01850174,0.9666519,0.00014062447,0.000092266346,0.00012834725,0.00008593734,0.00015979334,0.0026229087,0.000036114936],"about_ca_topic_score_codex":0.0066316323,"about_ca_topic_score_gemma":0.02671395,"teacher_disagreement_score":0.008081092,"about_ca_system_score_codex":0.0012440912,"about_ca_system_score_gemma":0.0018110787,"threshold_uncertainty_score":0.01723373},"labels":[],"label_agreement":null},{"id":"W2900751841","doi":"10.1016/j.euo.2018.10.010","title":"The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Lymph node; Dissection (medical); Oncology; Urology; Lymph; Internal medicine; Cancer; Surgery; Pathology","score_opus":0.012559255608214881,"score_gpt":0.29390614843341767,"score_spread":0.2813468928252028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900751841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99117494,0.0075175227,0.00010913992,0.00017616816,0.000022858825,0.0000027315607,0.00023786843,0.0000028710365,0.0007559883],"genre_scores_gemma":[0.9987382,0.00080864964,0.000031075662,0.00003850522,0.00004108855,0.0000011418887,0.0002413414,0.000001808148,0.000098216784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99957687,0.00013887545,0.00003872711,0.000083494735,0.00007674054,0.000085317166],"domain_scores_gemma":[0.99889475,0.0004495167,0.00035655458,0.00006725821,0.000051730174,0.00018034937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007537003,0.00019153958,0.0003871754,0.0005004024,0.00022337974,0.00052458857,0.0003369862,0.00035458506,0.0011102696],"category_scores_gemma":[0.0020566168,0.000121104466,0.0010001522,0.0008000745,0.00034968654,0.0005917515,0.00045281238,0.000469785,0.000110599794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015523224,0.00006463582,0.98674124,0.000051673014,0.0005760132,0.00008288101,0.000051627303,0.00041373298,0.00032922658,0.00006973553,0.00015767445,0.009909205],"study_design_scores_gemma":[0.000016549613,0.00028215823,0.9986437,0.000011000065,0.00026007197,0.0001353073,0.0000746527,0.0001984688,0.000045222318,0.00007155151,0.00025666825,0.0000047394],"about_ca_topic_score_codex":0.0025684678,"about_ca_topic_score_gemma":0.006804724,"teacher_disagreement_score":0.0025684678,"about_ca_system_score_codex":0.00038751288,"about_ca_system_score_gemma":0.00037020128,"threshold_uncertainty_score":0.005107045},"labels":[],"label_agreement":null},{"id":"W2901127133","doi":"10.1016/j.euo.2018.10.008","title":"Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Meta-analysis of Oncologic, Perioperative, and Complication-related outcomes","year":2018,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cystectomy; Medicine; Bladder cancer; Perioperative; Randomized controlled trial; Hazard ratio; Surgery; Confidence interval; Cancer; Internal medicine","score_opus":0.22061064428387933,"score_gpt":0.44183294748994956,"score_spread":0.22122230320607023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901127133","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07140061,0.9254626,0.0008553796,0.00029598078,0.000305468,0.00004962921,0.0011485543,0.000030012003,0.00045171817],"genre_scores_gemma":[0.7482465,0.24649441,0.0014218307,0.00097183813,0.00047035594,0.00012095049,0.0016550341,0.00004406964,0.0005749264],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99732924,0.0010046519,0.0006082012,0.0006362467,0.00025225867,0.00016936494],"domain_scores_gemma":[0.99587953,0.002795423,0.0007205277,0.00024488338,0.0002312739,0.00012845204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032388142,0.0015775257,0.0059348405,0.0012148353,0.00042378498,0.0016030838,0.0015023414,0.0015264301,0.0024828599],"category_scores_gemma":[0.00746626,0.00080203736,0.023001244,0.0027825374,0.00038090334,0.001053384,0.00094092905,0.002074158,0.00027074956],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00750404,0.00007584447,0.08124787,0.04311774,0.848703,0.00020531609,0.00011084046,0.00077180675,0.00039166078,0.00017390917,0.0011783909,0.016519587],"study_design_scores_gemma":[0.00073732145,0.00034961445,0.04528508,0.0021867186,0.94862944,0.00017201177,0.00010889476,0.00041812198,0.00013117852,0.000387205,0.0015566734,0.000037654278],"about_ca_topic_score_codex":0.004818717,"about_ca_topic_score_gemma":0.010314791,"teacher_disagreement_score":0.0059348405,"about_ca_system_score_codex":0.00057674886,"about_ca_system_score_gemma":0.0008369245,"threshold_uncertainty_score":0.017128706},"labels":[],"label_agreement":null},{"id":"W2902725138","doi":"10.1016/j.euo.2018.11.005","title":"Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Janssen Research and Development; Genentech; European Society for Medical Oncology; Astellas Pharma; Eisai; Bayer; Canada Millennium Scholarship Foundation; Phycological Society of America; Amgen; Boehringer Ingelheim; Gilead Sciences; AbbVie; Sanofi; Novartis; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; Clinical trial; Randomized controlled trial; Prostate-specific antigen; Cabazitaxel; Prostate; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.06802942518975472,"score_gpt":0.40857977959971103,"score_spread":0.3405503544099563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902725138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99585426,0.0024192391,0.00018934431,0.00014296807,0.000059012586,0.0007205019,0.0001934083,0.000012064213,0.00040926225],"genre_scores_gemma":[0.9973028,0.0005731666,0.0005453306,0.00016339289,0.00013468921,0.00066157465,0.00040600615,0.0000027940018,0.00021018353],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970264,0.0022029376,0.00018542606,0.00026682133,0.00019209259,0.00012644455],"domain_scores_gemma":[0.9960594,0.0013105338,0.00151276,0.00028943593,0.00019403607,0.00063382945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00656055,0.0006825484,0.0015846827,0.00027901534,0.00034749138,0.0008581313,0.0005740886,0.00086850504,0.0018852206],"category_scores_gemma":[0.004676453,0.00035174514,0.0013534229,0.0003843892,0.0009790059,0.00061157777,0.000352891,0.0009492279,0.00019494562],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9685347,0.0020651924,0.017669868,0.00027740657,0.001191174,0.000025840161,0.000031740354,0.00023408547,0.0011278783,0.000052439707,0.00017649808,0.008613109],"study_design_scores_gemma":[0.66717833,0.23355901,0.091777764,0.00012306936,0.0032439695,0.00015998929,0.000055546778,0.0013590532,0.0013011106,0.00025892386,0.0009435098,0.00003976645],"about_ca_topic_score_codex":0.0003826215,"about_ca_topic_score_gemma":0.0010695558,"teacher_disagreement_score":0.00656055,"about_ca_system_score_codex":0.00048152762,"about_ca_system_score_gemma":0.0011612738,"threshold_uncertainty_score":0.034695923},"labels":[],"label_agreement":null},{"id":"W2903023839","doi":"10.1016/j.euo.2018.11.006","title":"Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Cabozantinib; Docetaxel; Prostate cancer; Oncology; Abiraterone acetate; Internal medicine; Enzalutamide; Hazard ratio; Mitoxantrone; Prednisone; Cancer; Urology; Confidence interval; Chemotherapy; Androgen receptor; Androgen deprivation therapy","score_opus":0.11050460092748174,"score_gpt":0.4826046893328425,"score_spread":0.3721000884053608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903023839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93588287,0.054055057,0.0009202601,0.0011445447,0.0003292559,0.0019842153,0.0027213516,0.00015385162,0.0028086577],"genre_scores_gemma":[0.97255695,0.019881064,0.0013269027,0.0008506685,0.0002598716,0.0008450373,0.0027628492,0.000049971153,0.0014667974],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99857914,0.0007299578,0.00008084441,0.0002060247,0.00017642237,0.00022760965],"domain_scores_gemma":[0.99843246,0.00047410358,0.0004489067,0.00014703111,0.00012400783,0.00037337642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038242275,0.0018930247,0.0047226413,0.0009678773,0.00040930946,0.0016306442,0.00080944115,0.0011765778,0.0026283294],"category_scores_gemma":[0.0026125817,0.0006288586,0.0047106077,0.0012930484,0.0009520498,0.0011992406,0.00044357794,0.0023506696,0.0004888111],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7770164,0.005947903,0.008221639,0.00283583,0.023027178,0.00017459973,0.00018149854,0.0026359938,0.009868399,0.00023938235,0.0032692228,0.16658194],"study_design_scores_gemma":[0.7259197,0.17472017,0.05705542,0.0004499001,0.027284391,0.0005464059,0.00015582118,0.0014015416,0.0022887758,0.0006374573,0.0093774535,0.00016285627],"about_ca_topic_score_codex":0.002778427,"about_ca_topic_score_gemma":0.015783768,"teacher_disagreement_score":0.0047226413,"about_ca_system_score_codex":0.0019913465,"about_ca_system_score_gemma":0.002224133,"threshold_uncertainty_score":0.02022475},"labels":[],"label_agreement":null},{"id":"W2909961841","doi":"10.1016/j.euo.2018.12.007","title":"Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"Vlaamse regering; Kom op tegen Kanker; Leonard D. Schaeffer Center for Health Policy and Economics; KU Leuven; Fonds Wetenschappelijk Onderzoek","keywords":"Medicine; Interquartile range; Prostate cancer; Odds ratio; Prostatectomy; Cohort; Internal medicine; Population; Oncology; DECIPHER; Logistic regression; Cancer; Metastasis; Cohort study; Surgery; Bioinformatics; Biology","score_opus":0.014951533781855294,"score_gpt":0.2694467555458495,"score_spread":0.2544952217639942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909961841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99692184,0.00038812135,0.00049812655,0.00017167386,0.00008015817,0.000016619226,0.0009443883,0.00002426191,0.00095491094],"genre_scores_gemma":[0.9967991,0.00012627484,0.0005449944,0.00008520083,0.00005590447,0.000015401407,0.0012934688,0.000009083616,0.001070578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994394,0.00014172432,0.00004679678,0.00013577421,0.00012581289,0.00011048381],"domain_scores_gemma":[0.9979954,0.00081642164,0.00045216866,0.00016976972,0.00029551605,0.00027076344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014101348,0.00052000897,0.00050268683,0.0007737184,0.00042363288,0.0009887537,0.0005645276,0.0007748736,0.0018363808],"category_scores_gemma":[0.0040504467,0.0002909609,0.0005288366,0.00037889587,0.0003670797,0.0007289026,0.00082263566,0.0007457383,0.0007026075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006291917,0.00010060713,0.98857516,0.000020867612,0.000083210005,0.00010290598,0.000050535207,0.00035136694,0.0010491495,0.00005161623,0.0004875984,0.008497621],"study_design_scores_gemma":[0.000049223378,0.0014997316,0.9883647,0.000023628336,0.00018308283,0.0010378443,0.00023782802,0.0038368162,0.002398717,0.00019198301,0.0021557151,0.000020715468],"about_ca_topic_score_codex":0.0017121051,"about_ca_topic_score_gemma":0.0033956442,"teacher_disagreement_score":0.0018363808,"about_ca_system_score_codex":0.000284307,"about_ca_system_score_gemma":0.0004920634,"threshold_uncertainty_score":0.007457614},"labels":[],"label_agreement":null},{"id":"W2913311442","doi":"10.1016/j.euo.2019.01.009","title":"Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Janssen Research and Development; Fonds de Recherche du Québec - Santé; AbbVie; Merck; Sanofi; Janssen Biotech; Astellas Pharma; Genzyme; Bayer; Netherlands Leprosy Relief; Amgen","keywords":"Medicine; Abiraterone acetate; Prednisone; Asymptomatic; Internal medicine; Prostate cancer; Proportional hazards model; Oncology; Survival analysis; Placebo; Retrospective cohort study; Predictive marker; Neutrophil to lymphocyte ratio; Lymphocyte; Gastroenterology; Cancer; Pathology; Androgen deprivation therapy","score_opus":0.008421583608822449,"score_gpt":0.2784300486536095,"score_spread":0.27000846504478704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913311442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99855036,0.0006852941,0.00011789282,0.00001681517,0.0000047238195,0.000005160703,0.00028692075,0.0000032087935,0.0003295475],"genre_scores_gemma":[0.9995567,0.00009239249,0.0000346375,0.000012175732,0.00000545262,0.000002716918,0.00023545168,0.0000023650623,0.00005803495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998858,0.0004231106,0.00013745275,0.00025099193,0.00021964617,0.00011077287],"domain_scores_gemma":[0.9976043,0.00072705053,0.000781245,0.00043222882,0.00020571545,0.00024951703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013361649,0.00034656073,0.00052313856,0.0007770923,0.00032688453,0.0009019704,0.00039449232,0.00033382984,0.0007154704],"category_scores_gemma":[0.0025410557,0.00033281327,0.0005423098,0.0014356265,0.0004230409,0.0003987924,0.00040491452,0.0004392651,0.00020118516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007862865,0.000023033066,0.9968395,0.000009663453,0.00016628199,0.000121766396,0.00004502093,0.000059488186,0.000631705,0.000021144919,0.000053265958,0.001242804],"study_design_scores_gemma":[0.00004008996,0.00029154707,0.99720424,0.0000062174345,0.00023145767,0.0008545081,0.000122574,0.00033543582,0.0003759972,0.000034410463,0.0004940981,0.0000095154],"about_ca_topic_score_codex":0.0022924207,"about_ca_topic_score_gemma":0.0024385194,"teacher_disagreement_score":0.0022924207,"about_ca_system_score_codex":0.00029386187,"about_ca_system_score_gemma":0.00040526132,"threshold_uncertainty_score":0.0070664287},"labels":[],"label_agreement":null},{"id":"W2921052390","doi":"10.1016/j.euo.2019.02.004","title":"Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"EMD Serono; MedImmune; Exelixis; Novartis; Merck; Bayer; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Hazard ratio; Proportional hazards model; Oncology; Taxane; Liquid biopsy; Carcinoma; Cancer; Confidence interval; Breast cancer","score_opus":0.03538344053251901,"score_gpt":0.33735410156659135,"score_spread":0.30197066103407233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921052390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994429,0.00013263428,0.000068264046,0.000009798925,0.000004465649,0.000021179649,0.0001897557,0.0000021405729,0.00012895543],"genre_scores_gemma":[0.99914527,0.000086465996,0.00012208018,0.0000183214,0.00002064107,0.000027088687,0.00031755518,0.0000023161954,0.000260251],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99959904,0.00011309981,0.00003314699,0.00012023464,0.00004868674,0.000085811116],"domain_scores_gemma":[0.9981122,0.00047375672,0.0005327045,0.0001479837,0.00020650419,0.0005268383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006728874,0.00041351627,0.0005822035,0.0007807345,0.0005246284,0.00077466207,0.00038337932,0.00051858515,0.0020085005],"category_scores_gemma":[0.0018038212,0.0002481002,0.00051511324,0.0011259468,0.00039281184,0.00050823356,0.00054628693,0.0006098912,0.00031255922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045012855,0.0011211773,0.985076,0.000041574556,0.00017613641,0.0003134687,0.00024109756,0.0000752299,0.0031726742,0.000032172407,0.00010692407,0.0051421616],"study_design_scores_gemma":[0.00021689507,0.005325741,0.99235743,0.000008099564,0.00015839504,0.0005440929,0.0002845325,0.00015333577,0.00050674164,0.00004647529,0.00038886734,0.00000944709],"about_ca_topic_score_codex":0.0012074255,"about_ca_topic_score_gemma":0.0010128885,"teacher_disagreement_score":0.0020085005,"about_ca_system_score_codex":0.0002689835,"about_ca_system_score_gemma":0.00045765436,"threshold_uncertainty_score":0.0067191124},"labels":[],"label_agreement":null},{"id":"W2925184412","doi":"10.1016/j.euo.2019.02.007","title":"Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ferring; Astellas Pharma Canada; Sanofi; Merck; Bayer","keywords":"Medicine; Prostate cancer; Radium-223; Denosumab; Zoledronic acid; Androgen deprivation therapy; Oncology; Abiraterone acetate; Cancer; Internal medicine; Abiraterone; Bone metastasis; Osteoporosis; Androgen receptor","score_opus":0.06879219085183638,"score_gpt":0.359064597872905,"score_spread":0.2902724070210686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925184412","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023257493,0.65778476,0.0087121865,0.30080238,0.012827273,0.0005975371,0.001125951,0.00020596203,0.015618211],"genre_scores_gemma":[0.024225025,0.7532086,0.059462436,0.14132375,0.008050641,0.0013857145,0.0030714348,0.00029263942,0.008979845],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99100435,0.0033531203,0.0022933425,0.0005250593,0.0021560485,0.0006681264],"domain_scores_gemma":[0.9787851,0.008953109,0.0028825859,0.0005114041,0.00715582,0.00171206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03508539,0.0013005963,0.0027636623,0.0026717884,0.0009832418,0.0046241027,0.0057795094,0.00913376,0.0023475047],"category_scores_gemma":[0.023679866,0.0006925592,0.0039908015,0.0025911175,0.001737036,0.0034486924,0.002877344,0.010238034,0.0018454258],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058936625,0.00023950085,0.0018603697,0.01264991,0.0007911496,0.0004035819,0.0005656985,0.0023773408,0.0017679032,0.0076455213,0.25562114,0.7154886],"study_design_scores_gemma":[0.00041523145,0.0002702259,0.003744848,0.033959247,0.0015085565,0.00059502595,0.0006177362,0.0006685821,0.00085996446,0.0069361944,0.9503226,0.00010167817],"about_ca_topic_score_codex":0.009750293,"about_ca_topic_score_gemma":0.017734006,"teacher_disagreement_score":0.03508539,"about_ca_system_score_codex":0.0035661892,"about_ca_system_score_gemma":0.015395157,"threshold_uncertainty_score":0.18555152},"labels":[],"label_agreement":null},{"id":"W2931461559","doi":"10.1016/j.euo.2019.03.003","title":"Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Receiver operating characteristic; Stage (stratigraphy); Prostate cancer; Prostate-specific antigen; Logistic regression; Cohort; Prostate; Oncology; Cancer; Internal medicine; Confidence interval; Statistics; Mathematics","score_opus":0.06270675657138075,"score_gpt":0.34705480117989096,"score_spread":0.2843480446085102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2931461559","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48290285,0.0040310556,0.31918862,0.0022715444,0.0015912632,0.002147079,0.14050461,0.03955113,0.00781175],"genre_scores_gemma":[0.5008791,0.0009952277,0.4077903,0.0006175032,0.00043790412,0.0012850892,0.082480446,0.0007346783,0.0047797356],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985342,0.0002241655,0.0003287452,0.000395477,0.00042743687,0.00008991722],"domain_scores_gemma":[0.98468614,0.009183422,0.0010167541,0.0010378177,0.003642039,0.00043385848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031395077,0.001066709,0.0017653997,0.0040208506,0.0007428975,0.0027602345,0.0014412887,0.00096172356,0.008722773],"category_scores_gemma":[0.0148194125,0.0006581098,0.00082007627,0.0025359904,0.0002257792,0.0015892514,0.0008453409,0.00073412084,0.0037192414],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041839927,0.00087678886,0.41220155,0.0008376101,0.00080334145,0.0007318603,0.00024543982,0.0072329766,0.013025978,0.0016564432,0.04774702,0.51045704],"study_design_scores_gemma":[0.002252582,0.0030479566,0.3445728,0.0008318304,0.002366517,0.005446834,0.00087259244,0.4933523,0.062804475,0.0089353835,0.07506129,0.00045544692],"about_ca_topic_score_codex":0.007852426,"about_ca_topic_score_gemma":0.0093621155,"teacher_disagreement_score":0.008722773,"about_ca_system_score_codex":0.0007625166,"about_ca_system_score_gemma":0.0019192201,"threshold_uncertainty_score":0.029180586},"labels":[],"label_agreement":null},{"id":"W2939883602","doi":"10.1016/j.euo.2019.03.008","title":"Salvage Local Treatments After Focal Therapy for Prostate Cancer","year":2019,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia","funders":"UCLH Biomedical Research Centre; National Health Research Institutes; National Institute for Health and Care Research","keywords":"Medicine; Prostatectomy; Prostate cancer; Salvage therapy; Retrospective cohort study; Radiation therapy; Ablation; Surgery; Sexual function; Prostate; Cancer; Internal medicine; Chemotherapy","score_opus":0.06258989109579838,"score_gpt":0.3876547859406349,"score_spread":0.3250648948448365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939883602","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013796722,0.9989982,0.00005553632,0.00006839845,0.00008138512,0.000005676222,0.000023847044,0.0000045742977,0.0006243306],"genre_scores_gemma":[0.0014291026,0.9974734,0.00010669674,0.0002955562,0.00012277627,0.000008451341,0.000057913883,0.0000026214784,0.0005034225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998265,0.000040462142,0.000037751746,0.000038526596,0.000038940387,0.00001777775],"domain_scores_gemma":[0.9996947,0.00017136904,0.00007631685,0.000009894201,0.000030307252,0.00001748988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044671164,0.00080209656,0.0018523125,0.002030668,0.0002021971,0.00085152214,0.00093892444,0.00061682635,0.00713691],"category_scores_gemma":[0.000942312,0.00024332007,0.00088692014,0.0016934864,0.00036536998,0.00084365945,0.00058304146,0.0011524179,0.0014569882],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014482121,0.000046026347,0.00015892492,0.044931155,0.0003071806,0.00012166906,0.00004153188,0.00031352017,0.00052337116,0.0005872715,0.01643188,0.93639266],"study_design_scores_gemma":[0.00031645474,0.00056834996,0.0038067852,0.038971145,0.002903163,0.003985987,0.00012974131,0.0002186842,0.00079824694,0.0017756541,0.94646895,0.000056824287],"about_ca_topic_score_codex":0.0012358881,"about_ca_topic_score_gemma":0.004938018,"teacher_disagreement_score":0.00713691,"about_ca_system_score_codex":0.00061340985,"about_ca_system_score_gemma":0.0009215122,"threshold_uncertainty_score":0.023875356},"labels":[],"label_agreement":null},{"id":"W2946628936","doi":"10.1016/j.euo.2019.04.007","title":"Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?","year":2019,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"European Organisation for Research and Treatment of Cancer; Medtronic","keywords":"Medicine; Nephrectomy; Intensive care medicine; MEDLINE; Urology; Internal medicine; Kidney","score_opus":0.10100723821200605,"score_gpt":0.38861430127581376,"score_spread":0.2876070630638077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946628936","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030944264,0.997366,0.00026636728,0.0011363742,0.00018261802,0.00000625532,0.00004690868,0.000003604994,0.00068237877],"genre_scores_gemma":[0.0040911348,0.99292034,0.0010575306,0.0010286024,0.00050513976,0.000017538221,0.00012257959,0.000004264434,0.00025292794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994821,0.00013700152,0.00012762348,0.00010685676,0.00011346478,0.000033100216],"domain_scores_gemma":[0.99854267,0.0009585491,0.00024294347,0.000018456933,0.00018379498,0.0000536522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001569762,0.0007062555,0.0024665417,0.0015896268,0.00026225683,0.001591313,0.0011223764,0.0011491495,0.0034531052],"category_scores_gemma":[0.0037569215,0.00025324713,0.0012151547,0.0014912118,0.0006526601,0.001434687,0.00062796863,0.0020863952,0.00072356866],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029073516,0.000052332656,0.0025753092,0.02499791,0.0005023683,0.00014894373,0.00007282152,0.00080450904,0.00036545706,0.0038383487,0.019365033,0.94698614],"study_design_scores_gemma":[0.0005000567,0.0004788446,0.018863041,0.1126992,0.00460016,0.0039014344,0.0007374782,0.0011672735,0.000555175,0.016724467,0.8396083,0.00016456799],"about_ca_topic_score_codex":0.0017436624,"about_ca_topic_score_gemma":0.0049113166,"teacher_disagreement_score":0.0034531052,"about_ca_system_score_codex":0.0008669998,"about_ca_system_score_gemma":0.0017129765,"threshold_uncertainty_score":0.011551797},"labels":[],"label_agreement":null},{"id":"W2947253482","doi":"10.1016/j.euo.2019.05.001","title":"Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Neuropeptides and Animal Physiology","field":"Neuroscience","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Cancer Institute","keywords":"Prostate cancer; Medicine; Prostate; Cancer; Transcriptome; Identification (biology); Oncology; Neuropeptide; Cancer research; Internal medicine; Pathology; Gene expression; Biology; Gene; Receptor","score_opus":0.050242098600692696,"score_gpt":0.3534754279592582,"score_spread":0.3032333293585655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947253482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933862,0.0023429035,0.001238149,0.0001874354,0.000021035507,0.000030346904,0.0019035351,0.000022398865,0.0008678745],"genre_scores_gemma":[0.99594903,0.0007782988,0.0007246138,0.00011759647,0.000030557916,0.00003289472,0.0015190874,0.000012231112,0.0008356747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998053,0.000028288985,0.000013621365,0.00006028673,0.000038107384,0.00005440135],"domain_scores_gemma":[0.9998242,0.00003732444,0.00005826174,0.000009818841,0.00003652828,0.00003394542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024539544,0.00018964632,0.00043940544,0.0005814213,0.00025846757,0.00057166565,0.00020574594,0.00030235678,0.0015591497],"category_scores_gemma":[0.00038330222,0.00010456312,0.00025488707,0.0006613148,0.00026475053,0.00019851934,0.00033723642,0.00039004572,0.00027025258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002441325,0.00011673808,0.5726595,0.00034677383,0.00027533196,0.0013043304,0.00033148675,0.0004448373,0.38360196,0.00033149097,0.0011541287,0.036992054],"study_design_scores_gemma":[0.000034122182,0.00042204544,0.9760069,0.00003580318,0.00017698634,0.0029946405,0.00079582504,0.001296973,0.014564576,0.00039942094,0.0032527416,0.000019912233],"about_ca_topic_score_codex":0.0010366095,"about_ca_topic_score_gemma":0.0018484779,"teacher_disagreement_score":0.0015591497,"about_ca_system_score_codex":0.00020747598,"about_ca_system_score_gemma":0.0003647677,"threshold_uncertainty_score":0.0052158237},"labels":[],"label_agreement":null},{"id":"W2949728994","doi":"10.1016/j.euo.2019.06.003","title":"Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options?","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Mitomycin C; Disease; Cancer; Urology; Carcinoma in situ; Surgery; Internal medicine; Oncology","score_opus":0.023462383481248718,"score_gpt":0.3043653441791391,"score_spread":0.28090296069789034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949728994","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013679428,0.86512166,0.0021545207,0.108176485,0.0026591741,0.00005166083,0.00038384134,0.00008456187,0.0076886895],"genre_scores_gemma":[0.20216785,0.70773005,0.0048947176,0.04977158,0.024417348,0.00020854334,0.0017811572,0.00009717348,0.008931635],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878055,0.00042389001,0.00020039477,0.00019078962,0.00021098173,0.00019338002],"domain_scores_gemma":[0.9971529,0.0012263429,0.00054630503,0.000073377625,0.00043139284,0.00056959735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024948805,0.00041508267,0.0024815553,0.000722459,0.0005512342,0.003668399,0.0013027741,0.0024291037,0.0071112067],"category_scores_gemma":[0.0054330723,0.00022925017,0.0017267918,0.0005775273,0.0010469416,0.0043155565,0.0009009002,0.003369351,0.0015935329],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013595432,0.0003346237,0.015210472,0.0048033996,0.00049766863,0.0011368751,0.00021219002,0.0012524418,0.0009830458,0.0055087632,0.05265869,0.9160423],"study_design_scores_gemma":[0.0010282324,0.0039977026,0.069401875,0.042914778,0.0035350246,0.016938679,0.007824571,0.004911946,0.0016383759,0.062441785,0.7848202,0.0005468203],"about_ca_topic_score_codex":0.0017956806,"about_ca_topic_score_gemma":0.0086080935,"teacher_disagreement_score":0.0071112067,"about_ca_system_score_codex":0.0012225652,"about_ca_system_score_gemma":0.002563074,"threshold_uncertainty_score":0.023789406},"labels":[],"label_agreement":null},{"id":"W2949821396","doi":"10.1016/j.euo.2019.01.013","title":"Re: Shusuke Akamatsu, Masashi Kubota, Ryuji Uozumi, et al. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer. Eur Urol Oncol 2019;2:320–328","year":2019,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Overall survival; Cancer; Internal medicine; Gynecology","score_opus":0.07546158276393353,"score_gpt":0.3527123459148482,"score_spread":0.2772507631509147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949821396","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006035252,0.0035348358,0.00024095511,0.93787193,0.0523491,0.000026491049,0.00019442997,0.00009336818,0.005085319],"genre_scores_gemma":[0.007478456,0.0045431578,0.0004388208,0.83640444,0.121561036,0.00007266356,0.00022168648,0.00006950401,0.02921024],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987218,0.00026663832,0.00018847467,0.00018292277,0.00048075206,0.000159356],"domain_scores_gemma":[0.9957793,0.0015221041,0.00023631637,0.00015419809,0.001647527,0.00066059903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013922806,0.00091078907,0.0013438514,0.000759625,0.0017141722,0.0024545768,0.001083549,0.012789452,0.018449757],"category_scores_gemma":[0.017374849,0.00057852664,0.00092022994,0.0005306688,0.0010893558,0.0024783374,0.0008447656,0.018467799,0.024440303],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051519917,0.00002502766,0.0005436458,0.000036956826,0.000010363607,0.0014118793,0.000032429336,0.00003521303,0.000120869634,0.00031613305,0.9878491,0.009566794],"study_design_scores_gemma":[0.00016242714,0.00008707142,0.0022588861,0.00040758308,0.000041314863,0.007791734,0.00041910706,0.00074888545,0.00032441108,0.003863137,0.98382044,0.00007488808],"about_ca_topic_score_codex":0.0035597982,"about_ca_topic_score_gemma":0.005079406,"teacher_disagreement_score":0.018449757,"about_ca_system_score_codex":0.002253858,"about_ca_system_score_gemma":0.0018186666,"threshold_uncertainty_score":0.06172055},"labels":[],"label_agreement":null},{"id":"W2954147811","doi":"10.1016/j.euo.2019.06.002","title":"Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Roche; Merck","keywords":"Cystectomy; Medicine; Bladder cancer; Chemotherapy; Cisplatin; Oncology; Guideline; Cancer; Neoadjuvant therapy; Internal medicine; Clinical trial; DNA Damage Repair; DNA repair; Pathology; Gene; Breast cancer","score_opus":0.03674697873142426,"score_gpt":0.3119977905155355,"score_spread":0.27525081178411126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954147811","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0744948,0.5640393,0.031594276,0.27624607,0.010018101,0.0006450136,0.0036757344,0.00066991436,0.038616795],"genre_scores_gemma":[0.53826064,0.27471808,0.08303712,0.07390491,0.011469099,0.00093280623,0.005098484,0.00029062634,0.012288157],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99855083,0.0006947827,0.00026694583,0.0001250142,0.00026088892,0.00010148522],"domain_scores_gemma":[0.9928596,0.00277303,0.001222053,0.00028356691,0.0024797258,0.00038211813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053913137,0.0005952558,0.0016844093,0.0016375834,0.0004052712,0.0028110112,0.0008977807,0.0021361988,0.0036352405],"category_scores_gemma":[0.016721677,0.0003057999,0.0009954609,0.0013637904,0.0008130001,0.0028757653,0.0007619315,0.0029607138,0.0027914336],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014326229,0.0003490732,0.1893284,0.002892332,0.00048689643,0.0008191279,0.00035052127,0.002422415,0.0037991712,0.0053056763,0.12690194,0.6659118],"study_design_scores_gemma":[0.0005286654,0.002266233,0.20457467,0.019429669,0.0017026153,0.00617857,0.002903672,0.0099175675,0.0076266285,0.054478407,0.6899817,0.0004115393],"about_ca_topic_score_codex":0.0025717951,"about_ca_topic_score_gemma":0.005970267,"teacher_disagreement_score":0.0053913137,"about_ca_system_score_codex":0.0009148908,"about_ca_system_score_gemma":0.0017151313,"threshold_uncertainty_score":0.028512359},"labels":[],"label_agreement":null},{"id":"W2957715479","doi":"10.1016/j.euo.2019.06.014","title":"Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Hazard ratio; Interquartile range; Cystectomy; Proportional hazards model; Chemotherapy; Primary tumor; Internal medicine; Confidence interval; Metastasis; Carboplatin; Oncology; Clinical endpoint; Cancer; Bladder cancer; Surgery; Cisplatin; Clinical trial","score_opus":0.04766636536898497,"score_gpt":0.36295574273882414,"score_spread":0.3152893773698392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2957715479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930784,0.0010097284,0.00009716299,0.000113045404,0.00000848686,0.00002005812,0.005236839,0.0000048637685,0.00043127706],"genre_scores_gemma":[0.99103165,0.0003956089,0.00011415233,0.00008987408,0.000019111785,0.000024871024,0.008245979,0.000005867354,0.00007271703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959163,0.0015256142,0.0006977275,0.00096693164,0.0005893564,0.0003041061],"domain_scores_gemma":[0.98417443,0.00514867,0.007901979,0.0010216368,0.000852566,0.00090069365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042215954,0.00029855306,0.0009414383,0.0022143945,0.0004009691,0.0014618885,0.00094136887,0.0006189596,0.0009318224],"category_scores_gemma":[0.010715158,0.00022550511,0.0014511794,0.0038318536,0.00038538166,0.0011360802,0.001257695,0.00053720677,0.00015781306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056451565,0.0000649717,0.99615353,0.000055769782,0.00072538666,0.000020520882,0.00006370476,0.0001506076,0.000087428394,0.000027722685,0.00031302235,0.0017728809],"study_design_scores_gemma":[0.00004813214,0.0001521988,0.99843854,0.000020956166,0.00030582267,0.00014469838,0.00017642227,0.00033172686,0.000067833906,0.000021021018,0.00028475944,0.000007932481],"about_ca_topic_score_codex":0.0037677684,"about_ca_topic_score_gemma":0.0051981267,"teacher_disagreement_score":0.0042215954,"about_ca_system_score_codex":0.0007669868,"about_ca_system_score_gemma":0.00095180445,"threshold_uncertainty_score":0.022326171},"labels":[],"label_agreement":null},{"id":"W2958595932","doi":"10.1016/j.euo.2019.06.001","title":"Imaging and T Category for Prostate Cancer in the 8th Edition of the Union for International Cancer Control TNM Classification","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Oncology; Medical physics; Internal medicine; Radiology","score_opus":0.024791159646288065,"score_gpt":0.3455335534015078,"score_spread":0.32074239375521973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958595932","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.526049,0.06342275,0.018078398,0.006562772,0.0041220086,0.0012360524,0.1890172,0.0014268754,0.19008498],"genre_scores_gemma":[0.8194394,0.017171971,0.022917135,0.0020578885,0.00070181955,0.0011068003,0.105458036,0.0003398153,0.030807083],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936205,0.00011862035,0.000102680264,0.000091245456,0.00017053106,0.00015487085],"domain_scores_gemma":[0.9982374,0.0002278214,0.00069366244,0.0000921171,0.00051279936,0.00023622156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084395177,0.0011077363,0.0010480593,0.004276582,0.0007543604,0.0010003509,0.0011047655,0.0007187623,0.009677997],"category_scores_gemma":[0.0034820277,0.00023694026,0.0017896931,0.003600478,0.0005794554,0.001208963,0.00089470093,0.0022226074,0.0021594174],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023783492,0.00018175875,0.8383463,0.001730748,0.0009870434,0.0004564153,0.00045163988,0.0033938808,0.0027330467,0.0035785574,0.09111041,0.05465189],"study_design_scores_gemma":[0.00022551765,0.00068993,0.92223984,0.0011221231,0.00069025706,0.0032412596,0.00087099697,0.0045218356,0.00094351725,0.0049190666,0.060392458,0.00014313095],"about_ca_topic_score_codex":0.017190803,"about_ca_topic_score_gemma":0.02585103,"teacher_disagreement_score":0.017190803,"about_ca_system_score_codex":0.00095854705,"about_ca_system_score_gemma":0.0018627421,"threshold_uncertainty_score":0.034181476},"labels":[],"label_agreement":null},{"id":"W2960318035","doi":"10.1016/j.euo.2019.06.008","title":"Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone; Prostate cancer; Prostate-specific antigen; Oncology; Prostate; Internal medicine; Cancer; Urology; Androgen receptor","score_opus":0.021386679673091453,"score_gpt":0.335426463842839,"score_spread":0.31403978416974754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960318035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9655883,0.01816412,0.0025324249,0.00058011856,0.00013413254,0.00046087644,0.010194792,0.000059586666,0.0022857508],"genre_scores_gemma":[0.98825115,0.0020797013,0.001302534,0.0001622424,0.00007118403,0.00021177094,0.0075870785,0.00003205607,0.00030231135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.990026,0.0037056853,0.0015567265,0.0020093417,0.0020892343,0.00061314425],"domain_scores_gemma":[0.97724324,0.004879333,0.00925113,0.0037003248,0.0032768745,0.0016490759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015689328,0.0010819285,0.00259667,0.0023567316,0.0009486304,0.0020413636,0.002388235,0.0010260532,0.0012369066],"category_scores_gemma":[0.018778007,0.0005815695,0.0085526,0.0056218486,0.0003725185,0.0006460684,0.002067372,0.0012309315,0.00019575942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004116795,0.00010171261,0.9704109,0.00040398588,0.013373035,0.000073169445,0.00023767164,0.00070758164,0.00009280472,0.00007772865,0.0013161035,0.009088483],"study_design_scores_gemma":[0.0006372388,0.0004270335,0.98412275,0.00024114236,0.011268923,0.00016113408,0.0002133351,0.0011665241,0.000057044595,0.00006292404,0.001598075,0.000043870998],"about_ca_topic_score_codex":0.060542192,"about_ca_topic_score_gemma":0.06515493,"teacher_disagreement_score":0.060542192,"about_ca_system_score_codex":0.0017584036,"about_ca_system_score_gemma":0.0044113863,"threshold_uncertainty_score":0.12037963},"labels":[],"label_agreement":null},{"id":"W2961998542","doi":"10.1016/j.euo.2019.05.007","title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies","year":2019,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"SABR volatility model; Ablative case; Medicine; Meta-analysis; Radiation therapy; Renal cell carcinoma; Oncology; Radiosurgery; Stereotactic radiation therapy; Internal medicine; Radiology; Medical physics","score_opus":0.2666787028741161,"score_gpt":0.4176423623246922,"score_spread":0.1509636594505761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961998542","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006697842,0.9920596,0.00031414282,0.00009668683,0.000084012034,0.000053632957,0.00042720183,0.00001476515,0.0002521026],"genre_scores_gemma":[0.22778356,0.7681853,0.0012649065,0.0009964447,0.00016262324,0.0001614573,0.00088008255,0.000043875105,0.00052176986],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9974273,0.0009955189,0.0006903028,0.000445475,0.00030590125,0.00013543264],"domain_scores_gemma":[0.99576926,0.0028508783,0.0009163159,0.00015994319,0.000219498,0.00008415852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004173759,0.0018153145,0.008258696,0.0026114215,0.0003814826,0.001793248,0.0014442715,0.0013808379,0.0038713454],"category_scores_gemma":[0.0073013883,0.0009651685,0.021146845,0.004492859,0.00042049985,0.0011344273,0.0011412438,0.0014716471,0.00036275707],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035816643,0.000036715137,0.010403698,0.18733692,0.770858,0.00013929934,0.00010900091,0.00065015804,0.0005295346,0.00013977042,0.0011350376,0.025080165],"study_design_scores_gemma":[0.0005859179,0.00017670607,0.0068377876,0.0081684375,0.98115313,0.00010437508,0.00005150882,0.00009316784,0.00011036113,0.00017154976,0.0025237969,0.000023241391],"about_ca_topic_score_codex":0.004470922,"about_ca_topic_score_gemma":0.016268034,"teacher_disagreement_score":0.008258696,"about_ca_system_score_codex":0.001170578,"about_ca_system_score_gemma":0.0012367876,"threshold_uncertainty_score":0.02207321},"labels":[],"label_agreement":null},{"id":"W2963065632","doi":"10.1016/j.euo.2019.06.018","title":"Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"Meso Scale Diagnostics; Novartis Pharma; F. Hoffmann-La Roche; Roche; GlaxoSmithKline; AstraZeneca; Ipsen; Bayer Schering; Novartis; Pfizer; Bristol-Myers Squibb","keywords":"Temsirolimus; Sunitinib; Medicine; Everolimus; Internal medicine; Renal cell carcinoma; Oncology; Discovery and development of mTOR inhibitors; Refractory (planetary science); Pazopanib; Sorafenib; Tyrosine-kinase inhibitor; Progressive disease; Cancer; Progression-free survival; Urology; PI3K/AKT/mTOR pathway; Chemotherapy","score_opus":0.030486559560012918,"score_gpt":0.29029199453445287,"score_spread":0.25980543497444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963065632","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014586737,0.5086874,0.002804777,0.43452656,0.017796565,0.00032031053,0.00070386846,0.00031458403,0.02025932],"genre_scores_gemma":[0.15932508,0.5439844,0.01183516,0.1885176,0.07693471,0.0007259006,0.0024258425,0.00015856963,0.01609273],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99867296,0.00038723892,0.00025492226,0.00016514395,0.00023462332,0.00028516687],"domain_scores_gemma":[0.99567956,0.0014194757,0.0004690506,0.00008979134,0.0010812208,0.0012608978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024912118,0.0008245155,0.0037028613,0.0012945246,0.0018723514,0.0050528594,0.0015859455,0.006884905,0.009182985],"category_scores_gemma":[0.0061933477,0.00041489632,0.0028318847,0.0009505787,0.001484974,0.009010259,0.0011098656,0.0069817537,0.0031198126],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020432456,0.0010947088,0.024033748,0.0047927517,0.00088779675,0.006503628,0.00034423487,0.0015216555,0.0012879351,0.0062421043,0.32383963,0.62740856],"study_design_scores_gemma":[0.0014610223,0.002023874,0.04440105,0.021450289,0.0022914065,0.025397008,0.010693651,0.0028090363,0.0008997998,0.032579597,0.85527194,0.00072121044],"about_ca_topic_score_codex":0.0066696233,"about_ca_topic_score_gemma":0.023863163,"teacher_disagreement_score":0.009182985,"about_ca_system_score_codex":0.0025007355,"about_ca_system_score_gemma":0.009027788,"threshold_uncertainty_score":0.030720174},"labels":[],"label_agreement":null},{"id":"W2975538531","doi":"10.1016/j.euo.2019.09.001","title":"Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute; Ipsen Biopharmaceuticals; Dana-Farber/Harvard Cancer Center; University of Rochester; Pfizer; Eisai; AbbVie; Bristol-Myers Squibb","keywords":"Medicine; Hazard ratio; Internal medicine; Cohort; Renal cell carcinoma; Oncology; Proportional hazards model; Antibiotics; Confidence interval","score_opus":0.017095364068757186,"score_gpt":0.2640910312807955,"score_spread":0.24699566721203828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975538531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950068,0.0027579619,0.000067429355,0.0003342464,0.000045206332,0.0000061466917,0.00034337188,0.0000037073166,0.0014350851],"genre_scores_gemma":[0.99890316,0.00043588618,0.000026315967,0.000074113326,0.00004164504,0.0000038274,0.0002781924,0.000002441048,0.00023431714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930227,0.00020842443,0.00007642743,0.00010761778,0.00010197893,0.00020324903],"domain_scores_gemma":[0.99757797,0.00067101204,0.0010636802,0.00008653313,0.0001514274,0.0004494714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006800833,0.00013235738,0.00042881037,0.00029750174,0.00030466352,0.0008433986,0.00024484668,0.00037196797,0.0018476326],"category_scores_gemma":[0.0046433113,0.000071474475,0.0013028075,0.00065494684,0.00028419288,0.000579253,0.0005745312,0.0008978162,0.000115418596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065258527,0.00041832103,0.9682985,0.00014396911,0.001060756,0.00016932124,0.000141421,0.0003943311,0.00039176608,0.00014647035,0.00062030274,0.0216889],"study_design_scores_gemma":[0.00006661771,0.0011122567,0.9968947,0.00005046497,0.00039528427,0.00012317802,0.00023453367,0.00027364749,0.00011205234,0.0001489718,0.00057774567,0.000010399644],"about_ca_topic_score_codex":0.0042251064,"about_ca_topic_score_gemma":0.0069043487,"teacher_disagreement_score":0.0042251064,"about_ca_system_score_codex":0.00079518417,"about_ca_system_score_gemma":0.00081112783,"threshold_uncertainty_score":0.008401036},"labels":[],"label_agreement":null},{"id":"W2977743112","doi":"10.1016/j.euo.2019.09.002","title":"First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis","year":2019,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Axitinib; Medicine; Oncology; Internal medicine; Renal cell carcinoma; Population; Clinical endpoint; Pembrolizumab; Adverse effect; Progression-free survival; Clinical trial; Meta-analysis; Atezolizumab; Avelumab; Cancer; Overall survival; Immunotherapy; Sunitinib","score_opus":0.1707180087076591,"score_gpt":0.35836265979127085,"score_spread":0.18764465108361175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977743112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003274966,0.9955935,0.00020671633,0.00009299555,0.0000972638,0.000047048685,0.00048666578,0.000011663437,0.00018915125],"genre_scores_gemma":[0.16152242,0.83464694,0.0011539648,0.0011130385,0.000177807,0.00019216338,0.0008169198,0.000024347073,0.00035254235],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9968972,0.0011882466,0.00087777444,0.0005178973,0.00037041478,0.0001484303],"domain_scores_gemma":[0.99518025,0.0031362802,0.0010840825,0.00016838993,0.00032146194,0.000109535606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034015325,0.0014971786,0.010011146,0.003001462,0.0003940999,0.0015973306,0.0015016097,0.0015367072,0.0044018114],"category_scores_gemma":[0.009747333,0.00091366656,0.020906135,0.0047514937,0.0004727485,0.0012819506,0.0011456793,0.0018397332,0.00033337538],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023375358,0.00004561465,0.008208187,0.41211691,0.5561857,0.00011799855,0.000090397756,0.0006270891,0.00029161418,0.0001553682,0.0015644744,0.018259048],"study_design_scores_gemma":[0.0010162222,0.0002427197,0.008953397,0.02655651,0.95892614,0.0001360488,0.00006401942,0.00017004041,0.00010400499,0.00022013615,0.0035734812,0.000037226462],"about_ca_topic_score_codex":0.009371832,"about_ca_topic_score_gemma":0.03126871,"teacher_disagreement_score":0.010011146,"about_ca_system_score_codex":0.0017192813,"about_ca_system_score_gemma":0.0018644407,"threshold_uncertainty_score":0.018634558},"labels":[],"label_agreement":null},{"id":"W2979377184","doi":"10.1016/j.euo.2019.09.003","title":"What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review","year":2019,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Oncology; Internal medicine; Cancer; Clinical trial; Meta-analysis","score_opus":0.09390410564921418,"score_gpt":0.384706383792036,"score_spread":0.2908022781428218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979377184","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010508692,0.99783665,0.0000970107,0.00024076416,0.00010332183,0.000057733767,0.00043764157,0.000004439739,0.00017172721],"genre_scores_gemma":[0.0286518,0.9688122,0.00058917276,0.0010056873,0.00015823652,0.0001365641,0.0004714445,0.0000060152006,0.00016887265],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9979881,0.00063112745,0.0007232669,0.0002512576,0.0003128085,0.00009354687],"domain_scores_gemma":[0.9913693,0.0061143767,0.0015208634,0.00014911492,0.00070835935,0.00013799244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004364725,0.0008516951,0.0060736723,0.0026027197,0.00029545077,0.0015758835,0.0014067274,0.0016429769,0.0027040914],"category_scores_gemma":[0.017995898,0.00091723696,0.011372067,0.0029490888,0.00054343004,0.001366004,0.0011373861,0.0015282079,0.00034567807],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009981714,0.00003163701,0.011594455,0.77504456,0.12155528,0.000106125495,0.00022876113,0.00025544374,0.00029268843,0.00041967764,0.005669408,0.08380379],"study_design_scores_gemma":[0.001048654,0.0002479767,0.027984928,0.35896066,0.5822127,0.00032054845,0.0002345433,0.00021757158,0.00016893535,0.0009034429,0.027605342,0.00009478973],"about_ca_topic_score_codex":0.011586834,"about_ca_topic_score_gemma":0.041921724,"teacher_disagreement_score":0.011586834,"about_ca_system_score_codex":0.0014073424,"about_ca_system_score_gemma":0.0042573675,"threshold_uncertainty_score":0.02308315},"labels":[],"label_agreement":null},{"id":"W2980122297","doi":"10.1016/j.euo.2019.08.003","title":"Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Henry M. Jackson Foundation; Brigham Research Institute; Prostate Cancer Foundation","keywords":"Medicine; Androgen deprivation therapy; Dementia; Hazard ratio; Prostate cancer; Proportional hazards model; Depression (economics); Internal medicine; Cohort; Neurocognitive; Cohort study; Oncology; Cancer; Psychiatry; Confidence interval; Cognition","score_opus":0.012978189361594637,"score_gpt":0.2588309837939002,"score_spread":0.24585279443230554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980122297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980642,0.001371164,0.000022713772,0.00004371427,0.000015822328,0.0000059746535,0.00014253969,0.0000015414316,0.00033232904],"genre_scores_gemma":[0.9991743,0.0004320812,0.000016559621,0.00004070391,0.000022905757,0.0000037521575,0.00013838925,4.87999e-7,0.00017083887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996593,0.00010656518,0.000049002945,0.000050106395,0.00005648898,0.0000785268],"domain_scores_gemma":[0.999253,0.00013981112,0.00026484774,0.00003517596,0.000046387657,0.00026090659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005179501,0.0003209977,0.0006308113,0.000977934,0.00056733785,0.0010719396,0.00029004746,0.0006457105,0.0011846534],"category_scores_gemma":[0.0018145838,0.00048255804,0.0015724765,0.0011750001,0.00026590965,0.0005655998,0.0005250488,0.0007139661,0.000113792914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009903134,0.00015955092,0.99653614,0.000028451883,0.0004932623,0.00015219476,0.00012990042,0.000024266474,0.000121309924,0.000016954193,0.0000857259,0.0012619321],"study_design_scores_gemma":[0.000036607824,0.00031158878,0.9988445,0.000009399121,0.00015790174,0.00019149017,0.00026660523,0.00004996792,0.000015935044,0.000016110216,0.000095468495,0.0000044389076],"about_ca_topic_score_codex":0.014289078,"about_ca_topic_score_gemma":0.01797343,"teacher_disagreement_score":0.014289078,"about_ca_system_score_codex":0.00040943827,"about_ca_system_score_gemma":0.00043273912,"threshold_uncertainty_score":0.028411806},"labels":[],"label_agreement":null},{"id":"W2989830802","doi":"10.1016/j.euo.2019.11.001","title":"Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; CancerCare Manitoba; Health Sciences Centre; University of Manitoba; Princess Margaret Cancer Centre; University of Calgary","funders":"Instituto de Salud Carlos III; Genentech; Eisai; American Psychosocial Oncology Society; Exelixis; North Carolina GlaxoSmithKline Foundation; EMD Serono; Novartis; Merck; F. Hoffmann-La Roche; Roche; Astellas Pharma US; Health Research Fund of Central Denmark Region; Dana-Farber Cancer Institute; Pfizer; Ipsen Biopharmaceuticals; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine; Nivolumab; Immunotherapy; Cancer","score_opus":0.010604879800889895,"score_gpt":0.23012148977798388,"score_spread":0.219516609977094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989830802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980683,0.0006253558,0.00006996443,0.00009291075,0.000010042622,0.000017289029,0.00079101854,0.0000025724669,0.0003227083],"genre_scores_gemma":[0.998536,0.00013752369,0.000040154257,0.00003348544,0.000018467885,0.000017066666,0.0011444984,0.0000010672618,0.00007183053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925953,0.00017397817,0.00008865603,0.00015755797,0.00016077557,0.00015943497],"domain_scores_gemma":[0.99630415,0.00044774692,0.0025067893,0.00010813972,0.00023722241,0.00039600822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001245648,0.00019038773,0.0005306208,0.0004418565,0.00041010074,0.0005943791,0.00036651967,0.00037964236,0.0009560571],"category_scores_gemma":[0.0033963171,0.00014413308,0.0009634413,0.00086443144,0.00019463748,0.00046118913,0.00039675445,0.00070908497,0.000112920825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064298615,0.00008844286,0.9968748,0.000021730542,0.0001016607,0.000079307865,0.00003013634,0.00018669682,0.00008813763,0.000015130124,0.00014168877,0.001729165],"study_design_scores_gemma":[0.000084491345,0.000800977,0.9974598,0.000021446,0.00013629872,0.0003829874,0.00007964577,0.0004685028,0.00010797655,0.000050541657,0.00039938014,0.000007861273],"about_ca_topic_score_codex":0.0029148646,"about_ca_topic_score_gemma":0.003355572,"teacher_disagreement_score":0.0029148646,"about_ca_system_score_codex":0.0009175434,"about_ca_system_score_gemma":0.0007424626,"threshold_uncertainty_score":0.006657243},"labels":[],"label_agreement":null},{"id":"W2995340453","doi":"10.1016/j.euo.2019.11.005","title":"The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel","year":2019,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Lymphadenectomy; MEDLINE; Meta-analysis; Cochrane Library; Systematic review; Cancer; Surgery; Urology; Internal medicine","score_opus":0.04368535579554485,"score_gpt":0.3663460669193838,"score_spread":0.322660711123839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995340453","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00097135146,0.9964765,0.00016054965,0.00059162447,0.00018613432,0.00011798651,0.0012811082,0.0000089188,0.00020585395],"genre_scores_gemma":[0.02228844,0.97310984,0.001136104,0.0019343584,0.00016615895,0.0002659016,0.0008915457,0.0000149871275,0.00019272497],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9953981,0.0012295375,0.002016302,0.000491738,0.0006925009,0.00017186275],"domain_scores_gemma":[0.98603684,0.009330805,0.0029285108,0.00023214631,0.0012654619,0.0002061761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008095066,0.0011413639,0.0073209726,0.004980634,0.00038070604,0.0022079851,0.0018081393,0.0017043039,0.0030654708],"category_scores_gemma":[0.024004493,0.00094832166,0.015965458,0.005332165,0.00077078113,0.0014659348,0.0017567371,0.001886216,0.0003596019],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056063256,0.000025682271,0.007864923,0.84637994,0.07694925,0.000088367095,0.0002275014,0.0002458676,0.00021422039,0.0005016643,0.0075450316,0.05939693],"study_design_scores_gemma":[0.0006984995,0.00015969634,0.023565887,0.49034095,0.45179844,0.00024437744,0.00028168678,0.00019530648,0.00021315346,0.0008872632,0.03150973,0.000104958686],"about_ca_topic_score_codex":0.021739382,"about_ca_topic_score_gemma":0.06965989,"teacher_disagreement_score":0.021739382,"about_ca_system_score_codex":0.0022597935,"about_ca_system_score_gemma":0.007763724,"threshold_uncertainty_score":0.043225706},"labels":[],"label_agreement":null},{"id":"W3004436801","doi":"10.1016/j.euo.2020.01.001","title":"Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Ipsen Biopharmaceuticals; Sanofi; Health Research Fund of Central Denmark Region; AstraZeneca; National Health and Medical Research Council; Amgen; Pfizer; Health Research Foundation; Roche","keywords":"Medicine; Renal cell carcinoma; Metastasis; Oncology; Disease; Internal medicine; Outcome (game theory); Cancer","score_opus":0.05860378922905161,"score_gpt":0.3120376677610792,"score_spread":0.2534338785320276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004436801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807097,0.0014163576,0.00014927646,0.00015800394,0.000011576622,0.000056838355,0.016426032,0.0000081844455,0.0010639665],"genre_scores_gemma":[0.98777264,0.0002252992,0.00011547745,0.000053285767,0.000012511687,0.000051287006,0.011670682,0.000005834133,0.00009307678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971027,0.0009844212,0.00043657352,0.00047880184,0.00076607266,0.00023137692],"domain_scores_gemma":[0.9920293,0.002188807,0.0035878222,0.00047114663,0.0008951128,0.00082771137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041442476,0.00023789596,0.0006718155,0.0015340144,0.00030251304,0.0009253073,0.0006442257,0.00036287762,0.0011644779],"category_scores_gemma":[0.008083696,0.00008993334,0.0009802833,0.0032551729,0.00021261594,0.0006026682,0.0011555249,0.0003762046,0.0002247442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080144353,0.00002930861,0.9959585,0.00006332924,0.00031421325,0.000022355005,0.000044630964,0.00017459953,0.000045561734,0.000017857195,0.0004959592,0.002032248],"study_design_scores_gemma":[0.000050448012,0.00014962612,0.99830806,0.000026270634,0.0001950577,0.000126787,0.00013042112,0.0003867124,0.000072764466,0.000019474424,0.00052732974,0.000007103391],"about_ca_topic_score_codex":0.01578216,"about_ca_topic_score_gemma":0.02068302,"teacher_disagreement_score":0.01578216,"about_ca_system_score_codex":0.0009082395,"about_ca_system_score_gemma":0.0006977644,"threshold_uncertainty_score":0.031380594},"labels":[],"label_agreement":null},{"id":"W3012125381","doi":"10.1016/j.euo.2020.02.006","title":"Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non–muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University Health Centre","funders":"Ferring Pharmaceuticals","keywords":"Medicine; Bladder cancer; Meta-analysis; Cystectomy; Randomized controlled trial; Subgroup analysis; Cochrane Library; Internal medicine; Systematic review; Population; Oncology; MEDLINE; Clinical trial; Confidence interval; Carcinoma in situ; Cancer","score_opus":0.18456111749564127,"score_gpt":0.42578762561179667,"score_spread":0.2412265081161554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012125381","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029296216,0.99611276,0.00025510453,0.000082707214,0.00006888167,0.000105704254,0.00027961776,0.000010460871,0.0001550951],"genre_scores_gemma":[0.07490004,0.92209065,0.0013103998,0.00065907603,0.000101752776,0.00020752853,0.00048790447,0.000013899992,0.00022881999],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99696296,0.0010312524,0.0010392732,0.00040952727,0.000416889,0.00014002854],"domain_scores_gemma":[0.9947515,0.0035286627,0.0011456732,0.00013045268,0.00034329,0.0001004588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005957628,0.00214359,0.014354406,0.0034554393,0.0004168925,0.0024497653,0.0018622404,0.0017949885,0.0040994054],"category_scores_gemma":[0.012376799,0.0010516399,0.023252586,0.0045028343,0.0006478587,0.0017788894,0.0014273816,0.0018301177,0.00029849127],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026438995,0.00005427266,0.00228971,0.57409585,0.3885099,0.00009354448,0.000095283736,0.0005248893,0.00037533513,0.00015173576,0.0008110638,0.03035453],"study_design_scores_gemma":[0.0010454346,0.00028268129,0.0036596172,0.037497472,0.953948,0.00010197588,0.00006783871,0.0001449823,0.0001257446,0.00020380739,0.0028911384,0.000031208263],"about_ca_topic_score_codex":0.005540467,"about_ca_topic_score_gemma":0.019422667,"teacher_disagreement_score":0.014354406,"about_ca_system_score_codex":0.001609728,"about_ca_system_score_gemma":0.0023410276,"threshold_uncertainty_score":0.031507373},"labels":[],"label_agreement":null},{"id":"W3012478583","doi":"10.1016/j.euo.2020.02.010","title":"Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada); University of British Columbia","funders":"BC Cancer Agency; Decipher Biosciences","keywords":"Bladder cancer; Basal (medicine); Medicine; Cancer; Transcriptome; Subtyping; Internal medicine; Hormone; Androgen; Oncology; Physiology; Biology; Gene; Gene expression","score_opus":0.024928849280036216,"score_gpt":0.2774925359515167,"score_spread":0.2525636866714805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012478583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99114406,0.0032887363,0.00055095716,0.00029917082,0.00004625822,0.000011592614,0.0011391911,0.000025784075,0.003494194],"genre_scores_gemma":[0.99598074,0.00082387164,0.00018093277,0.00014021018,0.000031282823,0.000008792209,0.0007726262,0.000039273018,0.002022374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995334,0.000067986046,0.00003274673,0.00015651941,0.000060186536,0.0001491095],"domain_scores_gemma":[0.99940276,0.00012140055,0.00023315074,0.00004954701,0.000091831644,0.00010127747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035777997,0.00019468168,0.00031417547,0.0007888554,0.00030535914,0.00081754284,0.0003310191,0.00033528171,0.007187422],"category_scores_gemma":[0.001380471,0.00016834684,0.0004946174,0.0007156824,0.00026105737,0.00034780803,0.00047689144,0.0004538385,0.0011039191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014501628,0.00006437514,0.91957945,0.00012577287,0.0004192917,0.0003451115,0.0004962963,0.0001781378,0.035908952,0.00075426674,0.001176028,0.039502215],"study_design_scores_gemma":[0.000009934783,0.000109105116,0.99448377,0.00002348059,0.000064599684,0.00077198294,0.00033694014,0.0001424816,0.001180294,0.00041801855,0.0024501628,0.000009249661],"about_ca_topic_score_codex":0.0011956459,"about_ca_topic_score_gemma":0.0020741117,"teacher_disagreement_score":0.007187422,"about_ca_system_score_codex":0.00024341333,"about_ca_system_score_gemma":0.00024447788,"threshold_uncertainty_score":0.024044335},"labels":[],"label_agreement":null},{"id":"W3017283363","doi":"10.1016/j.euo.2020.03.002","title":"Intermediate-risk Prostate Cancer: Stratification and Management","year":2020,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Université de Montréal; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Radiation therapy; Cohort; Androgen deprivation therapy; Cancer; Intensive care medicine; Oncology; Internal medicine","score_opus":0.035243128424543364,"score_gpt":0.3445443246397805,"score_spread":0.30930119621523716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017283363","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000048914193,0.9990877,0.00004711153,0.00035435407,0.0001514005,0.000004506468,0.000030056177,0.0000035337926,0.00027236575],"genre_scores_gemma":[0.00066139374,0.99841166,0.000114175156,0.0004078465,0.0002174026,0.0000057705065,0.000047859005,9.93102e-7,0.00013300218],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994649,0.00014271605,0.000119364086,0.00009072172,0.0001396514,0.000042647604],"domain_scores_gemma":[0.9987878,0.00063883676,0.0002874294,0.000021322885,0.00019884243,0.00006578318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013337668,0.0011770059,0.0025316132,0.0031047564,0.00023401507,0.0014841662,0.0010556625,0.001109018,0.004271638],"category_scores_gemma":[0.0031450326,0.000390672,0.0013928032,0.0032090324,0.0005256467,0.0012308857,0.0009683703,0.0018406598,0.0009276275],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013465657,0.000046683464,0.00064888375,0.04279485,0.00056467846,0.000041315336,0.000041466363,0.0005756859,0.0001480954,0.0014632844,0.031464197,0.9220762],"study_design_scores_gemma":[0.00018418596,0.0003070728,0.006137639,0.091399595,0.0045092404,0.00084702764,0.0001922199,0.00047640034,0.00019362241,0.0037290247,0.89193696,0.00008701574],"about_ca_topic_score_codex":0.0059729926,"about_ca_topic_score_gemma":0.016335567,"teacher_disagreement_score":0.0059729926,"about_ca_system_score_codex":0.0014783329,"about_ca_system_score_gemma":0.0038313223,"threshold_uncertainty_score":0.014290035},"labels":[],"label_agreement":null},{"id":"W3025062498","doi":"10.1016/j.euo.2020.04.005","title":"Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"Associazione Italiana per la Ricerca sul Cancro; Merck","keywords":"Fibroblast growth factor receptor 3; Bladder cancer; Medicine; Fibroblast growth factor receptor 4; Cancer research; Oncology; Pathological; Fibroblast growth factor receptor 2; Fibroblast growth factor receptor; Cancer; Internal medicine; Biology; Receptor; Fibroblast growth factor","score_opus":0.03695168064423887,"score_gpt":0.29507588222711273,"score_spread":0.25812420158287386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025062498","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45435786,0.48489007,0.0034641416,0.021465568,0.0015423563,0.0002490399,0.018260917,0.000098142904,0.015671873],"genre_scores_gemma":[0.8584039,0.101361245,0.0035406356,0.011883487,0.0014089089,0.00021153665,0.021934653,0.00008945672,0.0011661088],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99851185,0.00043096166,0.00033806995,0.00019469122,0.00039592094,0.00012851],"domain_scores_gemma":[0.9962115,0.0016259928,0.0009745621,0.00021760211,0.0007579477,0.00021246853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004240699,0.0003295653,0.0015724922,0.00062727864,0.00025365144,0.0015048769,0.0006692867,0.00059583224,0.0011518537],"category_scores_gemma":[0.006479002,0.00026100734,0.0018031294,0.0018273661,0.00026607042,0.0018561453,0.00067449064,0.0011025602,0.0003069724],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077182436,0.00011945536,0.42448524,0.00659777,0.008580944,0.0004648479,0.00035663633,0.0016731883,0.0021149945,0.0010229595,0.026293091,0.52057254],"study_design_scores_gemma":[0.00092664815,0.00086154684,0.872702,0.004360404,0.017507527,0.0015148328,0.0009185849,0.0010613085,0.00076171017,0.0019056936,0.09735716,0.00012254038],"about_ca_topic_score_codex":0.0030255988,"about_ca_topic_score_gemma":0.011835976,"teacher_disagreement_score":0.004240699,"about_ca_system_score_codex":0.00070680864,"about_ca_system_score_gemma":0.0014029111,"threshold_uncertainty_score":0.02242726},"labels":[],"label_agreement":null},{"id":"W3034070398","doi":"10.1016/j.euo.2020.05.008","title":"Pearls to Pivoting a Multidisciplinary Prostate Cancer Survivorship Program During the COVID-19 Pandemic","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; University of British Columbia","funders":"","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Pandemic; 2019-20 coronavirus outbreak; Multidisciplinary approach; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Survivorship curve; Prostate cancer; Betacoronavirus; Cancer; Intensive care medicine; Medical physics; Oncology; Internal medicine; Virology; Disease; Infectious disease (medical specialty)","score_opus":0.1582575525331245,"score_gpt":0.44981029469922473,"score_spread":0.2915527421661002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034070398","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037972394,0.003940753,0.0017203736,0.9605767,0.016156685,0.00013753379,0.0001569173,0.00015085006,0.013362956],"genre_scores_gemma":[0.16830707,0.01375634,0.022900585,0.7612316,0.019924242,0.0007032593,0.00061930576,0.00039423324,0.012163383],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.96525574,0.017869275,0.0016956175,0.0014873547,0.0056556975,0.008036374],"domain_scores_gemma":[0.9188222,0.010877884,0.0031522838,0.002806349,0.011864898,0.05247632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.034550037,0.0010454899,0.0010071391,0.0019240351,0.010102582,0.016735222,0.00408408,0.014305496,0.030190216],"category_scores_gemma":[0.08095118,0.0007817161,0.0019411028,0.0010917411,0.007613467,0.010122028,0.020168185,0.027263448,0.0044025118],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035694602,0.0010447355,0.010630324,0.00092362333,0.00024181238,0.0011237768,0.0042551043,0.0018451426,0.0006048536,0.05208614,0.74807835,0.17880906],"study_design_scores_gemma":[0.00028353333,0.00093711505,0.017011402,0.009514437,0.00015761092,0.0006451905,0.02694932,0.0009727584,0.0006665502,0.0719586,0.8705813,0.0003221579],"about_ca_topic_score_codex":0.019905124,"about_ca_topic_score_gemma":0.06000299,"teacher_disagreement_score":0.034550037,"about_ca_system_score_codex":0.011035453,"about_ca_system_score_gemma":0.09335111,"threshold_uncertainty_score":0.18272024},"labels":[],"label_agreement":null},{"id":"W3034688971","doi":"10.1016/j.euo.2020.05.006","title":"Key Perspectives on Managing Older Patients with Prostate Cancer: What We Know About the Fit and What We Need to Know About the Frail","year":2020,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Need to know; Key (lock); Prostate cancer; Cancer; Intensive care medicine; Internal medicine; Computer science; Computer security","score_opus":0.019628359395526648,"score_gpt":0.294576433477559,"score_spread":0.27494807408203237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034688971","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016920768,0.0016778078,0.000037510035,0.98880005,0.008511092,0.0000031612246,0.000006190994,0.0000042766264,0.00079068873],"genre_scores_gemma":[0.0025525454,0.0024631694,0.00019527091,0.9637296,0.029298576,0.000020850739,0.000010548034,0.000011476271,0.0017178796],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99027586,0.0038554664,0.0013544825,0.00074620656,0.0021177884,0.0016501431],"domain_scores_gemma":[0.9516001,0.020894341,0.0029645443,0.0009111032,0.006825644,0.016804293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009073227,0.0009270038,0.0024381878,0.0009324734,0.010227361,0.007992591,0.0024957305,0.06648934,0.011386261],"category_scores_gemma":[0.05191226,0.0010717947,0.0017260688,0.0011123213,0.008338222,0.0155706685,0.0065722987,0.08131449,0.003994469],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042389544,0.00008160348,0.0017551372,0.00019183506,0.000028335475,0.0035178033,0.0012195418,0.00007419325,0.00013439725,0.0036887028,0.9711546,0.0181115],"study_design_scores_gemma":[0.0001261765,0.00013784741,0.0017480949,0.0022647197,0.000050208793,0.008094163,0.007633279,0.00028086727,0.00007880855,0.019420074,0.9599828,0.0001829621],"about_ca_topic_score_codex":0.009064562,"about_ca_topic_score_gemma":0.019857146,"teacher_disagreement_score":0.06648934,"about_ca_system_score_codex":0.0066656847,"about_ca_system_score_gemma":0.014043759,"threshold_uncertainty_score":0.04836321},"labels":[],"label_agreement":null},{"id":"W3035162230","doi":"10.1016/j.euo.2020.05.001","title":"Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"National Institutes of Health; National Cancer Institute; Prostate Cancer Foundation","keywords":"Medicine; Prostatectomy; Prostate cancer; Oncology; Internal medicine; Somatic cell; Prostate; Cancer; Urology; Gene","score_opus":0.01715925271617926,"score_gpt":0.29760320811789287,"score_spread":0.28044395540171363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035162230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999361,0.00024938182,0.00007521711,0.00002752914,0.0000021561032,0.0000034167851,0.00014381848,0.0000048700654,0.00013257004],"genre_scores_gemma":[0.9997441,0.000043480828,0.000035123074,0.000007608875,0.0000033917022,0.00000211113,0.00011568776,7.747903e-7,0.00004778323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99983144,0.000040564686,0.000010756818,0.0000534134,0.000038269907,0.000025617766],"domain_scores_gemma":[0.9993438,0.000114277835,0.00033461003,0.000042996406,0.000049972634,0.00011438577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031043257,0.0001466403,0.00018158492,0.0003164052,0.000257321,0.00030696217,0.00024439098,0.00021982717,0.0012690164],"category_scores_gemma":[0.001187522,0.00013959933,0.00023416997,0.0004524836,0.00023178296,0.00012934425,0.00029037753,0.00037323142,0.00012280601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011890636,0.000009264116,0.99768245,0.0000080845975,0.000032457934,0.00005545693,0.000027340377,0.000055986893,0.00061164395,0.000009541305,0.00008996295,0.0012989728],"study_design_scores_gemma":[0.000002940115,0.000035415535,0.9994611,0.0000020271293,0.000022528493,0.00018605267,0.000030439365,0.000107251144,0.00007646379,0.000012467035,0.00006225023,0.0000011481607],"about_ca_topic_score_codex":0.003622663,"about_ca_topic_score_gemma":0.005309981,"teacher_disagreement_score":0.003622663,"about_ca_system_score_codex":0.00018567682,"about_ca_system_score_gemma":0.0002196097,"threshold_uncertainty_score":0.007203102},"labels":[],"label_agreement":null},{"id":"W3037625979","doi":"10.1016/j.euo.2020.06.005","title":"Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Movember Foundation","keywords":"Prostate cancer; Prostatectomy; Medicine; Biochemical recurrence; Biomarker; Oncology; Precision medicine; Prostate; Disease; Internal medicine; Prospective cohort study; Radiation therapy; Localized disease; Spatial heterogeneity; Cancer; Pathology; Biology; Genetics","score_opus":0.04332919131118951,"score_gpt":0.34275509482311817,"score_spread":0.29942590351192866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037625979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99035734,0.0023893218,0.004571495,0.0004945233,0.000036894675,0.000011993926,0.0006055471,0.00004145395,0.0014913542],"genre_scores_gemma":[0.99892175,0.00013257586,0.0005308231,0.00004492374,0.000023454317,0.0000044615163,0.0002005319,0.000009560266,0.00013197491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846053,0.00066692213,0.00009669826,0.00032871278,0.00025588265,0.00019131819],"domain_scores_gemma":[0.99368626,0.0038621547,0.0011082024,0.00071229774,0.0004460988,0.00018500027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002290062,0.00035756925,0.00055559643,0.0012468303,0.00048792918,0.0016365998,0.00053827517,0.00056518544,0.0019710436],"category_scores_gemma":[0.013212846,0.0002657046,0.00061465794,0.0014627506,0.0007197765,0.0010293978,0.00092873204,0.00045074872,0.000311764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012276671,0.00005276219,0.9405099,0.00009882115,0.00073975447,0.00022018931,0.00016182056,0.008339046,0.008480477,0.00082977733,0.00055628264,0.03878356],"study_design_scores_gemma":[0.00006316611,0.00035278735,0.95886725,0.0000436345,0.0009159749,0.00097468816,0.00067702006,0.023886353,0.006596988,0.0048299427,0.0027452647,0.00004699952],"about_ca_topic_score_codex":0.005062193,"about_ca_topic_score_gemma":0.0068031773,"teacher_disagreement_score":0.005062193,"about_ca_system_score_codex":0.0005765898,"about_ca_system_score_gemma":0.0005002288,"threshold_uncertainty_score":0.012111127},"labels":[],"label_agreement":null},{"id":"W3041182614","doi":"10.1016/j.euo.2020.06.002","title":"Learning from Our Past Mistakes: A Call for Randomized Controlled Trials in Localized Renal Cell Carcinoma","year":2020,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Renal cell carcinoma; Randomized controlled trial; Carcinoma; MEDLINE; Oncology; Internal medicine","score_opus":0.05152276207536935,"score_gpt":0.29299089704263576,"score_spread":0.2414681349672664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041182614","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00055328675,0.019454893,0.0007016855,0.94307065,0.0340327,0.00017301591,0.00019065505,0.00008509806,0.0017379682],"genre_scores_gemma":[0.0067112832,0.0044116857,0.0028709276,0.9399927,0.044341784,0.00048104368,0.00008574096,0.000061832856,0.0010429685],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.88774705,0.086376935,0.010581721,0.0040094373,0.009245331,0.0020395154],"domain_scores_gemma":[0.50012094,0.44109955,0.019286675,0.00849425,0.015408554,0.015590088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.098836705,0.001365608,0.0078012007,0.0018160421,0.0036138576,0.008705634,0.0052949637,0.060657017,0.009199629],"category_scores_gemma":[0.29355815,0.0014008938,0.0059729503,0.002024944,0.0072834417,0.009302579,0.003184248,0.052439895,0.003886344],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075404816,0.00029719167,0.0010362735,0.0035337901,0.0019646243,0.00070195325,0.00026579972,0.00044009864,0.00054419425,0.01048172,0.88911116,0.084082805],"study_design_scores_gemma":[0.05053915,0.0027579402,0.003316726,0.014625586,0.0030705798,0.0011016448,0.00060982205,0.0028817866,0.00062803243,0.10019716,0.8198204,0.00045112937],"about_ca_topic_score_codex":0.0033471705,"about_ca_topic_score_gemma":0.00903238,"teacher_disagreement_score":0.098836705,"about_ca_system_score_codex":0.007365101,"about_ca_system_score_gemma":0.0124937575,"threshold_uncertainty_score":0.5227047},"labels":[],"label_agreement":null},{"id":"W3047382221","doi":"10.1016/j.euo.2020.07.002","title":"Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cabazitaxel; Prostate cancer; Enzalutamide; Taxane; Urology; Docetaxel; Adverse effect; Prostate-specific antigen; Internal medicine; Oncology; Cancer; Surgery; Androgen deprivation therapy; Breast cancer; Androgen receptor","score_opus":0.0444505241222058,"score_gpt":0.33219623933308134,"score_spread":0.28774571521087555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047382221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927786,0.0018938177,0.0004588114,0.00047481706,0.00019525815,0.0009145943,0.00063782785,0.00016380922,0.0024825202],"genre_scores_gemma":[0.9900227,0.0014352122,0.0009190519,0.00060191035,0.0001364982,0.00081193255,0.0015586957,0.00002613744,0.0044878344],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998416,0.000057591547,0.000004223036,0.000030260204,0.000009303264,0.000057120156],"domain_scores_gemma":[0.9997595,0.00002575933,0.00003218188,0.000017058579,0.000007415242,0.0001581278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061482604,0.0012970491,0.0013226105,0.0003083751,0.00032452465,0.0007586072,0.0007190504,0.00088102004,0.004187128],"category_scores_gemma":[0.00033296214,0.0004198486,0.0009866214,0.00024827814,0.0008529458,0.0005326236,0.00031968203,0.0019758586,0.000828022],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8523171,0.043421097,0.0028763078,0.00047049284,0.00088014046,0.00020367028,0.00017948453,0.0021333492,0.026463022,0.0004980195,0.0035261093,0.06703131],"study_design_scores_gemma":[0.69406265,0.29341063,0.006011992,0.000020639889,0.0003198243,0.00018454487,0.00006570199,0.0010305011,0.0024660346,0.0002440152,0.0021580113,0.000025450281],"about_ca_topic_score_codex":0.0017046682,"about_ca_topic_score_gemma":0.0034936606,"teacher_disagreement_score":0.004187128,"about_ca_system_score_codex":0.0006956911,"about_ca_system_score_gemma":0.0009926708,"threshold_uncertainty_score":0.01400739},"labels":[],"label_agreement":null},{"id":"W3083033920","doi":"10.1016/j.euo.2020.08.007","title":"Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Chemotherapy; Internal medicine; Oncology; Germ cell tumors; Cumulative incidence; Testicular cancer; Regimen; Cancer; Chemotherapy regimen; Retrospective cohort study; Surgery; Cohort","score_opus":0.020159717392734144,"score_gpt":0.2737333821340344,"score_spread":0.2535736647413003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083033920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970294,0.0016243608,0.00015206519,0.0001412085,0.00001894433,0.000013713067,0.00021982442,0.000009910139,0.0007905415],"genre_scores_gemma":[0.99876213,0.00025723755,0.0001083287,0.00007483492,0.000029146904,0.000009107417,0.0005118652,0.000002464782,0.0002448712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997795,0.000051259583,0.000027965196,0.000038884005,0.00004549757,0.000056840567],"domain_scores_gemma":[0.99901557,0.0002486484,0.00033227995,0.000056850786,0.00011493783,0.00023169506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057188096,0.0001403655,0.00042545528,0.0005397211,0.000362787,0.00045498527,0.0002521449,0.00042395366,0.00055062317],"category_scores_gemma":[0.001671238,0.00008114008,0.00035525093,0.0004573715,0.00015562818,0.0004238177,0.00026658966,0.00040491836,0.00011629134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014506289,0.00014291315,0.9690355,0.00004109909,0.00006290173,0.0011793209,0.0001584923,0.00014509588,0.0021479675,0.000021755097,0.000384905,0.025229461],"study_design_scores_gemma":[0.000026347207,0.0013131351,0.9931023,0.000017427798,0.00009307115,0.0028777746,0.00019725027,0.000471428,0.0007233134,0.000047432888,0.0011236656,0.000007034144],"about_ca_topic_score_codex":0.0013026753,"about_ca_topic_score_gemma":0.0032096424,"teacher_disagreement_score":0.0013026753,"about_ca_system_score_codex":0.0002807723,"about_ca_system_score_gemma":0.00033894728,"threshold_uncertainty_score":0.0030243993},"labels":[],"label_agreement":null},{"id":"W3084968377","doi":"10.1016/j.euo.2020.08.010","title":"Hospital-level Effects Contribute to Variations in Prostate Cancer Quality of Care","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Health Sciences Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Benchmarking; Medicine; Case mix index; Prostate cancer; Standardization; Quality (philosophy); Cancer; Health care; Emergency medicine; Intensive care medicine; Internal medicine; Nursing","score_opus":0.07394108093913258,"score_gpt":0.3823975231627333,"score_spread":0.3084564422236007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084968377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858766,0.001619385,0.0033105132,0.0018079617,0.00017731938,0.000054911652,0.0022854623,0.000060580907,0.0048072394],"genre_scores_gemma":[0.99844825,0.00006992388,0.0002615192,0.00021082748,0.00003349853,0.000008819751,0.00047936157,0.000026237816,0.0004615258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.987668,0.005900624,0.0011427788,0.0018019543,0.0012355489,0.0022510642],"domain_scores_gemma":[0.95722264,0.022283094,0.009158373,0.0048653116,0.0027155569,0.0037550742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005195282,0.00032499185,0.0007499548,0.0013263463,0.000883577,0.0023648895,0.0014278615,0.0010635366,0.008255287],"category_scores_gemma":[0.02420858,0.00045701218,0.0022579816,0.0035536198,0.0007840273,0.0008616959,0.0018692939,0.0012915166,0.00048284908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011180722,0.000052318654,0.9942683,0.000027094042,0.0007943213,0.000053439402,0.00018349022,0.00061748846,0.00013502457,0.00028326895,0.0004070163,0.0030664555],"study_design_scores_gemma":[0.000004111702,0.000027399756,0.99876475,0.000010161848,0.0000746767,0.000031087515,0.00020599598,0.0003440935,0.00005771807,0.00020162422,0.00026992426,0.000008435547],"about_ca_topic_score_codex":0.04605888,"about_ca_topic_score_gemma":0.07035447,"teacher_disagreement_score":0.04605888,"about_ca_system_score_codex":0.002496001,"about_ca_system_score_gemma":0.002412834,"threshold_uncertainty_score":0.09158158},"labels":[],"label_agreement":null},{"id":"W3088737306","doi":"10.1016/j.euo.2020.08.013","title":"Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment","year":2020,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Queen's University","funders":"Ontario Ministry of Research, Innovation and Science; Queen's University","keywords":"Medicine; Bladder cancer; Immunotherapy; Context (archaeology); Immune system; Oncology; Cancer; Incidence (geometry); Clinical trial; Internal medicine; Bioinformatics; Immunology; Biology","score_opus":0.07633012349854808,"score_gpt":0.4030424398314802,"score_spread":0.32671231633293213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088737306","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000061496954,0.9996518,0.000017052642,0.00011557079,0.000057281402,0.0000033199597,0.00002897545,0.000001023421,0.000063496525],"genre_scores_gemma":[0.00065501634,0.9989542,0.000059817976,0.0001954244,0.00005994315,0.0000063252933,0.000028074704,5.020656e-7,0.00004071346],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994081,0.00017001247,0.00015245125,0.00010686526,0.00011996349,0.000042523796],"domain_scores_gemma":[0.99789053,0.0014645094,0.0003403299,0.000031510284,0.00021480926,0.000058256628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019218142,0.0006879419,0.00285014,0.0021224087,0.00020701182,0.0013046545,0.0009935853,0.0011106827,0.0037288088],"category_scores_gemma":[0.0039848145,0.0003355716,0.002297302,0.0029159896,0.000344464,0.00092796126,0.00088799145,0.0012512744,0.00041240145],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004294981,0.000069182744,0.0015064806,0.23381408,0.0046267016,0.00013189141,0.00013428512,0.0004537624,0.00040903105,0.001588053,0.025069714,0.73176724],"study_design_scores_gemma":[0.0005123955,0.0005782344,0.013159443,0.21891981,0.031035585,0.001407399,0.0004120067,0.0003160934,0.00036292727,0.0028709513,0.73029494,0.00013023781],"about_ca_topic_score_codex":0.003175495,"about_ca_topic_score_gemma":0.008974587,"teacher_disagreement_score":0.0037288088,"about_ca_system_score_codex":0.00076012063,"about_ca_system_score_gemma":0.0028823072,"threshold_uncertainty_score":0.01247412},"labels":[],"label_agreement":null},{"id":"W3090235171","doi":"10.1016/j.euo.2020.09.001","title":"Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Barrie Urology Group","funders":"","keywords":"Medicine; Cystoscopy; Cytology; Bladder cancer; Urology; Urine cytology; Urine; Prostate cancer; Confidence interval; Internal medicine; Cancer; Urinary system; Pathology","score_opus":0.01914884813810823,"score_gpt":0.27980414680220383,"score_spread":0.2606552986640956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090235171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892419,0.0022771966,0.0053681247,0.00027779237,0.00007348153,0.00011580837,0.00060507853,0.00007328041,0.001967392],"genre_scores_gemma":[0.9953348,0.0002862639,0.0034145657,0.00014499555,0.00003319955,0.000061811275,0.0004780368,0.000009489577,0.00023673115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983766,0.0005005373,0.00019355286,0.00023817878,0.00061238155,0.00007877497],"domain_scores_gemma":[0.9945549,0.0027816272,0.0011200436,0.00025042857,0.0010983386,0.00019468776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026372317,0.00037097337,0.00039464954,0.000900387,0.00022648447,0.00069202244,0.0003877128,0.00047950767,0.0010461465],"category_scores_gemma":[0.00970872,0.00013560997,0.00023537224,0.0005645609,0.0004795669,0.00046267235,0.00024531918,0.00040262568,0.00055757095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001798135,0.000058690843,0.9830819,0.000056122637,0.000038641007,0.00013935838,0.00004913775,0.00018775857,0.005768001,0.000037331723,0.0002216905,0.010181677],"study_design_scores_gemma":[0.000029388179,0.0012058768,0.9708322,0.000107429136,0.00012282137,0.0026792944,0.00013560851,0.00407178,0.018607145,0.00008818964,0.0021059825,0.000014136646],"about_ca_topic_score_codex":0.0007242896,"about_ca_topic_score_gemma":0.0006348075,"teacher_disagreement_score":0.0026372317,"about_ca_system_score_codex":0.00026966215,"about_ca_system_score_gemma":0.00035666008,"threshold_uncertainty_score":0.013947189},"labels":[],"label_agreement":null},{"id":"W3111044160","doi":"10.1016/j.euo.2020.11.005","title":"Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Incidence (geometry); Proportional hazards model; Urology; Stage (stratigraphy); Epidemiology; Internal medicine; Cancer; Oncology; Biology","score_opus":0.032265003367357104,"score_gpt":0.2766939002745177,"score_spread":0.24442889690716058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111044160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664474,0.0009098781,0.00008961897,0.00007281038,0.0000071083346,0.0000032415285,0.0008978038,0.000006704463,0.0013681226],"genre_scores_gemma":[0.9988268,0.00028195628,0.000024788535,0.000014419463,0.000017520919,0.0000031427298,0.00069237425,0.0000015935818,0.00013739002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999813,0.000027524156,0.000023165421,0.00004885629,0.00004288731,0.000044627745],"domain_scores_gemma":[0.99928683,0.00015978029,0.00030663,0.000053557476,0.00008970473,0.000103514336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003667259,0.00012300056,0.00021244126,0.0008969145,0.00031275323,0.0006690864,0.0002970222,0.00040219468,0.0020410875],"category_scores_gemma":[0.001512077,0.00013136119,0.00039572868,0.0014861929,0.0003144215,0.0005527876,0.0004835307,0.0003820329,0.00023377087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014187836,0.000014088995,0.99717355,0.000008631112,0.000032924425,0.00004507249,0.00006846932,0.000106498774,0.00011818328,0.0000535439,0.00013626587,0.0021008675],"study_design_scores_gemma":[0.0000033866872,0.00003683597,0.9989421,0.0000026137993,0.000023078854,0.0002934195,0.00014141072,0.00012774882,0.000027185755,0.000041178027,0.0003584421,0.0000026534265],"about_ca_topic_score_codex":0.0037154586,"about_ca_topic_score_gemma":0.0036574285,"teacher_disagreement_score":0.0037154586,"about_ca_system_score_codex":0.00038520226,"about_ca_system_score_gemma":0.00022998688,"threshold_uncertainty_score":0.007387638},"labels":[],"label_agreement":null},{"id":"W3111713883","doi":"10.1016/j.euo.2020.11.004","title":"Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Fundação para a Ciência e a Tecnologia; Canadian Urological Oncology Group","keywords":"Medicine; Testicular cancer; Seminoma; Odds ratio; Confidence interval; Internal medicine; Oncology; Human chorionic gonadotropin; Stage (stratigraphy); Biomarker; Orchiectomy; Logistic regression; Cohort; Cancer; Chemotherapy","score_opus":0.02854266477537129,"score_gpt":0.3100855794733484,"score_spread":0.2815429146979771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111713883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99371666,0.00273289,0.00040069313,0.0003201738,0.000091247006,0.000021364114,0.00041295265,0.00004534686,0.0022586824],"genre_scores_gemma":[0.9984339,0.00027229812,0.0004586437,0.00007728464,0.000037773443,0.00001018246,0.0003394014,0.0000051242823,0.00036537106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996326,0.000105369574,0.000036389618,0.00007093243,0.00008775867,0.00006701659],"domain_scores_gemma":[0.9992705,0.00023941936,0.00017793255,0.00003436958,0.00012373268,0.00015401101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075309444,0.00040119104,0.0005109123,0.00091100176,0.00047020073,0.0011173466,0.00041722448,0.00056407304,0.0011205128],"category_scores_gemma":[0.0023661926,0.0002094453,0.00044735722,0.00066753617,0.00040828183,0.00046255355,0.00041575904,0.00065269734,0.00026112233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076447387,0.00006289824,0.98244226,0.000036938465,0.00013245505,0.00017816553,0.00008774203,0.00034386927,0.001657117,0.000074614625,0.00045733224,0.013762099],"study_design_scores_gemma":[0.000050738156,0.0006722564,0.98207885,0.0000666388,0.00048520518,0.001617467,0.00056428957,0.007934234,0.0030881618,0.0005595809,0.0028461597,0.000036443802],"about_ca_topic_score_codex":0.0024112253,"about_ca_topic_score_gemma":0.0047168043,"teacher_disagreement_score":0.0024112253,"about_ca_system_score_codex":0.00053605635,"about_ca_system_score_gemma":0.00058119383,"threshold_uncertainty_score":0.004794419},"labels":[],"label_agreement":null},{"id":"W3119966384","doi":"10.1016/j.euo.2020.12.008","title":"A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Takeda Canada; Roche Products; Pfizer UK; Shionogi; Astellas Pharma; European Association of Urology; Sir John Fisher Foundation; Ipsen Fund; Cancer Australia; Cancer Research UK; Novartis; Janssen Biotech; Les Laboratories Pierre Fabre; Medical Research Council; Bayer; AstraZeneca; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Prostatectomy; Prostate cancer; Retrospective cohort study; Randomized controlled trial; Radiation therapy; Systematic review; Adverse effect; Surgery; MEDLINE; Internal medicine; Cancer","score_opus":0.3987709870444513,"score_gpt":0.553696313638174,"score_spread":0.15492532659372266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119966384","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047226454,0.99872977,0.00009682087,0.00012891555,0.000097012,0.00011105947,0.00021897006,0.0000045835995,0.0001406554],"genre_scores_gemma":[0.0100034345,0.9885365,0.0005046119,0.00051438756,0.000060988546,0.00015120833,0.00012833545,0.000005193394,0.00009532307],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99399215,0.0021064805,0.0023501145,0.00054874795,0.00082526373,0.00017723895],"domain_scores_gemma":[0.9856631,0.010335538,0.0027198314,0.0001910384,0.000898343,0.00019231174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007647278,0.0015595633,0.011673635,0.006290832,0.0005889194,0.0033184844,0.0018353027,0.0020206007,0.005621945],"category_scores_gemma":[0.03058496,0.00097440905,0.01061454,0.0070827333,0.0010007375,0.0022777154,0.0016858012,0.0017235318,0.00037378693],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036454375,0.000010509112,0.00031040446,0.95392513,0.02330325,0.000056040022,0.00007899842,0.000087733555,0.00014004963,0.00016727636,0.00087169406,0.020684257],"study_design_scores_gemma":[0.0006639335,0.00024949585,0.0029885005,0.70392954,0.27266315,0.00027391012,0.0001892824,0.000088554865,0.00015117442,0.00048277646,0.018270042,0.000049569295],"about_ca_topic_score_codex":0.011354593,"about_ca_topic_score_gemma":0.04201748,"teacher_disagreement_score":0.011673635,"about_ca_system_score_codex":0.0035018825,"about_ca_system_score_gemma":0.008578447,"threshold_uncertainty_score":0.040443122},"labels":[],"label_agreement":null},{"id":"W3120001159","doi":"10.1016/j.euo.2020.12.002","title":"Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non–muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non–muscle-invasive Bladder Cancer Guidelines Panel Study","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Bladder cancer; Cystectomy; Internal medicine; Urology; Concomitant; Stage (stratigraphy); Oncology; Concordance; Cancer; Univariate analysis; Clinical endpoint; Multivariate analysis; Clinical trial","score_opus":0.05179884433526188,"score_gpt":0.32581378281523016,"score_spread":0.2740149384799683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120001159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9367315,0.0081488,0.0017807164,0.0026903301,0.00036456986,0.0005412466,0.03960202,0.000078299825,0.010062439],"genre_scores_gemma":[0.96779555,0.0014009858,0.0015782923,0.00068060093,0.00007298332,0.00027773652,0.026834302,0.000054104086,0.0013054532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985228,0.00057509856,0.00020988668,0.00019128597,0.00030141041,0.00019961112],"domain_scores_gemma":[0.9971252,0.00054349954,0.0008651638,0.00015837386,0.00091534894,0.00039235983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035587633,0.0006296569,0.0009568978,0.0013589846,0.000492439,0.0014602677,0.0010717389,0.000967602,0.0013489659],"category_scores_gemma":[0.005115527,0.0003092858,0.0018740748,0.0021361073,0.0003402997,0.0009096941,0.00095740246,0.00080250605,0.00042301993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014150987,0.0001088349,0.9615765,0.00022062883,0.0012007853,0.00005657432,0.00017209175,0.0010026216,0.00040464592,0.00018152206,0.017558405,0.0161023],"study_design_scores_gemma":[0.00040426877,0.00026629792,0.9864638,0.0002659467,0.0012704807,0.0002337371,0.0004010434,0.001851107,0.00044476608,0.0003348522,0.0080065,0.00005722044],"about_ca_topic_score_codex":0.0128508685,"about_ca_topic_score_gemma":0.03197863,"teacher_disagreement_score":0.0128508685,"about_ca_system_score_codex":0.0011503493,"about_ca_system_score_gemma":0.0015416817,"threshold_uncertainty_score":0.025552154},"labels":[],"label_agreement":null},{"id":"W3120377060","doi":"10.1016/j.euo.2020.12.011","title":"Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Bayer Yakuhin; Astellas Pharma; Roche Italia; GlaxoSmithKline; Novartis; Pfizer","keywords":"Medicine; Kidney cancer; Medical physics; Cancer; Intensive care medicine; Pathology; Engineering ethics; Internal medicine; Engineering","score_opus":0.04897353009965996,"score_gpt":0.38862529324275014,"score_spread":0.3396517631430902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120377060","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013205147,0.999508,0.000039022358,0.00014885863,0.00003737147,0.000014438189,0.000059790553,0.0000014593658,0.000058906775],"genre_scores_gemma":[0.0019601267,0.9974126,0.00022668518,0.0002569829,0.000047325946,0.000024807818,0.000048134523,9.1978865e-7,0.000022439413],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99693006,0.00094135856,0.0011127598,0.00033386934,0.00057592354,0.00010609005],"domain_scores_gemma":[0.9847387,0.011556906,0.0022857273,0.00015057012,0.0011276917,0.00014042188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052581206,0.0011881109,0.0065816953,0.0062799524,0.0004403678,0.0025604859,0.0014918284,0.0019212672,0.0034754782],"category_scores_gemma":[0.019745491,0.0006922563,0.0058083585,0.006711812,0.0006753442,0.00229598,0.0013225343,0.0014322528,0.00032629672],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003929207,0.000040361287,0.001717396,0.7624756,0.009089681,0.00011175686,0.00012153557,0.000208569,0.00027194122,0.0005437821,0.0044826013,0.22054379],"study_design_scores_gemma":[0.00037175056,0.00030507127,0.008737209,0.82155836,0.0829032,0.0007714444,0.00033801838,0.00028040956,0.0003504601,0.0010573053,0.083229,0.000097758784],"about_ca_topic_score_codex":0.005014617,"about_ca_topic_score_gemma":0.0143158,"teacher_disagreement_score":0.0065816953,"about_ca_system_score_codex":0.0017131494,"about_ca_system_score_gemma":0.0068949615,"threshold_uncertainty_score":0.027807951},"labels":[],"label_agreement":null},{"id":"W3126442745","doi":"10.1016/j.euo.2021.01.003","title":"Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Biochemical recurrence; Magnetic resonance imaging; Radiation therapy; Prostate; Radiology; Medical physics; Cancer; Internal medicine","score_opus":0.06560416963650754,"score_gpt":0.3869610336598013,"score_spread":0.3213568640232937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126442745","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016667509,0.9923833,0.0011447275,0.003085378,0.00091664924,0.0002293744,0.0006443501,0.000045607474,0.0013839261],"genre_scores_gemma":[0.0013613577,0.9877137,0.004933437,0.0027916082,0.00030301407,0.0003173895,0.001920811,0.000022755983,0.00063585717],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954847,0.0011363316,0.0017588631,0.000378658,0.0010068996,0.00023461551],"domain_scores_gemma":[0.9946978,0.0019499942,0.0013862996,0.00012363661,0.0016325458,0.00020968591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008955421,0.0017694675,0.0046242564,0.007778122,0.0006991629,0.0023805832,0.0039676125,0.0032052458,0.0032929936],"category_scores_gemma":[0.011311291,0.00085101364,0.0050953566,0.006635594,0.0009432637,0.0018385429,0.0022701016,0.0035504268,0.0022679185],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019801341,0.00008840713,0.0011399037,0.08246328,0.0009885019,0.00013521472,0.0001460402,0.0007009304,0.0008856637,0.0025735635,0.11215524,0.7985252],"study_design_scores_gemma":[0.00026280276,0.00013360684,0.0061653783,0.19126692,0.00370031,0.0011726401,0.00022802364,0.00047107847,0.0007028366,0.0025034507,0.7932843,0.00010865123],"about_ca_topic_score_codex":0.01711697,"about_ca_topic_score_gemma":0.021437341,"teacher_disagreement_score":0.01711697,"about_ca_system_score_codex":0.0030993212,"about_ca_system_score_gemma":0.011154086,"threshold_uncertainty_score":0.047361374},"labels":[],"label_agreement":null},{"id":"W3139733574","doi":"10.1016/j.euo.2021.02.007","title":"Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Prostate cancer; Systematic review; Cancer; Kidney cancer; Bladder cancer; CINAHL; MEDLINE; Internal medicine; Oncology; Psychological intervention","score_opus":0.030855555202399024,"score_gpt":0.27920069884354676,"score_spread":0.24834514364114774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139733574","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004468478,0.9989035,0.00003623599,0.00034540606,0.00006334869,0.000019877418,0.00013199955,0.0000016814034,0.000051099236],"genre_scores_gemma":[0.011218602,0.98741364,0.00020341994,0.0008601149,0.00009040438,0.000043729167,0.00011994008,0.0000018964311,0.000048234888],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9962035,0.0013962573,0.001335627,0.00029283616,0.00062439014,0.00014732775],"domain_scores_gemma":[0.98103964,0.013471778,0.0039820126,0.00023993546,0.0010274525,0.00023924679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007884077,0.00079161866,0.0064866403,0.0033136806,0.00026245744,0.0019936468,0.0010812568,0.0015589339,0.002684249],"category_scores_gemma":[0.026808593,0.00058914867,0.0093514845,0.005016409,0.00059440004,0.0015821583,0.0013388857,0.0015429644,0.00014432013],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005104397,0.00003420992,0.006185926,0.8323297,0.050300326,0.00012630389,0.00011071896,0.0003894777,0.00013671993,0.0005845119,0.0064550275,0.10283664],"study_design_scores_gemma":[0.000941858,0.0003659868,0.03143834,0.6516919,0.26271918,0.00057511544,0.00045386882,0.00026934265,0.00013448606,0.0020480193,0.04924733,0.00011465635],"about_ca_topic_score_codex":0.011863609,"about_ca_topic_score_gemma":0.044949047,"teacher_disagreement_score":0.011863609,"about_ca_system_score_codex":0.0028656512,"about_ca_system_score_gemma":0.007292732,"threshold_uncertainty_score":0.041695476},"labels":[],"label_agreement":null},{"id":"W3151619115","doi":"10.1016/j.euo.2021.03.005","title":"Incidental Prostate Cancer (cT1a–cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Prostate; Oncology; Medical physics; Internal medicine","score_opus":0.22262775962300127,"score_gpt":0.5128784833823907,"score_spread":0.29025072375938943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151619115","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0104914475,0.33617842,0.027267884,0.23629573,0.03291378,0.0010760934,0.009028423,0.00086314784,0.345885],"genre_scores_gemma":[0.15672046,0.41961113,0.096481726,0.19458997,0.025884496,0.0013969078,0.0247354,0.0011490361,0.07943091],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965125,0.0010360323,0.00081723277,0.00019046113,0.0011177999,0.0003260114],"domain_scores_gemma":[0.98737574,0.0058398363,0.0017010825,0.00052996626,0.0033931392,0.001160187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003824918,0.00043728625,0.00096017634,0.0017295139,0.0011539009,0.0016616454,0.0012037135,0.0030213788,0.008815466],"category_scores_gemma":[0.016897058,0.0002851137,0.001328741,0.0019173758,0.0013805019,0.0016549384,0.0015796046,0.005055682,0.004067191],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019325127,0.000118118056,0.009488754,0.0035768151,0.00012347398,0.001408787,0.00040857663,0.0005260986,0.0016742545,0.028485069,0.5902309,0.36376587],"study_design_scores_gemma":[0.00003949304,0.000060663882,0.0063221958,0.00420932,0.00009202263,0.0044342796,0.00023278296,0.00011579047,0.0005537674,0.006186881,0.9777094,0.00004332745],"about_ca_topic_score_codex":0.0101513285,"about_ca_topic_score_gemma":0.031289138,"teacher_disagreement_score":0.0101513285,"about_ca_system_score_codex":0.00093646295,"about_ca_system_score_gemma":0.0073280423,"threshold_uncertainty_score":0.02949065},"labels":[],"label_agreement":null},{"id":"W3163731137","doi":"10.1016/j.euo.2021.04.008","title":"Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Clinical endpoint; Prostate cancer; Hazard ratio; Androgen deprivation therapy; Population; Prostatectomy; Internal medicine; Urology; Testosterone (patch); Prostate-specific antigen; Biochemical recurrence; Randomized controlled trial; Confidence interval; Oncology; Cancer","score_opus":0.0251811069725022,"score_gpt":0.33797486306754854,"score_spread":0.31279375609504634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163731137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98155457,0.0053513856,0.0008989795,0.0011156331,0.0011236456,0.004562045,0.0022735028,0.0002707384,0.0028494473],"genre_scores_gemma":[0.9837632,0.0024379273,0.0016196904,0.0015803186,0.00037858693,0.0037674934,0.0016117058,0.00005095311,0.004790189],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995048,0.00024101445,0.000025420937,0.00010850058,0.000033942924,0.00008630528],"domain_scores_gemma":[0.9992125,0.0002481236,0.00017238516,0.00006217091,0.000041619496,0.00026322648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001336287,0.0016116273,0.0028169306,0.0004179613,0.0004990689,0.0012391383,0.0011918349,0.0014317224,0.012679441],"category_scores_gemma":[0.0014212419,0.00065826724,0.002598255,0.00053437566,0.0013076116,0.00091937365,0.0004069682,0.0036787887,0.0013614239],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9885796,0.002865736,0.00021768469,0.00031034625,0.0008230301,0.000017599037,0.000025101957,0.00023399595,0.00078735774,0.00007326655,0.00062114134,0.005445155],"study_design_scores_gemma":[0.9816171,0.016811617,0.0006713142,0.000013923151,0.0002844523,0.000011371485,0.000012219629,0.00018593685,0.00008228981,0.00007725386,0.00022503058,0.0000075765806],"about_ca_topic_score_codex":0.0043864497,"about_ca_topic_score_gemma":0.011029673,"teacher_disagreement_score":0.012679441,"about_ca_system_score_codex":0.0013174646,"about_ca_system_score_gemma":0.0018962241,"threshold_uncertainty_score":0.04241693},"labels":[],"label_agreement":null},{"id":"W3165599343","doi":"10.1016/j.euo.2021.05.004","title":"Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press","year":2021,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre","funders":"","keywords":"Medicine; Prostate cancer; Gynecology; Cancer; Internal medicine","score_opus":0.055677404488332166,"score_gpt":0.37010723138857665,"score_spread":0.31442982690024446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165599343","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012792199,0.00095235923,0.00003023291,0.98335785,0.01453393,0.00000856354,0.00006999193,0.000017637709,0.0009015832],"genre_scores_gemma":[0.0010646265,0.000685172,0.00007238818,0.9797925,0.014177015,0.00002480641,0.000040484556,0.000015849686,0.004127104],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976375,0.000622434,0.00034962315,0.00028765717,0.00072204164,0.0003807057],"domain_scores_gemma":[0.99284726,0.0033872554,0.0005253743,0.00013642706,0.0016508219,0.0014529048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00350896,0.0009671228,0.0015695384,0.0010729035,0.00348062,0.0029370526,0.0019267282,0.042963102,0.009266262],"category_scores_gemma":[0.023583833,0.0010863004,0.0012282886,0.0009823809,0.002028553,0.0039193225,0.0019843131,0.037210718,0.010772593],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038638034,0.000009521186,0.00026340273,0.000030879728,0.000006179757,0.00056052295,0.000054328084,0.00002125701,0.000037129463,0.0003961983,0.99674535,0.0018365104],"study_design_scores_gemma":[0.00012558131,0.000058575715,0.0019118838,0.00041070813,0.00003521805,0.0024331054,0.0006281123,0.000276007,0.00018322491,0.0036760909,0.99017453,0.00008693298],"about_ca_topic_score_codex":0.013677624,"about_ca_topic_score_gemma":0.02299926,"teacher_disagreement_score":0.042963102,"about_ca_system_score_codex":0.004427934,"about_ca_system_score_gemma":0.004678828,"threshold_uncertainty_score":0.032127082},"labels":[],"label_agreement":null},{"id":"W3176723026","doi":"10.1016/j.euo.2021.06.003","title":"Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Androgen deprivation therapy; Interquartile range; Prostate-specific antigen; Hazard ratio; Lymph node; Proportional hazards model; Oncology; Dissection (medical); Multimodal therapy; Urology; Internal medicine; Cancer; Surgery","score_opus":0.058550550389696844,"score_gpt":0.3746373579487231,"score_spread":0.31608680755902624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176723026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955201,0.0016412527,0.00018946228,0.000700563,0.00006453738,0.000009793108,0.0004005901,0.000005050718,0.0014686426],"genre_scores_gemma":[0.9992762,0.00015961594,0.000061094885,0.000075537,0.000061713275,0.000003790674,0.0002488288,0.0000037321827,0.00010943504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969908,0.0013300183,0.00032780218,0.00037756943,0.00049364,0.00048020817],"domain_scores_gemma":[0.9858701,0.0055156,0.0048963707,0.0007786299,0.0012929173,0.0016464844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00523032,0.00042049383,0.0004866637,0.0015327156,0.0005748229,0.0028878658,0.0014843061,0.0010867935,0.0025001122],"category_scores_gemma":[0.022909844,0.00018474282,0.0014759818,0.0019193635,0.0011670202,0.0021403478,0.0022764835,0.0014142671,0.00028930124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004088616,0.000058438567,0.9946778,0.00001866258,0.00014892599,0.000041961423,0.00008422484,0.00012379281,0.000058094436,0.00008749732,0.00011757771,0.004174226],"study_design_scores_gemma":[0.000009388304,0.000203083,0.9982907,0.00001701702,0.00013578808,0.00012526887,0.00039845685,0.00037281876,0.000049960698,0.00021588527,0.00017155484,0.000010034615],"about_ca_topic_score_codex":0.0034807655,"about_ca_topic_score_gemma":0.0051767332,"teacher_disagreement_score":0.00523032,"about_ca_system_score_codex":0.0011956305,"about_ca_system_score_gemma":0.001372683,"threshold_uncertainty_score":0.027660906},"labels":[],"label_agreement":null},{"id":"W3178692749","doi":"10.1016/j.euo.2021.05.007","title":"Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Axitinib; Pembrolizumab; Discontinuation; Sunitinib; Adverse effect; Internal medicine; Renal cell carcinoma; Gastroenterology; Incidence (geometry); Cancer; Immunotherapy","score_opus":0.020506700954942267,"score_gpt":0.24325640937435572,"score_spread":0.22274970841941344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178692749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99065757,0.0054352856,0.00019571927,0.0004035009,0.0000716793,0.00022246913,0.00090668217,0.000028960889,0.0020781038],"genre_scores_gemma":[0.99408734,0.0015471238,0.00036022512,0.00063392124,0.00009409845,0.0001552186,0.0024098805,0.000010726306,0.0007013784],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993691,0.00034671117,0.000035939796,0.00009054172,0.00006606218,0.00009160454],"domain_scores_gemma":[0.9993438,0.00019076218,0.0002085027,0.00006179772,0.0000453061,0.0001499087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017334472,0.0005336305,0.0012766059,0.0002114962,0.0002175604,0.0010365063,0.0004116987,0.0004600405,0.0013249675],"category_scores_gemma":[0.0016569945,0.00020077277,0.0013914972,0.0004656618,0.00037897757,0.0007340851,0.00032455125,0.0017209615,0.00021413076],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6050307,0.0077268486,0.07790118,0.0023700765,0.009241236,0.00028912057,0.00030663842,0.005503471,0.013321231,0.0006545126,0.007946094,0.2697088],"study_design_scores_gemma":[0.37464774,0.19010669,0.39067993,0.0004828422,0.010575527,0.0017624393,0.00043808992,0.005995205,0.0056574903,0.0026242868,0.016866988,0.00016275921],"about_ca_topic_score_codex":0.0008380193,"about_ca_topic_score_gemma":0.0032767819,"teacher_disagreement_score":0.0017334472,"about_ca_system_score_codex":0.0009873261,"about_ca_system_score_gemma":0.0007682431,"threshold_uncertainty_score":0.009167492},"labels":[],"label_agreement":null},{"id":"W3185280489","doi":"10.1016/j.euo.2021.07.002","title":"The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Meta-analysis; Prostate cancer; Subgroup analysis; Relative risk; Adverse effect; Randomized controlled trial; Systematic review; Internal medicine; Confidence interval; Urology; Oncology; Gynecology; MEDLINE; Cancer","score_opus":0.13708938105967342,"score_gpt":0.43064019404415815,"score_spread":0.2935508129844847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185280489","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032809407,0.95305675,0.007131889,0.0009690206,0.0006898035,0.0020376034,0.0020962006,0.00016025943,0.0010490508],"genre_scores_gemma":[0.72867996,0.24569386,0.013657681,0.0020711785,0.000558675,0.005626558,0.002726908,0.00014492372,0.00084027246],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.96602803,0.024394915,0.004579377,0.0025714731,0.0018869865,0.0005390759],"domain_scores_gemma":[0.9611259,0.030981818,0.0046322946,0.0015172516,0.0013279881,0.000414732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.034148753,0.003949886,0.018602379,0.0069645415,0.00061602675,0.0036399034,0.0024796145,0.0025727896,0.0043140366],"category_scores_gemma":[0.05941636,0.0018141158,0.06032127,0.0056653586,0.0008169564,0.002193977,0.002045691,0.0026460423,0.0003998747],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004217322,0.000025384623,0.002934332,0.051967606,0.9360573,0.000059552094,0.000028385784,0.0010943976,0.00013042388,0.000105460545,0.00020480924,0.0031749427],"study_design_scores_gemma":[0.0014056716,0.0002375324,0.0015304284,0.002808156,0.9925196,0.00003605733,0.000014224554,0.00064273074,0.00006805189,0.00025993385,0.0004621359,0.000015377875],"about_ca_topic_score_codex":0.0051446557,"about_ca_topic_score_gemma":0.006936854,"teacher_disagreement_score":0.034148753,"about_ca_system_score_codex":0.002947327,"about_ca_system_score_gemma":0.002817268,"threshold_uncertainty_score":0.18059802},"labels":[],"label_agreement":null},{"id":"W3201577472","doi":"10.1016/j.euo.2021.08.001","title":"Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Positron emission tomography; Lymph node; Meta-analysis; Confidence interval; Receiver operating characteristic; Glutamate carboxypeptidase II; Prostate-specific antigen; Radiology; Subgroup analysis; Dissection (medical); Nuclear medicine; Internal medicine; Cancer","score_opus":0.033752146628727,"score_gpt":0.3139504814814593,"score_spread":0.2801983348527323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201577472","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049743215,0.99398625,0.00021159743,0.00014775812,0.0001190482,0.000038030063,0.00033850342,0.000008339991,0.00017618647],"genre_scores_gemma":[0.18852232,0.8080084,0.0010404345,0.0010400466,0.0003038534,0.0001380236,0.00066375814,0.000017619535,0.00026549463],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.997428,0.0010244799,0.00073059724,0.00044661877,0.00025081358,0.00011960394],"domain_scores_gemma":[0.9931171,0.0051790713,0.0010786223,0.00019151776,0.00034156322,0.000092146955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039121783,0.0015330022,0.008841152,0.002256445,0.00036540726,0.0017275533,0.0014950053,0.0019736155,0.0033874824],"category_scores_gemma":[0.012937487,0.0011233204,0.020279735,0.003286452,0.00057775184,0.0014082092,0.0009625151,0.0018667947,0.00036374366],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038656928,0.000047896287,0.015456089,0.35208666,0.5930687,0.00016714944,0.00011364942,0.0005402184,0.00033302337,0.00020732301,0.001372753,0.0327409],"study_design_scores_gemma":[0.0011867794,0.00026811613,0.013367775,0.022797398,0.95901746,0.00013889214,0.000077367295,0.00021603896,0.000113149086,0.00028503465,0.0024879533,0.000044040495],"about_ca_topic_score_codex":0.007214599,"about_ca_topic_score_gemma":0.022093043,"teacher_disagreement_score":0.008841152,"about_ca_system_score_codex":0.0010771588,"about_ca_system_score_gemma":0.0016481683,"threshold_uncertainty_score":0.020689845},"labels":[],"label_agreement":null},{"id":"W3211281229","doi":"10.1016/j.euo.2021.09.006","title":"Epidemiology and Prevention of Prostate Cancer","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":609,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"World Health Organization","keywords":"Medicine; Incidence (geometry); Epidemiology; Prostate cancer; Family history; Disease; Demography; Mortality rate; Cancer; Diabetes mellitus; Cumulative incidence; Internal medicine","score_opus":0.10638041372015321,"score_gpt":0.43002780410647046,"score_spread":0.32364739038631724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211281229","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026011108,0.99958915,0.000018540542,0.00011108614,0.00008231449,0.0000025364463,0.000023936178,0.0000016127847,0.00014484911],"genre_scores_gemma":[0.00030280728,0.9994186,0.00003774664,0.00008559549,0.00007580353,0.0000026014745,0.000020146232,3.5600948e-7,0.000056346053],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993024,0.00017527798,0.0001355097,0.00011442839,0.00022129042,0.00005095153],"domain_scores_gemma":[0.99857223,0.00080453826,0.00032846248,0.000026954078,0.00020888861,0.000058899175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011967915,0.0011309712,0.0026720897,0.003957846,0.00026913508,0.0013457059,0.0011599367,0.0013906128,0.005966632],"category_scores_gemma":[0.003291116,0.0005009775,0.0019503392,0.0058800345,0.00048210792,0.0011495245,0.0008776798,0.0017762369,0.0010712291],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014343605,0.00007399746,0.0015698584,0.14143492,0.0011667225,0.000092007576,0.00006171703,0.0005899044,0.00019139796,0.0024828988,0.031899467,0.8202937],"study_design_scores_gemma":[0.00014202109,0.00032326917,0.015351736,0.16906214,0.006053259,0.0013107293,0.00025079318,0.00033891958,0.00022850752,0.0041197482,0.8027293,0.00008963849],"about_ca_topic_score_codex":0.012043369,"about_ca_topic_score_gemma":0.02004163,"teacher_disagreement_score":0.012043369,"about_ca_system_score_codex":0.0014498354,"about_ca_system_score_gemma":0.0037326193,"threshold_uncertainty_score":0.023946524},"labels":[],"label_agreement":null},{"id":"W3212268582","doi":"10.1016/j.euo.2021.10.005","title":"Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Janssen Pharmaceuticals; National Cancer Institute; National Institutes of Health; RefleXion Medical; Ipsen; Stand Up To Cancer; Ferring Pharmaceuticals; Prostate Cancer Foundation; AstraZeneca; Movember Foundation; Merck; Bayer; Kom op tegen Kanker; Astellas Pharma US; Pfizer","keywords":"Medicine; Disease; Biomarker; Prostate cancer; Oncology; Clinical trial; Internal medicine; Cancer; Bioinformatics; Biology; Genetics","score_opus":0.06133329220559403,"score_gpt":0.3943840527493043,"score_spread":0.3330507605437103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212268582","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030333042,0.9992805,0.00005102311,0.00006286978,0.00003661071,0.00002180252,0.00017114112,0.0000024547585,0.00007029407],"genre_scores_gemma":[0.0058273277,0.9933217,0.0002112796,0.0003307146,0.000044546523,0.000036786423,0.00016778478,0.0000018848958,0.000057896625],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.998869,0.00032453256,0.000348614,0.00020013654,0.00020194703,0.000055687007],"domain_scores_gemma":[0.9953194,0.0035986195,0.0007153959,0.00006717847,0.00024104454,0.00005826612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002476671,0.0011737143,0.0059969095,0.0032804378,0.00023974193,0.0015368324,0.0015185385,0.0014192774,0.0044795536],"category_scores_gemma":[0.010106999,0.00061090256,0.007591199,0.00430392,0.00050165964,0.0014063249,0.0010723838,0.0010465662,0.00036160107],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006428082,0.00003317715,0.0024594509,0.8229284,0.035807785,0.00010448734,0.00011060644,0.00028907342,0.0003089652,0.00032841906,0.004514946,0.13247192],"study_design_scores_gemma":[0.0011126199,0.00054112694,0.01770131,0.5292039,0.39123532,0.0006926368,0.00033741727,0.00024919663,0.00039838467,0.0011525559,0.05723538,0.0001402195],"about_ca_topic_score_codex":0.0059341737,"about_ca_topic_score_gemma":0.01867865,"teacher_disagreement_score":0.0059969095,"about_ca_system_score_codex":0.0009518457,"about_ca_system_score_gemma":0.0029361811,"threshold_uncertainty_score":0.014985621},"labels":[],"label_agreement":null},{"id":"W4200305543","doi":"10.1016/j.euo.2021.11.002","title":"Somatic Features of Response and Relapse in Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Canadian Institutes of Health Research; Krebsliga Schweiz","keywords":"Medicine; Bladder cancer; Immunotherapy; Somatic cell; Bacillus (shape); Oncology; Cancer immunotherapy; Complete response; Internal medicine; Urology; Cancer; Chemotherapy; Microbiology","score_opus":0.013395024961628378,"score_gpt":0.28206992650191864,"score_spread":0.2686749015402903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200305543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985964,0.00024831208,0.000042313593,0.00005727055,0.0000065782388,0.000006748245,0.00015498867,0.0000046738605,0.0008828567],"genre_scores_gemma":[0.9995011,0.000046386212,0.0000281143,0.000024865976,0.0000050439153,0.0000037211296,0.00017909548,0.0000011464591,0.00021055566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997836,0.000033821252,0.000019628504,0.00004477397,0.000041172767,0.000077048455],"domain_scores_gemma":[0.9996902,0.00006093872,0.00014184158,0.000013162268,0.000030506242,0.0000634437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022507229,0.0001130997,0.00026324484,0.00039183287,0.00024781105,0.0004582544,0.00020472462,0.0003160052,0.0017068117],"category_scores_gemma":[0.00070672715,0.00007700616,0.00031585098,0.00048477284,0.00018506245,0.00021636944,0.00022627768,0.00026230759,0.00015402726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00247097,0.00014544906,0.96625894,0.00004552728,0.00015780068,0.0012779569,0.00014612713,0.0004159124,0.008820649,0.000119680575,0.00044813793,0.0196928],"study_design_scores_gemma":[0.000018535657,0.00033808325,0.99618465,0.0000072293337,0.0000608849,0.0015745162,0.000116246934,0.0005278711,0.0005710609,0.00011407617,0.0004817757,0.000004928985],"about_ca_topic_score_codex":0.001002372,"about_ca_topic_score_gemma":0.0014855745,"teacher_disagreement_score":0.0017068117,"about_ca_system_score_codex":0.00034090874,"about_ca_system_score_gemma":0.00016594445,"threshold_uncertainty_score":0.005709827},"labels":[],"label_agreement":null},{"id":"W4206710181","doi":"10.1016/j.euo.2021.12.007","title":"Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy","year":2022,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Pazopanib; Internal medicine; Renal cell carcinoma; Hazard ratio; Kidney cancer; Adverse effect; Oncology; Placebo; Nephrectomy; Adjuvant; Confidence interval; Cancer; Kidney; Sunitinib; Immunotherapy; Pathology","score_opus":0.006648434148015535,"score_gpt":0.20948290704344646,"score_spread":0.20283447289543094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206710181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752873,0.020251693,0.0002676851,0.0011889432,0.00019164155,0.000025299085,0.00012617517,0.000012659009,0.0026486453],"genre_scores_gemma":[0.99606234,0.002789282,0.00019338857,0.0002586616,0.00010973729,0.000008698067,0.00017046198,0.000003272094,0.00040421734],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998497,0.00004983451,0.00001428875,0.00002510278,0.000021837335,0.000039234958],"domain_scores_gemma":[0.9996799,0.00012939605,0.00006742512,0.000012397126,0.000017981223,0.000092872186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040532736,0.0001536699,0.00067235285,0.00011516749,0.0001607566,0.00040219736,0.00011106714,0.00022244839,0.0013271505],"category_scores_gemma":[0.0013512765,0.00006266871,0.00052465306,0.00018709841,0.000095780924,0.00038253618,0.00013360882,0.00065096415,0.00010244404],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14498292,0.001970355,0.17391612,0.0010994176,0.0024054262,0.00090195495,0.00018393292,0.0041016093,0.022979222,0.00086324237,0.0045924196,0.6420034],"study_design_scores_gemma":[0.0077126683,0.035952263,0.91874313,0.0003666689,0.004126957,0.0023004657,0.00033638589,0.005284042,0.0054727583,0.0015614586,0.018090349,0.00005294031],"about_ca_topic_score_codex":0.00078406505,"about_ca_topic_score_gemma":0.0029075935,"teacher_disagreement_score":0.0013271505,"about_ca_system_score_codex":0.00033372547,"about_ca_system_score_gemma":0.0005156393,"threshold_uncertainty_score":0.004439771},"labels":[],"label_agreement":null},{"id":"W4214711830","doi":"10.1016/j.euo.2021.11.005","title":"TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells","year":2022,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Council for Science, Technology and Innovation; A.P. Giannini Foundation; Svenska Läkaresällskapet; National Cancer Institute; National Institutes of Health; Vetenskapsrådet; National Institute of General Medical Sciences; Giannini Foundation of Agricultural Economics","keywords":"Medicine; Gene knockdown; Bladder cancer; Cancer research; Cancer; Oncology; Internal medicine; Gene; Biology; Genetics","score_opus":0.01368146384953848,"score_gpt":0.27848123575721934,"score_spread":0.26479977190768084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214711830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946169,0.00061068934,0.00054580293,0.00009809697,0.000020418109,0.000017829027,0.0011985417,0.000036531295,0.002855211],"genre_scores_gemma":[0.9934303,0.00029813577,0.00039788836,0.000060725135,0.0000058536098,0.000031352454,0.0016410234,0.000015442401,0.0041193007],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99968696,0.000037347978,0.000027192333,0.0000622978,0.00008139372,0.00010488764],"domain_scores_gemma":[0.99988186,0.000022715092,0.000017211536,0.000017670936,0.00002892372,0.00003158485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015889553,0.00015288214,0.00018311811,0.00036100933,0.00040727892,0.0007046853,0.00016198927,0.00041196728,0.003684802],"category_scores_gemma":[0.00022994567,0.00018070008,0.00026689997,0.00046682445,0.00024993785,0.00035360575,0.00022393651,0.00044469247,0.00043686296],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007133706,0.00006480287,0.0048961104,0.00006528828,0.00003198615,0.00021706402,0.0001788424,0.0001975565,0.9899777,0.0004538345,0.00043781113,0.0027655321],"study_design_scores_gemma":[0.00010583825,0.0015600071,0.17974363,0.000026123755,0.00013129743,0.0039884457,0.0025230043,0.0034660806,0.7833896,0.00033164106,0.024704974,0.000029337629],"about_ca_topic_score_codex":0.0034213464,"about_ca_topic_score_gemma":0.0031773204,"teacher_disagreement_score":0.003684802,"about_ca_system_score_codex":0.0003477694,"about_ca_system_score_gemma":0.00029899,"threshold_uncertainty_score":0.012326837},"labels":[],"label_agreement":null},{"id":"W4220776275","doi":"10.1016/j.euo.2022.03.001","title":"Establishing a Foundation for Studying the Immune Contexture Across the Spectrum of Bladder Cancer","year":2022,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Bladder cancer; Immune system; Cancer; Medicine; Broad spectrum; Cancer therapy; Foundation (evidence); Bioinformatics; Immunology; Cancer research; Internal medicine; Biology","score_opus":0.04373693572779449,"score_gpt":0.3407628625726476,"score_spread":0.2970259268448531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220776275","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038687245,0.004173987,0.00019811031,0.98651737,0.0075346706,0.000009325315,0.000008321941,0.000011611952,0.0011596029],"genre_scores_gemma":[0.0074144574,0.005822578,0.0010765459,0.9026386,0.080819674,0.000056810888,0.000020887843,0.000017331764,0.0021330272],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939757,0.002985475,0.00063487975,0.0005434486,0.0011858275,0.0006746446],"domain_scores_gemma":[0.9721672,0.01667097,0.0011671669,0.0010679977,0.0039889547,0.004937686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008677114,0.000630229,0.0022217394,0.0008700846,0.0046951375,0.0052834866,0.002144105,0.035414387,0.0046622385],"category_scores_gemma":[0.026344363,0.00054724864,0.0014291375,0.0006535212,0.007452403,0.011709596,0.0050644027,0.05334738,0.0026418024],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015474598,0.00036295768,0.004537335,0.00034025777,0.00008601804,0.004182279,0.00077558303,0.0002152424,0.0009766032,0.02066012,0.87825775,0.08945104],"study_design_scores_gemma":[0.00024460626,0.0003141004,0.003670803,0.0013843206,0.00008231463,0.0047631855,0.0033112618,0.00071567536,0.0004031229,0.10371467,0.8812749,0.00012109338],"about_ca_topic_score_codex":0.002717406,"about_ca_topic_score_gemma":0.005661916,"teacher_disagreement_score":0.035414387,"about_ca_system_score_codex":0.004880063,"about_ca_system_score_gemma":0.0084430035,"threshold_uncertainty_score":0.045889497},"labels":[],"label_agreement":null},{"id":"W4229059608","doi":"10.1016/j.euo.2021.07.001","title":"Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non–muscle-invasive Bladder Cancer","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"FP7 Health; University of Sheffield; University of Birmingham; Instituto de Salud Carlos III; National Institute for Health and Care Research; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Cancer Research UK","keywords":"Single-nucleotide polymorphism; Hazard ratio; Genome-wide association study; Bladder cancer; Oncology; SNP; Medicine; Candidate gene; Locus (genetics); Proportional hazards model; Expression quantitative trait loci; 1000 Genomes Project; Genetic association; Genetics; Gene; Internal medicine; Confidence interval; Genotype; Biology; Cancer","score_opus":0.1060085893577181,"score_gpt":0.38479782066120766,"score_spread":0.27878923130348954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229059608","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5806833,0.4045821,0.0055475323,0.001495366,0.0004173521,0.000081445665,0.0055482043,0.00031242686,0.0013322473],"genre_scores_gemma":[0.96609026,0.029167721,0.001596518,0.00040103914,0.00015246782,0.0000747293,0.002088872,0.00005750189,0.0003709331],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99730194,0.0010524801,0.00029734688,0.00087012956,0.0002568708,0.00022114588],"domain_scores_gemma":[0.9963367,0.002406998,0.00046359166,0.00043177017,0.0002030829,0.00015782211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004232285,0.0015163039,0.0040068435,0.0024611556,0.0006479998,0.002059248,0.0011234008,0.0014001856,0.0018112428],"category_scores_gemma":[0.007245821,0.0007521018,0.017609231,0.0044398666,0.00043219744,0.00056872197,0.0010296882,0.001434497,0.00020215834],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008929853,0.0000783585,0.39419496,0.009001388,0.55204076,0.0010480373,0.00015232696,0.004764553,0.0049217045,0.0003883941,0.0024323273,0.022047287],"study_design_scores_gemma":[0.00085201056,0.00055841805,0.36768505,0.0010143247,0.6185197,0.00077798567,0.00013512932,0.0045658653,0.0011855089,0.0010404127,0.00360587,0.000059697773],"about_ca_topic_score_codex":0.00760193,"about_ca_topic_score_gemma":0.009884064,"teacher_disagreement_score":0.00760193,"about_ca_system_score_codex":0.00067192654,"about_ca_system_score_gemma":0.0007627666,"threshold_uncertainty_score":0.022382736},"labels":[],"label_agreement":null},{"id":"W4281725891","doi":"10.1016/j.euo.2022.04.009","title":"First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature","year":2022,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Androgen deprivation therapy; Docetaxel; Oncology; Systematic review; Prostate-specific antigen; Systemic therapy; Internal medicine; Radiation therapy; Quality of life (healthcare); Cancer; Watchful waiting; MEDLINE; Intensive care medicine; Breast cancer","score_opus":0.05646314654128041,"score_gpt":0.37166315697840985,"score_spread":0.3152000104371294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281725891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042099672,0.99926823,0.00002220512,0.000046652247,0.000029167097,0.000015290345,0.000113435744,0.0000014553871,0.00008259752],"genre_scores_gemma":[0.0058517735,0.99368757,0.00010698709,0.00017826907,0.000029454071,0.000023344171,0.00008368293,0.0000011873377,0.000037696987],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9985065,0.00040087817,0.00052710925,0.00023242993,0.00027069368,0.00006246389],"domain_scores_gemma":[0.9942622,0.0041650734,0.0011460055,0.000056983932,0.0002817907,0.000088022905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019288054,0.00077610696,0.0044990997,0.003559937,0.00032698366,0.0014110483,0.0011797117,0.0012377109,0.004138034],"category_scores_gemma":[0.0084546525,0.0004728979,0.0057060476,0.0048146597,0.0004863402,0.0011031003,0.00072153285,0.0009754089,0.00022655271],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039583197,0.000029967929,0.0013568512,0.91169006,0.010468159,0.00011529841,0.00012380208,0.00014307156,0.00020611954,0.0001582106,0.0026073826,0.07270526],"study_design_scores_gemma":[0.0006366694,0.0005153817,0.016606564,0.7975993,0.13885508,0.0013143435,0.00039823024,0.00015107766,0.00029939407,0.00036027542,0.043187108,0.00007653718],"about_ca_topic_score_codex":0.008031323,"about_ca_topic_score_gemma":0.028993439,"teacher_disagreement_score":0.008031323,"about_ca_system_score_codex":0.0014697186,"about_ca_system_score_gemma":0.0036425171,"threshold_uncertainty_score":0.015969098},"labels":[],"label_agreement":null},{"id":"W4282915663","doi":"10.1016/j.euo.2022.04.006","title":"Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography–targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis","year":2022,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Positron emission tomography; Meta-analysis; Glutamate carboxypeptidase II; Confidence interval; Magnetic resonance imaging; Prostate; Biopsy; Prospective cohort study; Nuclear medicine; Radiology; Internal medicine; Cancer","score_opus":0.08277012584212112,"score_gpt":0.37797085764769944,"score_spread":0.2952007318055783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282915663","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004418025,0.9937084,0.00047675776,0.00020090197,0.000110178975,0.0002367926,0.0006309795,0.000024749745,0.00019324495],"genre_scores_gemma":[0.19285302,0.80056566,0.002473352,0.0010005165,0.0003406395,0.0013872468,0.0010542823,0.000041230767,0.000284006],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9861763,0.006824141,0.0035607624,0.0015011205,0.0015435161,0.00039412582],"domain_scores_gemma":[0.96033907,0.030572513,0.0052768523,0.0009870419,0.002480946,0.00034356047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019852027,0.002985347,0.020761626,0.007880837,0.00073573616,0.0034550712,0.0027376763,0.0026625153,0.0029791754],"category_scores_gemma":[0.05401387,0.0017068662,0.03990542,0.008977463,0.00094462855,0.0018906723,0.0015307174,0.0017884993,0.00034460836],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012309757,0.000016793656,0.005600393,0.39482963,0.58934003,0.00013316111,0.00007543396,0.0004866689,0.00019392757,0.00009205829,0.00053096766,0.0074700033],"study_design_scores_gemma":[0.0002864411,0.00010714664,0.0036347352,0.02628481,0.96834767,0.00008866941,0.000028864266,0.00016476544,0.000097875156,0.00010933121,0.00082948053,0.00002018859],"about_ca_topic_score_codex":0.009477822,"about_ca_topic_score_gemma":0.017411426,"teacher_disagreement_score":0.020761626,"about_ca_system_score_codex":0.0030897858,"about_ca_system_score_gemma":0.003779634,"threshold_uncertainty_score":0.10498881},"labels":[],"label_agreement":null},{"id":"W4282926990","doi":"10.1016/j.euo.2022.04.001","title":"Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer","year":2022,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Propensity score matching; Lymph node; Cisplatin; Oncology; Internal medicine; Proportional hazards model; Cohort; Urology; Clinical endpoint; Lymph; Stage (stratigraphy); Cancer; Chemotherapy; Randomized controlled trial; Pathology","score_opus":0.009836005636316718,"score_gpt":0.266905499013577,"score_spread":0.2570694933772603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282926990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963983,0.0014684593,0.00019914123,0.0006383422,0.000070713584,0.000029817405,0.00015337513,0.0000040261134,0.0010377731],"genre_scores_gemma":[0.998587,0.0004754881,0.00023485206,0.00020551198,0.000060659724,0.000013432962,0.00020615663,0.0000028533082,0.00021390928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99978,0.000056795623,0.000032058175,0.00003792189,0.00003226847,0.000060900446],"domain_scores_gemma":[0.9995426,0.00013035396,0.00009908922,0.0000128063975,0.0000450731,0.0001700639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026325163,0.00017806608,0.00046827784,0.00053860823,0.00053619844,0.0006838047,0.00024618075,0.0005531313,0.0018354981],"category_scores_gemma":[0.0019978636,0.00013026799,0.00053543696,0.00059844175,0.0001746284,0.00055336696,0.00028855773,0.00048124677,0.00025126655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007494703,0.0001291838,0.9821837,0.000037801423,0.000055829114,0.0003263446,0.00009100222,0.00023512916,0.0005682792,0.00004008103,0.00072114565,0.01486218],"study_design_scores_gemma":[0.00009066569,0.00075738673,0.99164283,0.000087630244,0.00029044526,0.001239031,0.0011212666,0.0014597682,0.00044433906,0.00040739588,0.0024353138,0.0000239491],"about_ca_topic_score_codex":0.0015274036,"about_ca_topic_score_gemma":0.003767092,"teacher_disagreement_score":0.0018354981,"about_ca_system_score_codex":0.0002763454,"about_ca_system_score_gemma":0.0006949486,"threshold_uncertainty_score":0.0061403513},"labels":[],"label_agreement":null},{"id":"W4284887428","doi":"10.1016/j.euo.2022.06.003","title":"Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis","year":2022,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Mount Sinai Hospital; Ottawa Hospital; University of Ottawa; University Health Network; University of Toronto; Université de Montréal","funders":"","keywords":"Docetaxel; Androgen deprivation therapy; Medicine; Prostate cancer; Oncology; Internal medicine; Hazard ratio; Clinical endpoint; Randomized controlled trial; Confidence interval; Androgen receptor; Meta-analysis; Cancer","score_opus":0.1584241569403467,"score_gpt":0.38862274295798793,"score_spread":0.23019858601764123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284887428","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00972193,0.9878307,0.0006128612,0.00022964702,0.00032187623,0.00008702987,0.00062910106,0.000037162074,0.00052964466],"genre_scores_gemma":[0.3418412,0.65133154,0.0018203296,0.0017283774,0.0004505477,0.0002212035,0.0013688958,0.00008765266,0.0011502814],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9973308,0.0013732606,0.00045804481,0.00042696527,0.00026049558,0.00015044444],"domain_scores_gemma":[0.9960355,0.002787457,0.0006321517,0.0001800023,0.0002407907,0.00012405202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004731534,0.002241877,0.009987723,0.0016651421,0.00028100528,0.0018082346,0.001543972,0.0012902766,0.005498182],"category_scores_gemma":[0.009175013,0.0010587662,0.030046036,0.0026887052,0.00037340084,0.0011000093,0.0009894416,0.0028117907,0.00045174945],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015815692,0.00007040752,0.0049710334,0.10950303,0.8320661,0.0001139325,0.00005818137,0.001668412,0.00041238812,0.00020585896,0.0017955246,0.033319324],"study_design_scores_gemma":[0.002634618,0.00049287727,0.00459164,0.0046153786,0.98452306,0.0000684172,0.000027463338,0.0002920421,0.00010156374,0.00026126733,0.0023641624,0.000027433967],"about_ca_topic_score_codex":0.0081762085,"about_ca_topic_score_gemma":0.024558296,"teacher_disagreement_score":0.009987723,"about_ca_system_score_codex":0.0019108633,"about_ca_system_score_gemma":0.0014728121,"threshold_uncertainty_score":0.025023043},"labels":[],"label_agreement":null},{"id":"W4292178027","doi":"10.1016/j.euo.2022.08.001","title":"Erratum to “Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)” [Eur Urol Oncol 2021;4:543–52]","year":2022,"lang":"en","type":"erratum","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Prostate cancer; Oncology; Randomized controlled trial; Internal medicine; Urology; Cancer","score_opus":0.022105357981230114,"score_gpt":0.3328123005631535,"score_spread":0.3107069425819234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292178027","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006170897,0.008428987,0.0005765394,0.21425891,0.7594512,0.0006578722,0.006542805,0.00032075297,0.009145789],"genre_scores_gemma":[0.008235399,0.009282242,0.0029262211,0.68224853,0.19330247,0.0017387987,0.0057401075,0.00044513008,0.09608105],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962418,0.0014595619,0.0007169907,0.0003744047,0.0009011033,0.00030616304],"domain_scores_gemma":[0.98533416,0.007168129,0.0017504464,0.00046481294,0.004176725,0.0011057957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007506488,0.0024836643,0.0037716473,0.0018058685,0.0018649491,0.002675266,0.0023724774,0.006822996,0.04454132],"category_scores_gemma":[0.034612752,0.0013545668,0.004166616,0.0012618804,0.0010591017,0.0013490635,0.0008609913,0.009638839,0.016581004],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011798621,0.000034496756,0.00007907343,0.00042324958,0.000121947916,0.00008605175,0.0000048778365,0.000036422705,0.00004034553,0.00018400209,0.99222517,0.005584503],"study_design_scores_gemma":[0.022617845,0.0009253178,0.003142614,0.0028537642,0.0022450811,0.0004043501,0.000049363058,0.0006555869,0.00053596514,0.0016378041,0.96480685,0.0001253939],"about_ca_topic_score_codex":0.010906025,"about_ca_topic_score_gemma":0.022331037,"teacher_disagreement_score":0.04454132,"about_ca_system_score_codex":0.003933421,"about_ca_system_score_gemma":0.006105662,"threshold_uncertainty_score":0.14900559},"labels":[],"label_agreement":null},{"id":"W4307153601","doi":"10.1016/j.euo.2022.09.007","title":"Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers","year":2022,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Genitourinary system; Prospective cohort study; Clinical trial; Oncology; Radiosurgery; Radiation therapy; Cancer; Prostate; Internal medicine","score_opus":0.14529858941571672,"score_gpt":0.46872939060602287,"score_spread":0.32343080119030615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307153601","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015971769,0.9993241,0.000058470043,0.00008613848,0.0000648568,0.000041892195,0.0000998318,0.0000034623874,0.00016151457],"genre_scores_gemma":[0.0012906237,0.99800235,0.00018810124,0.00028887237,0.000038867303,0.000037068454,0.000079268575,0.000001532429,0.00007320652],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99896157,0.00028114015,0.00039393583,0.00014472366,0.00017593251,0.000042765547],"domain_scores_gemma":[0.9965132,0.0025158147,0.00062253146,0.0000487489,0.00024710124,0.000052710533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027433701,0.0011598709,0.0049186274,0.002332963,0.00024800393,0.0012639102,0.0017358831,0.0011448179,0.004643754],"category_scores_gemma":[0.0068219034,0.00049612555,0.0040495563,0.0032469616,0.00038033875,0.0008180326,0.00066134403,0.0010921698,0.00046161198],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010811579,0.0000478045,0.00038258833,0.7022916,0.008483484,0.00012161897,0.000058431215,0.00032096446,0.0006494905,0.000442644,0.0074558714,0.27866432],"study_design_scores_gemma":[0.0027411596,0.0014387462,0.008074809,0.58160394,0.13450402,0.0012540816,0.00019117088,0.00024318819,0.0008616168,0.0014573693,0.2675176,0.00011222238],"about_ca_topic_score_codex":0.0037226973,"about_ca_topic_score_gemma":0.008609258,"teacher_disagreement_score":0.0049186274,"about_ca_system_score_codex":0.0012482116,"about_ca_system_score_gemma":0.0031825139,"threshold_uncertainty_score":0.015534937},"labels":[],"label_agreement":null},{"id":"W4308034719","doi":"10.1016/j.euo.2022.10.004","title":"Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","year":2022,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cabozantinib; Medicine; Radiation therapy; Discontinuation; Renal cell carcinoma; Oncology; Adverse effect; Internal medicine","score_opus":0.035861587331712935,"score_gpt":0.3030438251672152,"score_spread":0.2671822378355022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308034719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98299766,0.002080833,0.00014418334,0.00034932912,0.0000099963545,0.000033633387,0.013173532,0.00001344646,0.0011974418],"genre_scores_gemma":[0.9917189,0.00049685745,0.00015558435,0.00013664068,0.000014389398,0.00003195394,0.0073221023,0.000009222645,0.000114295784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965681,0.00079886476,0.00080730504,0.0008050685,0.0007674369,0.00025321395],"domain_scores_gemma":[0.9843038,0.0031900245,0.010123558,0.0005995519,0.0010564071,0.0007266627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017949919,0.00022808352,0.0006922979,0.0015519114,0.00030298697,0.0011861009,0.00075294194,0.000742855,0.0016019418],"category_scores_gemma":[0.011241327,0.00023806457,0.0011524975,0.004517272,0.00030196007,0.0010222845,0.0009714021,0.0005940441,0.00023284306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005712127,0.00003462222,0.9956524,0.00007437885,0.0004399308,0.000030221916,0.000089042755,0.00018399586,0.000053999847,0.0000480532,0.0006020776,0.0022201382],"study_design_scores_gemma":[0.00007198839,0.000091513764,0.99764687,0.000040974664,0.00021442957,0.00020056001,0.0002521519,0.0004988086,0.000070975395,0.00003743074,0.0008610642,0.000013336466],"about_ca_topic_score_codex":0.018448748,"about_ca_topic_score_gemma":0.026274906,"teacher_disagreement_score":0.018448748,"about_ca_system_score_codex":0.0019312477,"about_ca_system_score_gemma":0.0013764311,"threshold_uncertainty_score":0.036682725},"labels":[],"label_agreement":null},{"id":"W4317690982","doi":"10.1016/j.euo.2023.01.004","title":"Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non–muscle-invasive Spectrum","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Sorbonne Université; Universitat Autònoma de Barcelona; Karl-Franzens-Universität Graz; European Association of Urology; Radboud Universiteit; Radboud Universitair Medisch Centrum; Royal Free London NHS Foundation Trust; Medizinische Universität Graz; Univerzita Karlova v Praze","keywords":"Medicine; Bladder cancer; Confidence interval; Concomitant; Internal medicine; Risk stratification; Urology; Incidence (geometry); Proportional hazards model; Cumulative incidence; Oncology; Gastroenterology; Cancer; Cohort","score_opus":0.03348403002527243,"score_gpt":0.3052974684279435,"score_spread":0.271813438402671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317690982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99956423,0.0001175308,0.0000534358,0.00002038005,0.0000018142294,0.00000231411,0.00011942263,0.0000039629285,0.000116855634],"genre_scores_gemma":[0.9997656,0.00003880271,0.000022449041,0.0000034238683,0.0000021316023,0.0000011376908,0.00014297165,8.50117e-7,0.00002260296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99974996,0.0000521218,0.000019908875,0.000049503004,0.000045663273,0.00008288951],"domain_scores_gemma":[0.99859077,0.0002493311,0.0005714325,0.00007923963,0.00015555375,0.00035371084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059228786,0.00017567587,0.0002362865,0.0005406458,0.0002453267,0.00050207484,0.00024382239,0.00030120532,0.0008400036],"category_scores_gemma":[0.002193117,0.00012747041,0.00041396555,0.00057647075,0.00028713045,0.0002687146,0.0004267663,0.00027310906,0.00019554619],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015842609,0.0000060166326,0.9978841,0.0000037570169,0.000017547673,0.00011319892,0.0000371037,0.00010533876,0.00020240352,0.000009479801,0.00006699169,0.0013955984],"study_design_scores_gemma":[0.0000028236,0.00007264569,0.9989176,0.0000035601752,0.000019985358,0.0005059195,0.00007671641,0.00024931706,0.00005706807,0.000030018493,0.00006185189,0.0000026043444],"about_ca_topic_score_codex":0.0051688785,"about_ca_topic_score_gemma":0.006577279,"teacher_disagreement_score":0.0051688785,"about_ca_system_score_codex":0.0004735134,"about_ca_system_score_gemma":0.00044406278,"threshold_uncertainty_score":0.010277569},"labels":[],"label_agreement":null},{"id":"W4318293174","doi":"10.1016/j.euo.2023.01.003","title":"Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer—A Report of a Movember International Consensus Meeting","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada; Occupational Cancer Research Centre; Lunenfeld-Tanenbaum Research Institute; Sinai Health System; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institute for Health and Care Research; Movember Foundation","keywords":"Medicine; Prostate cancer; Rectal examination; Likert scale; Best practice; Medical physics; Family medicine; Prostate-specific antigen; Cancer; Internal medicine; Psychology","score_opus":0.08208314405228695,"score_gpt":0.4447289611247385,"score_spread":0.3626458170724515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318293174","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020110143,0.12265569,0.0250726,0.7650139,0.04490759,0.009158025,0.0014590103,0.00044265867,0.011180387],"genre_scores_gemma":[0.24173127,0.20633014,0.32385048,0.1570802,0.012947335,0.03556301,0.008815198,0.000888904,0.012793443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.7050899,0.14080966,0.070733964,0.011487865,0.0563535,0.015525088],"domain_scores_gemma":[0.698731,0.09833923,0.028645921,0.008548181,0.12808461,0.03765108],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.415867,0.0029587396,0.0048408476,0.009706968,0.0070008873,0.014438451,0.015787309,0.021713544,0.002610063],"category_scores_gemma":[0.253256,0.0029773486,0.009604852,0.009219003,0.0054563056,0.013798642,0.025180966,0.023614379,0.0014093784],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094992557,0.001310571,0.013517887,0.063306436,0.001800253,0.0021525256,0.06475045,0.00375981,0.0064791064,0.01936648,0.27742967,0.54517686],"study_design_scores_gemma":[0.0007373958,0.0012533714,0.022584215,0.13287331,0.0020818494,0.0015656746,0.07372742,0.004459869,0.0031798102,0.025029017,0.73150957,0.0009986188],"about_ca_topic_score_codex":0.014141089,"about_ca_topic_score_gemma":0.013728382,"teacher_disagreement_score":0.415867,"about_ca_system_score_codex":0.03026511,"about_ca_system_score_gemma":0.13066652,"threshold_uncertainty_score":0.72034},"labels":[],"label_agreement":null},{"id":"W4318754961","doi":"10.1016/j.euo.2023.01.010","title":"Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute; Eisai Incorporated; Genentech; Ipsen; Astellas Pharma; EUSA Pharma; Seagen; Sanofi; Exelixis; Memorial Sloan-Kettering Cancer Center; Merck Sharp and Dohme; Ono Pharmaceutical; Eisai; Merck KGaA; Handok; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Lenvatinib; Sunitinib; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Everolimus; Subgroup analysis; Kidney cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Cancer; Phases of clinical research; Meta-analysis; Immunotherapy","score_opus":0.03463152331413209,"score_gpt":0.3178959216777795,"score_spread":0.2832643983636474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318754961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956241,0.0017709394,0.00031526224,0.00019415817,0.00003180691,0.0006347269,0.0010412538,0.000016278338,0.0003714828],"genre_scores_gemma":[0.995684,0.00034299877,0.0006457987,0.00024829258,0.00006663802,0.00090080407,0.0018247312,0.000010166392,0.00027661287],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99586356,0.0030450614,0.000180105,0.0004035894,0.00034238893,0.00016532201],"domain_scores_gemma":[0.9968105,0.00094450207,0.0009946756,0.00038123992,0.00016084289,0.00070812326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077610724,0.0007141267,0.002046835,0.00039614973,0.00025036547,0.0007045037,0.0010331662,0.0007701038,0.0013533095],"category_scores_gemma":[0.0035127369,0.0003237277,0.0040903008,0.00046886006,0.00048886496,0.00064637914,0.00075887574,0.0016682666,0.00015679057],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.915854,0.0022486597,0.05463419,0.00043715196,0.010256226,0.000062113664,0.000108951135,0.0015580364,0.0035058062,0.00015534986,0.0010592177,0.010120374],"study_design_scores_gemma":[0.44282633,0.15617833,0.3729932,0.0001316921,0.013781042,0.0002881572,0.0002042128,0.006620509,0.0031065424,0.0007613222,0.0029961267,0.0001125518],"about_ca_topic_score_codex":0.0009656947,"about_ca_topic_score_gemma":0.0026244798,"teacher_disagreement_score":0.0077610724,"about_ca_system_score_codex":0.0008830501,"about_ca_system_score_gemma":0.0012973233,"threshold_uncertainty_score":0.04104501},"labels":[],"label_agreement":null},{"id":"W4319226694","doi":"10.1016/j.euo.2023.01.008","title":"A Matched Analysis of Active Surveillance Versus Nephrectomy for T1a Small Renal Masses","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Nephrectomy; Hazard ratio; Confidence interval; Internal medicine; Proportional hazards model; Cohort; Renal cell carcinoma; Urology; Surgery; Kidney","score_opus":0.06771732435127352,"score_gpt":0.32778051386068147,"score_spread":0.26006318950940793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319226694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99760026,0.0011601481,0.00034301204,0.000049284852,0.00008852874,0.000048843704,0.0002123281,0.0000046631417,0.0004928878],"genre_scores_gemma":[0.9990017,0.00013014633,0.000111254034,0.00007125482,0.000060790335,0.000022638158,0.0002398739,0.0000036155616,0.00035876303],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979492,0.0010032695,0.0001212471,0.0005430965,0.00013674496,0.00024659839],"domain_scores_gemma":[0.9978137,0.0011369223,0.00041188946,0.0002781738,0.000094566814,0.00026472137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018789254,0.0004530991,0.0011629355,0.00030071926,0.00033989185,0.00085475517,0.0006581493,0.00078565435,0.0031167073],"category_scores_gemma":[0.0042612706,0.00033008537,0.0018669821,0.00035806454,0.00043133312,0.0006158973,0.00047659766,0.0008588826,0.00027845515],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8008491,0.002926749,0.15187004,0.0004018644,0.009727374,0.00042052378,0.00022582553,0.0011409409,0.007615582,0.0005470711,0.0010474776,0.023227459],"study_design_scores_gemma":[0.05280246,0.17105252,0.7229065,0.00016691339,0.023694124,0.0012260546,0.0010239132,0.013045715,0.004542656,0.0024395823,0.0069856653,0.00011400897],"about_ca_topic_score_codex":0.0011911415,"about_ca_topic_score_gemma":0.0015202985,"teacher_disagreement_score":0.0031167073,"about_ca_system_score_codex":0.0005342771,"about_ca_system_score_gemma":0.00048416533,"threshold_uncertainty_score":0.010426402},"labels":[],"label_agreement":null},{"id":"W4323032055","doi":"10.1016/j.euo.2023.02.003","title":"Where To Draw the Line: Stratifying Risk for High-grade Ta Bladder Cancer","year":2023,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Oncology; Line (geometry); Internal medicine; Cancer","score_opus":0.04740955244551244,"score_gpt":0.3424454065617327,"score_spread":0.2950358541162203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323032055","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000549388,0.00080711074,0.00008566466,0.9905173,0.0067068934,0.000008155276,0.00005227983,0.000012440626,0.0012608881],"genre_scores_gemma":[0.007906219,0.0013074655,0.00052947074,0.941924,0.04487392,0.00003365442,0.00009031463,0.000024452238,0.0033105386],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99566674,0.0019424502,0.0006682725,0.0003865253,0.00083676504,0.0004992463],"domain_scores_gemma":[0.98773825,0.006085322,0.0006549281,0.00036739276,0.0022153314,0.002938869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042681047,0.0006297403,0.0018009577,0.0012895125,0.003887297,0.0033546935,0.0015276558,0.038466986,0.0056082625],"category_scores_gemma":[0.027426954,0.0008148953,0.0014701841,0.0009607872,0.0020725569,0.0039877114,0.0015643769,0.036764644,0.004798545],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017643023,0.0001147354,0.008229563,0.000074697855,0.00006761266,0.0015836634,0.00017278065,0.00013442138,0.0002906336,0.0021329734,0.9565891,0.030433409],"study_design_scores_gemma":[0.00079806393,0.000499882,0.019724814,0.001773538,0.00028453025,0.0071056397,0.0028422691,0.003681005,0.0005734714,0.05450054,0.9078866,0.00032951956],"about_ca_topic_score_codex":0.017458411,"about_ca_topic_score_gemma":0.03000099,"teacher_disagreement_score":0.038466986,"about_ca_system_score_codex":0.0045268177,"about_ca_system_score_gemma":0.007148733,"threshold_uncertainty_score":0.034713566},"labels":[],"label_agreement":null},{"id":"W4362469300","doi":"10.1016/j.euo.2023.03.004","title":"Radiation-based Therapy for Muscle-invasive Bladder Cancer: Contemporary Outcomes Across Tertiary Centers","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Université de Sherbrooke; University of Toronto; Western University; University of Calgary; McGill University Health Centre; University of Ottawa; McGill University; Queen's University; McMaster University; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Medicine; Bladder cancer; Cystectomy; Confidence interval; Internal medicine; Odds ratio; Urology; Stage (stratigraphy); Hazard ratio; Radiation therapy; Chemotherapy; Retrospective cohort study; Neoadjuvant therapy; Oncology; Cancer; Gastroenterology; Breast cancer","score_opus":0.04950774386209853,"score_gpt":0.3620813512570833,"score_spread":0.31257360739498474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362469300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912005,0.004328475,0.00022091552,0.00089836685,0.00003342525,0.000017630018,0.001126675,0.000013660293,0.002160268],"genre_scores_gemma":[0.9974577,0.0010705306,0.000062771316,0.00020776529,0.000032876633,0.0000062323497,0.00090420997,0.000008528643,0.00024943135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983808,0.00030329326,0.0002158191,0.0002955053,0.0003062524,0.00049841346],"domain_scores_gemma":[0.9958274,0.0005079007,0.0022118764,0.00019856851,0.00058938353,0.0006648631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013596928,0.00018372465,0.00043672742,0.0011493525,0.0007172737,0.0017900151,0.000634272,0.0005250453,0.0026652173],"category_scores_gemma":[0.004751807,0.00016102032,0.000618487,0.003941165,0.0007517425,0.0012449536,0.0022329884,0.000493621,0.00030344343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017641317,0.000056490157,0.98220116,0.00007065978,0.00016149909,0.00006398494,0.00047955744,0.00020010774,0.00020506348,0.00019773832,0.0007965162,0.0153907165],"study_design_scores_gemma":[0.000005682289,0.00007967913,0.9973762,0.000051519983,0.000059099617,0.0001542102,0.0012223689,0.000111649904,0.00007523565,0.00007781162,0.0007798479,0.0000066815883],"about_ca_topic_score_codex":0.016228864,"about_ca_topic_score_gemma":0.032979544,"teacher_disagreement_score":0.016228864,"about_ca_system_score_codex":0.0027138493,"about_ca_system_score_gemma":0.0019462958,"threshold_uncertainty_score":0.032268763},"labels":[],"label_agreement":null},{"id":"W4365812973","doi":"10.1016/j.euo.2023.03.002","title":"Adaptive Immunity in Genitourinary Cancers","year":2023,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia; Queen's University","funders":"Cancer Research Institute","keywords":"Immune system; Medicine; Prostate cancer; Cancer; Tumor microenvironment; Immunotherapy; Acquired immune system; Immune checkpoint; Genitourinary system; Immunology; Cancer research; Immunity; Oncology; Internal medicine","score_opus":0.12046106995638806,"score_gpt":0.3908199258552533,"score_spread":0.27035885589886527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365812973","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000728317,0.99619055,0.0001827641,0.0018468769,0.00023399213,0.000009954282,0.00004000603,0.0000039394718,0.00076352415],"genre_scores_gemma":[0.015584321,0.98129314,0.00033335827,0.0015764114,0.00079654634,0.000028971795,0.000058152382,0.0000017910621,0.00032735884],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99940467,0.00027868774,0.00011232856,0.00007098365,0.0001021684,0.00003105615],"domain_scores_gemma":[0.9974928,0.0016848693,0.00044576713,0.00003481078,0.0002813435,0.000060458704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014368513,0.00040428623,0.0006470911,0.0010439393,0.0001888176,0.001013937,0.00042605877,0.00086161913,0.0019853683],"category_scores_gemma":[0.0038322418,0.000121216064,0.00048366692,0.0010400524,0.00053752353,0.00085427274,0.0005596869,0.0010223229,0.00027608682],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048241374,0.00005655888,0.004731327,0.1362148,0.00070163317,0.0009787511,0.00045380747,0.00062157813,0.0025411167,0.010432636,0.026698329,0.81608707],"study_design_scores_gemma":[0.00012537026,0.0010079847,0.01658085,0.11893554,0.0018843805,0.0073594446,0.0011467111,0.00035647457,0.0025454804,0.01663935,0.8333664,0.000051879677],"about_ca_topic_score_codex":0.0005733947,"about_ca_topic_score_gemma":0.0009549714,"teacher_disagreement_score":0.0019853683,"about_ca_system_score_codex":0.0005422529,"about_ca_system_score_gemma":0.0019424888,"threshold_uncertainty_score":0.007598877},"labels":[],"label_agreement":null},{"id":"W4383874542","doi":"10.1016/j.euo.2023.05.013","title":"Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524—A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; NRG Oncology","keywords":"Medicine; Cystectomy; Internal medicine; Oncology; Clinical endpoint; Radiation therapy; Trastuzumab; Bladder cancer; Toxicity; Paclitaxel; Chemotherapy; Urology; Randomized controlled trial; Cancer; Breast cancer","score_opus":0.050891716655193604,"score_gpt":0.3631017691669565,"score_spread":0.3122100525117629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383874542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98868495,0.008049373,0.0001196805,0.00040032377,0.00010560307,0.000047123693,0.0009890266,0.000013005431,0.0015908785],"genre_scores_gemma":[0.99524707,0.0011935636,0.000078646975,0.00036321217,0.00011466064,0.00004590646,0.002051238,0.0000066961466,0.00089903845],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994475,0.00021246276,0.000045909266,0.00006434469,0.000086019405,0.00014379405],"domain_scores_gemma":[0.9983923,0.00028777955,0.0005249817,0.00010279657,0.000106240586,0.0005858153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011816381,0.00029067695,0.00066660164,0.00023386498,0.00036004232,0.0008317267,0.0004987253,0.0006447008,0.0013962089],"category_scores_gemma":[0.0021049348,0.00013219216,0.0014046503,0.00033886422,0.00031720017,0.00047682077,0.0004878741,0.0011050823,0.00027343372],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2869269,0.011123923,0.4010079,0.0011926431,0.007249976,0.00094023993,0.00058836496,0.006055332,0.008385465,0.00045430753,0.013895864,0.26217908],"study_design_scores_gemma":[0.009788682,0.07097763,0.9077289,0.00020897311,0.0034331535,0.0006357176,0.00025538684,0.0011018197,0.0011461052,0.00031911762,0.004337254,0.00006722944],"about_ca_topic_score_codex":0.0023416993,"about_ca_topic_score_gemma":0.006229783,"teacher_disagreement_score":0.0023416993,"about_ca_system_score_codex":0.00083120813,"about_ca_system_score_gemma":0.0005887855,"threshold_uncertainty_score":0.00624913},"labels":[],"label_agreement":null},{"id":"W4384701084","doi":"10.1016/j.euo.2023.06.006","title":"Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant Therapy","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Shanghai Education Development Foundation; Changhai Hospital of Shanghai; Shanghai Municipal Health Bureau; Shanghai Municipal Education Commission; National Natural Science Foundation of China","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Hazard ratio; Clear cell renal cell carcinoma; Oncology; Nephrectomy; Proportional hazards model; Adjuvant therapy; Cancer; Urology; Confidence interval; Kidney","score_opus":0.038756231525032145,"score_gpt":0.2903480757409217,"score_spread":0.25159184421588954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384701084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987914,0.00015033393,0.000104270905,0.000035648303,0.000005857013,0.0000028684522,0.00058321713,0.000003232863,0.00032331527],"genre_scores_gemma":[0.9992926,0.000039098642,0.00004856285,0.0000062216914,0.000005386325,0.0000017194725,0.0005357135,0.0000026626583,0.00006800455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907994,0.0003421264,0.00015648437,0.00016186196,0.00013008331,0.00012946325],"domain_scores_gemma":[0.99498355,0.0012275379,0.0021642454,0.00069581,0.00048254564,0.00044630308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012341253,0.0001168899,0.00031644836,0.0010694589,0.00029019653,0.00082167983,0.0004276296,0.0003156788,0.0014824034],"category_scores_gemma":[0.007250926,0.00015153385,0.00036465298,0.0020290317,0.0002875145,0.0006209669,0.0006093186,0.00034362252,0.0001902273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000074703275,0.000004334709,0.99918205,0.0000020631662,0.000016374208,0.000018493407,0.0000156052,0.000023174285,0.000054749446,0.000017906434,0.000038472106,0.0005521065],"study_design_scores_gemma":[0.0000047534604,0.000037886126,0.99913245,0.0000023568032,0.000026426593,0.00019342233,0.0001132352,0.00022650615,0.0000748621,0.0000450458,0.000140832,0.0000023210832],"about_ca_topic_score_codex":0.0039173793,"about_ca_topic_score_gemma":0.004657711,"teacher_disagreement_score":0.0039173793,"about_ca_system_score_codex":0.0002969605,"about_ca_system_score_gemma":0.0005516475,"threshold_uncertainty_score":0.007789135},"labels":[],"label_agreement":null},{"id":"W4384937683","doi":"10.1016/j.euo.2023.06.010","title":"Efficacy and Effectiveness: Bridging the Gap Between Clinical Trials and Real-world Practice","year":2023,"lang":"en","type":"editorial","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Clinical trial; Oncology; Androgen deprivation therapy; Internal medicine; Cancer","score_opus":0.19224935275203967,"score_gpt":0.5299734068866627,"score_spread":0.33772405413462303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384937683","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017612942,0.013368358,0.0002088542,0.054359693,0.93135613,0.000020089019,0.000038373688,0.000040842817,0.0005900607],"genre_scores_gemma":[0.000317981,0.006196646,0.00023076209,0.030260926,0.9613801,0.00003368035,0.000012994593,0.00003393583,0.0015328709],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.95274335,0.018105088,0.0069585326,0.0033891145,0.017444037,0.001359913],"domain_scores_gemma":[0.6668225,0.26363254,0.008948255,0.004752958,0.04342498,0.012418778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06739248,0.0059474595,0.010762101,0.0068219835,0.0050028544,0.017618464,0.0083667375,0.041860662,0.008590638],"category_scores_gemma":[0.19737826,0.0030465066,0.0051870374,0.0046326392,0.009668641,0.012454396,0.0036310947,0.05827101,0.006962193],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000728957,0.000014046907,0.00002692641,0.0009361431,0.00011019494,0.00007773253,0.000032454802,0.000034104327,0.000032085412,0.0008601381,0.9908835,0.0069196913],"study_design_scores_gemma":[0.00046650728,0.00009324372,0.0005028134,0.0050352816,0.0005654685,0.00046445307,0.00017156886,0.00059818,0.00017750697,0.010985032,0.9808348,0.00010529434],"about_ca_topic_score_codex":0.0034939959,"about_ca_topic_score_gemma":0.010316763,"teacher_disagreement_score":0.06739248,"about_ca_system_score_codex":0.009205533,"about_ca_system_score_gemma":0.01164763,"threshold_uncertainty_score":0.3564098},"labels":[],"label_agreement":null},{"id":"W4385552827","doi":"10.1016/j.euo.2023.07.001","title":"Navigating Nomograms To Identify Prostate Cancer Patients for Lymph Node Dissection","year":2023,"lang":"en","type":"editorial","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Nomogram; Prostate cancer; Medicine; Lymph node; Positron emission tomography; Dissection (medical); Prostate-specific antigen; Cancer; Prostate; Radiology; Nuclear medicine; Oncology; Internal medicine","score_opus":0.018976499963864062,"score_gpt":0.3726251895906243,"score_spread":0.3536486896267602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385552827","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004689514,0.009266274,0.00094645965,0.053737156,0.9338791,0.0000491298,0.0001577428,0.00015828559,0.0017589881],"genre_scores_gemma":[0.00062975916,0.008198156,0.0009903596,0.033453435,0.94928443,0.00006900929,0.00011800229,0.00010756758,0.0071493387],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.992897,0.0023506652,0.0010056288,0.00064876967,0.0028358586,0.0002622174],"domain_scores_gemma":[0.9415432,0.0319385,0.0018550606,0.0010265375,0.02067211,0.0029644081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01713396,0.0031742742,0.0037824344,0.0054329513,0.002667406,0.007883443,0.003301357,0.01506921,0.010516891],"category_scores_gemma":[0.058200452,0.0019929411,0.0040669246,0.0020279603,0.0023653642,0.004826207,0.0017895023,0.022979505,0.009616444],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038366088,0.000007696348,0.00004101363,0.00020541952,0.00004637982,0.000046360543,0.000012201878,0.0000437997,0.000027076807,0.00015896994,0.98957705,0.009795685],"study_design_scores_gemma":[0.00029506086,0.00006783487,0.00068550435,0.0015200408,0.00041497248,0.00047390736,0.0000896857,0.0011776024,0.0001692349,0.0028534217,0.9921928,0.000059901417],"about_ca_topic_score_codex":0.006144058,"about_ca_topic_score_gemma":0.015616872,"teacher_disagreement_score":0.01713396,"about_ca_system_score_codex":0.002880118,"about_ca_system_score_gemma":0.0038227525,"threshold_uncertainty_score":0.09061414},"labels":[],"label_agreement":null},{"id":"W4385649872","doi":"10.1016/j.euo.2023.07.011","title":"Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Else Kröner-Fresenius-Stiftung","keywords":"Medicine; Bladder cancer; Oncology; Cystectomy; Grading (engineering); Immune checkpoint; Immune system; Internal medicine; Adjuvant; Extracellular matrix; Pathology; Cancer; Immunotherapy; Immunology; Biology","score_opus":0.029991755215776218,"score_gpt":0.2978869095146267,"score_spread":0.26789515429885047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385649872","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33874613,0.008896479,0.6248205,0.0062506953,0.0016917484,0.0037677016,0.0041732746,0.0024889014,0.009164618],"genre_scores_gemma":[0.37981832,0.0010781438,0.610118,0.00061964046,0.0006203677,0.0021772573,0.0042672334,0.00010434467,0.001196696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797183,0.0006784965,0.00033032603,0.0003080954,0.00056283566,0.0001484103],"domain_scores_gemma":[0.99362344,0.001091663,0.00082617917,0.00038077412,0.0035387615,0.0005391852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0078983605,0.0016398209,0.001346785,0.006224725,0.00077320106,0.002561252,0.0022610205,0.0012285748,0.0019488076],"category_scores_gemma":[0.011152836,0.00040039248,0.0014959096,0.002671701,0.0010001574,0.0020192128,0.0013826374,0.0018205227,0.0015735638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008425396,0.0007404304,0.574236,0.00078351394,0.00058858166,0.0004768532,0.00047833988,0.009151484,0.020750904,0.008072625,0.01543194,0.36844674],"study_design_scores_gemma":[0.0009818866,0.005667834,0.6055858,0.001236311,0.002706702,0.005431563,0.003109257,0.26617724,0.012520021,0.048442915,0.04751322,0.0006271746],"about_ca_topic_score_codex":0.0031554021,"about_ca_topic_score_gemma":0.0037179075,"teacher_disagreement_score":0.0078983605,"about_ca_system_score_codex":0.0014635588,"about_ca_system_score_gemma":0.004100354,"threshold_uncertainty_score":0.041770995},"labels":[],"label_agreement":null},{"id":"W4386052342","doi":"10.1016/j.euo.2023.07.015","title":"Re: Francesco Giganti, Louise Dickinson, Clement Orczyk, et al. Prostate Imaging After Focal Ablation (PI-FAB): A Proposal for a Scoring System for Multiparametric MRI of the Prostate After Focal Therapy. Eur Urol Oncol. 2023;6:629–634","year":2023,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate; Multiparametric MRI; Magnetic resonance imaging; Ablation Therapy; Ablation; Prostate cancer; Radiology; Nuclear medicine; Medical physics; Internal medicine","score_opus":0.020006935837552156,"score_gpt":0.29612002832099477,"score_spread":0.2761130924834426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386052342","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00064776227,0.0030478137,0.00017915259,0.9576892,0.030408664,0.000023917282,0.00013585386,0.00007295914,0.0077945893],"genre_scores_gemma":[0.0072977147,0.0032098417,0.00025797167,0.9056565,0.059111338,0.00005010179,0.00012038767,0.00005483662,0.024241338],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990471,0.00018502175,0.0001242201,0.00014765012,0.0003485517,0.00014744145],"domain_scores_gemma":[0.99711037,0.0009666047,0.00018803925,0.000089445006,0.0011236313,0.00052193017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010000989,0.000987354,0.001005928,0.00084859936,0.0020317673,0.0022315865,0.000995562,0.017227456,0.017496625],"category_scores_gemma":[0.011701764,0.00063317915,0.0009052343,0.00056133507,0.0010420618,0.0026250838,0.0007919442,0.020311031,0.019165277],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040361752,0.000027038122,0.00076973194,0.000027010754,0.000010583193,0.0027578692,0.000040560284,0.00004282545,0.00011286866,0.00044569277,0.98923445,0.0064910753],"study_design_scores_gemma":[0.00015273054,0.00006208835,0.003674057,0.0004498133,0.000034266213,0.01424821,0.00044818633,0.0006113188,0.00030630137,0.0037348436,0.9761929,0.00008537783],"about_ca_topic_score_codex":0.007907767,"about_ca_topic_score_gemma":0.010892563,"teacher_disagreement_score":0.017496625,"about_ca_system_score_codex":0.0028502687,"about_ca_system_score_gemma":0.0019429325,"threshold_uncertainty_score":0.058532},"labels":[],"label_agreement":null},{"id":"W4386753000","doi":"10.1016/j.euo.2023.08.004","title":"Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer","year":2023,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"AstraZeneca","keywords":"Medicine; Prostate cancer; Genetic testing; Guideline; Molecular diagnostics; Disease; Clinical trial; Cancer; Bioinformatics; Homologous recombination; Intensive care medicine; Internal medicine; Pathology; Gene; Genetics","score_opus":0.19306534459357183,"score_gpt":0.4938495154396637,"score_spread":0.3007841708460919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386753000","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025183698,0.27100584,0.02329414,0.6690391,0.0074297157,0.0021685548,0.0026751528,0.0006089203,0.021260165],"genre_scores_gemma":[0.046284474,0.39346236,0.23737112,0.2985968,0.006530529,0.0077343103,0.003752702,0.0002572721,0.006010487],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9375902,0.03838719,0.013827608,0.0018032518,0.0072267507,0.0011649943],"domain_scores_gemma":[0.69745785,0.21697691,0.022250555,0.004953221,0.053631753,0.004729738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05076549,0.0013347949,0.0024416267,0.0070961695,0.0018650354,0.0053829234,0.004663044,0.013512889,0.010915715],"category_scores_gemma":[0.24158186,0.0011371006,0.0044210767,0.00505697,0.0031901742,0.010111723,0.0047107153,0.008191721,0.0048933565],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020463947,0.00024576767,0.0031869025,0.09728312,0.00047571753,0.0011732861,0.0038616096,0.0012360231,0.00084432506,0.021657366,0.48390058,0.38593063],"study_design_scores_gemma":[0.00034964184,0.00017386333,0.0034935023,0.35375157,0.0009109943,0.0011904562,0.0033507268,0.00073848164,0.00043742848,0.036251552,0.59914654,0.00020534576],"about_ca_topic_score_codex":0.009858728,"about_ca_topic_score_gemma":0.021479063,"teacher_disagreement_score":0.05076549,"about_ca_system_score_codex":0.0049874918,"about_ca_system_score_gemma":0.03343363,"threshold_uncertainty_score":0.26847672},"labels":[],"label_agreement":null},{"id":"W4387422001","doi":"10.1016/j.euo.2023.09.023","title":"Corrigendum to “Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes” [European Urology Oncology (2023)]","year":2023,"lang":"en","type":"erratum","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Grading (engineering); Bladder cancer; Urothelial cancer; Stromal cell; Disease; Regret; Pathology; Cancer; Oncology; Urology; Internal medicine","score_opus":0.03803041929556203,"score_gpt":0.30375274419700765,"score_spread":0.26572232490144565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387422001","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021977456,0.0024963228,0.002023721,0.12280649,0.86493504,0.00009605773,0.00083615823,0.00041807073,0.006168317],"genre_scores_gemma":[0.008644117,0.010898553,0.011388422,0.2279446,0.5034346,0.0004262789,0.0032201959,0.0012766748,0.23276657],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99703395,0.00073134847,0.0005456122,0.00035762196,0.0011219669,0.0002094115],"domain_scores_gemma":[0.9741424,0.005663492,0.001179838,0.0009716431,0.016916707,0.001125922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033666957,0.0012815539,0.0012813153,0.0027182074,0.0018532693,0.002710973,0.0024479423,0.0045817997,0.043231927],"category_scores_gemma":[0.048083805,0.00076546473,0.0018945822,0.001304603,0.0019160677,0.0013686338,0.0014117715,0.00924461,0.042024948],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013058714,0.0000054612783,0.0000688745,0.00006969467,0.000007067817,0.00014060036,0.000012557963,0.000021880684,0.000043891916,0.00034249038,0.9936533,0.0056212177],"study_design_scores_gemma":[0.000028218834,0.000029249659,0.0009617728,0.00032450966,0.000044893743,0.0007990431,0.000048095517,0.00024623575,0.00030498818,0.0014350155,0.99573505,0.000042963842],"about_ca_topic_score_codex":0.015406676,"about_ca_topic_score_gemma":0.015961068,"teacher_disagreement_score":0.043231927,"about_ca_system_score_codex":0.0026471775,"about_ca_system_score_gemma":0.0034725976,"threshold_uncertainty_score":0.14462525},"labels":[],"label_agreement":null},{"id":"W4387581643","doi":"10.1016/j.euo.2023.09.013","title":"Magnetic Resonance Imaging–Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE)","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University; London Health Sciences Centre; University of British Columbia; Health Sciences Centre; Western University; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Magnetic resonance imaging; Prostate cancer; Biopsy; Prospective cohort study; Randomized controlled trial; Cohort; Prostate; Clinical trial; Radiology; Cancer; Internal medicine","score_opus":0.01715593541524281,"score_gpt":0.28339348363802047,"score_spread":0.2662375482227777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387581643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987568,0.0071027796,0.0010185372,0.0006293764,0.00075953704,0.0010308329,0.0007125993,0.00008664124,0.0010915872],"genre_scores_gemma":[0.99195427,0.0019562852,0.0012492118,0.00071854447,0.00065924024,0.0010210284,0.0009724077,0.000028828277,0.0014402383],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99690706,0.0018355695,0.00017411087,0.00065636734,0.00015953514,0.00026739537],"domain_scores_gemma":[0.99540836,0.0018021446,0.0012504866,0.0006949066,0.0002290215,0.00061506947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046691718,0.002440961,0.0064271586,0.00043373936,0.00068953796,0.0018168179,0.0013282987,0.0028789407,0.0056261583],"category_scores_gemma":[0.006310192,0.0013264492,0.006102957,0.00062624045,0.0021367741,0.0022112832,0.00089884456,0.0045446856,0.00094874244],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9935737,0.0008910724,0.0006628838,0.00019569746,0.0018786436,0.00001953671,0.00002241861,0.00016944313,0.000427667,0.00004819665,0.00015036616,0.0019604217],"study_design_scores_gemma":[0.95403606,0.037096683,0.0037009614,0.000052514803,0.0038938993,0.00004517872,0.000036977683,0.00039367232,0.00025121332,0.00021149464,0.0002563697,0.000024997526],"about_ca_topic_score_codex":0.0012921176,"about_ca_topic_score_gemma":0.0016405572,"teacher_disagreement_score":0.0064271586,"about_ca_system_score_codex":0.0008196461,"about_ca_system_score_gemma":0.0012016537,"threshold_uncertainty_score":0.02469325},"labels":[],"label_agreement":null},{"id":"W4388039327","doi":"10.1016/j.euo.2023.10.002","title":"Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Western University; Dalhousie University; University of Alberta; Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; University of Calgary","funders":"Genentech; Yasuda Memorial Medical Foundation; Bristol-Myers Squibb","keywords":"Medicine; Renal cell carcinoma; Subgroup analysis; Systemic therapy; Internal medicine; Nephrectomy; Oncology; Proportional hazards model; Immunotherapy; Urology; Cancer; Surgery; Kidney; Breast cancer; Confidence interval","score_opus":0.027935149860748514,"score_gpt":0.25839536693978665,"score_spread":0.23046021707903813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388039327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98906857,0.00087928085,0.000103712206,0.000118624375,0.0000077022805,0.000020685884,0.008860783,0.000005028089,0.00093558495],"genre_scores_gemma":[0.98698574,0.0003803657,0.00014904344,0.00011441429,0.000016202423,0.000021083792,0.012199762,0.000004517075,0.00012888711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993635,0.000110248286,0.00010271998,0.00021682392,0.0001264185,0.000080331425],"domain_scores_gemma":[0.99875176,0.00020434329,0.0006308441,0.000089042,0.00014800708,0.00017594724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057721743,0.0002135894,0.00063200825,0.0007991883,0.00030505765,0.00083742867,0.00052492146,0.00046280536,0.0009047045],"category_scores_gemma":[0.0019989223,0.00011067807,0.00061306974,0.0019976567,0.00018190657,0.0005421405,0.0006669505,0.00037429217,0.00017079638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002894552,0.000028507973,0.9964839,0.000033392287,0.00013444008,0.00005971309,0.00003742106,0.00010615235,0.00021292892,0.000043425753,0.00048562678,0.0020850624],"study_design_scores_gemma":[0.000021839805,0.000060696275,0.99831533,0.000012558385,0.000088482855,0.00031266228,0.000118578406,0.00024830736,0.000090863396,0.00004118973,0.00068425917,0.0000051831607],"about_ca_topic_score_codex":0.0068061263,"about_ca_topic_score_gemma":0.011518156,"teacher_disagreement_score":0.0068061263,"about_ca_system_score_codex":0.00060023565,"about_ca_system_score_gemma":0.0007652956,"threshold_uncertainty_score":0.013533056},"labels":[],"label_agreement":null},{"id":"W4388182309","doi":"10.1016/j.euo.2023.10.004","title":"Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Abiraterone; Medicine; Prostate cancer; Pharmacokinetics; Pharmacology; Oncology; Internal medicine; Drug; Abiraterone acetate; Urology; Cancer; Androgen deprivation therapy; Androgen receptor; Chemistry","score_opus":0.20734976340744182,"score_gpt":0.4296062803691044,"score_spread":0.2222565169616626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388182309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714606,0.013871711,0.0013697078,0.0008331825,0.00011984704,0.0011048312,0.006142065,0.00013147343,0.0049665514],"genre_scores_gemma":[0.9777362,0.004320798,0.0024384006,0.0009993738,0.00017302025,0.0010629455,0.01108401,0.00004543652,0.0021398193],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9994848,0.00022387445,0.000033149936,0.00006324614,0.00013752551,0.000057473677],"domain_scores_gemma":[0.99922264,0.00022315525,0.00020395804,0.000060647304,0.00009144422,0.00019811417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012098282,0.00047064404,0.0009166551,0.00030200012,0.0002659913,0.0007911039,0.00036409253,0.00035212527,0.0032354973],"category_scores_gemma":[0.0014373583,0.00023404567,0.0007308529,0.00058859866,0.0002872257,0.0004764246,0.0002756794,0.0015786407,0.00047619463],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4741653,0.0071815643,0.052481014,0.0032702645,0.0040582144,0.0014511552,0.00034424427,0.007120908,0.089479476,0.00061959063,0.0196414,0.34018686],"study_design_scores_gemma":[0.4012484,0.21882412,0.25660813,0.000529331,0.003601998,0.0078761205,0.00027292926,0.009021981,0.02661367,0.0020031016,0.073207915,0.00019239413],"about_ca_topic_score_codex":0.00071248505,"about_ca_topic_score_gemma":0.0024276022,"teacher_disagreement_score":0.0032354973,"about_ca_system_score_codex":0.00065021944,"about_ca_system_score_gemma":0.0013068838,"threshold_uncertainty_score":0.010823786},"labels":[],"label_agreement":null},{"id":"W4388448664","doi":"10.1016/j.euo.2023.10.008","title":"Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Western University","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Abiraterone acetate; Pembrolizumab; Internal medicine; Oncology; Cohort; Interquartile range; Adverse effect; Clinical endpoint; Androgen deprivation therapy; Cancer; Clinical trial; Androgen receptor; Immunotherapy","score_opus":0.024215989961962586,"score_gpt":0.33157935936329525,"score_spread":0.3073633694013327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388448664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997012,0.0010071077,0.00011609454,0.00010769396,0.00002564206,0.00049154455,0.0008020465,0.000007395936,0.00043033774],"genre_scores_gemma":[0.9966568,0.00038679267,0.0002736388,0.00021377654,0.00006834254,0.00033121795,0.0017224493,0.0000039107517,0.00034296897],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991085,0.00038752955,0.00007916496,0.00017148297,0.00013086609,0.00012240165],"domain_scores_gemma":[0.9989673,0.000114194256,0.0003261059,0.0001344206,0.00008145823,0.00037656786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024565356,0.0008941525,0.0011296232,0.00030568623,0.0005855422,0.00082471827,0.00069783523,0.00071650546,0.0016844101],"category_scores_gemma":[0.0014354535,0.0004888116,0.0015504292,0.00040506065,0.00038932633,0.0006022938,0.00045834808,0.0013562442,0.00034016056],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5217081,0.016698714,0.41007861,0.0006115078,0.004280325,0.0005114009,0.0004971198,0.0011770608,0.0111098755,0.00019486874,0.0035591035,0.029573306],"study_design_scores_gemma":[0.15490237,0.13399838,0.69387233,0.00015962371,0.0031428447,0.0010793591,0.0004382077,0.0019240391,0.0028413876,0.00020755657,0.00734572,0.00008809358],"about_ca_topic_score_codex":0.0031076535,"about_ca_topic_score_gemma":0.0056102946,"teacher_disagreement_score":0.0031076535,"about_ca_system_score_codex":0.0011225145,"about_ca_system_score_gemma":0.0019973638,"threshold_uncertainty_score":0.012991548},"labels":[],"label_agreement":null},{"id":"W4388573879","doi":"10.1016/j.euo.2023.10.014","title":"Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lymphovascular invasion; Proportional hazards model; Seminoma; Oncology; Testicular cancer; Hazard ratio; Internal medicine; Stage (stratigraphy); Cohort; Nomogram; Cancer; Confidence interval; Chemotherapy; Metastasis","score_opus":0.2090117117722878,"score_gpt":0.43286572740200224,"score_spread":0.22385401562971444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388573879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8294591,0.013001143,0.009823089,0.009258465,0.00026815763,0.0013526593,0.12950163,0.00016097385,0.0071748574],"genre_scores_gemma":[0.91225165,0.0040828045,0.018652283,0.0015848986,0.0001082301,0.001378788,0.060795847,0.00009783493,0.0010476824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969278,0.0013760284,0.00064015895,0.0002807137,0.00060413143,0.00017116907],"domain_scores_gemma":[0.9909546,0.0042743306,0.0020879866,0.000591674,0.0017211898,0.0003702903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050476026,0.00025472333,0.00090011343,0.0018894362,0.00036187473,0.0008606378,0.00047606236,0.00048032723,0.001653],"category_scores_gemma":[0.014634745,0.00025829658,0.0017447294,0.0031914678,0.00018435849,0.00059706415,0.0006565915,0.00073360885,0.00023175779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001393494,0.00012529013,0.89698786,0.0005990515,0.0017906884,0.00009961887,0.00029554826,0.00088488567,0.0004633647,0.00075612887,0.03272298,0.06388109],"study_design_scores_gemma":[0.0006759353,0.00022258394,0.97441465,0.00087962655,0.0016864535,0.00036195345,0.0006748642,0.0019490649,0.00051403476,0.0011915418,0.017380087,0.00004910179],"about_ca_topic_score_codex":0.0066368547,"about_ca_topic_score_gemma":0.016451586,"teacher_disagreement_score":0.0066368547,"about_ca_system_score_codex":0.0005703486,"about_ca_system_score_gemma":0.002246032,"threshold_uncertainty_score":0.026694596},"labels":[],"label_agreement":null},{"id":"W4388783891","doi":"10.1016/j.euo.2023.11.001","title":"Metastatic Organotropism Differential Treatment Response in Urothelial Carcinoma: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials","year":2023,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Oncology; Internal medicine; Hazard ratio; Metastasectomy; Durvalumab; Metastasis; Atezolizumab; Meta-analysis; Clinical endpoint; Randomized controlled trial; Confidence interval; Cancer; Pembrolizumab; Immunotherapy; Bladder cancer","score_opus":0.1729184333299326,"score_gpt":0.41188422629875726,"score_spread":0.23896579296882467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388783891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0062464993,0.9906949,0.0008841611,0.000309035,0.00016206651,0.00058536563,0.0008043866,0.00003046017,0.00028297323],"genre_scores_gemma":[0.34344685,0.64385915,0.0044819503,0.0019971537,0.00042147638,0.003800834,0.0015516048,0.000057603633,0.00038335807],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9799692,0.01201917,0.0042693317,0.0018389925,0.001445522,0.00045766562],"domain_scores_gemma":[0.96555907,0.025754947,0.0058017327,0.0010938529,0.001481453,0.00030903067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020857448,0.0023917435,0.018224435,0.004786596,0.00056232896,0.0028858809,0.001980926,0.0021582567,0.003503427],"category_scores_gemma":[0.049539134,0.0011827552,0.03485258,0.0059359292,0.00089559465,0.0017857009,0.0015010042,0.0018787883,0.00025930654],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022254349,0.000019929541,0.004379355,0.3737429,0.61010057,0.000084013955,0.000067106,0.00046752824,0.000184749,0.00014559149,0.0005543034,0.008028465],"study_design_scores_gemma":[0.00097259704,0.00020823399,0.0034638196,0.027899377,0.9656632,0.00006477629,0.000029977104,0.00020687554,0.00009342609,0.00023137254,0.0011464815,0.00001982354],"about_ca_topic_score_codex":0.0054148273,"about_ca_topic_score_gemma":0.012430906,"teacher_disagreement_score":0.020857448,"about_ca_system_score_codex":0.0028589459,"about_ca_system_score_gemma":0.003895622,"threshold_uncertainty_score":0.110306084},"labels":[],"label_agreement":null},{"id":"W4388784547","doi":"10.1016/j.euo.2023.10.024","title":"Liquid Biopsies Will Drive Treatment Decisions in the Future","year":2023,"lang":"en","type":"editorial","venue":"European Urology Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; Positron emission tomography; Biopsy; Cancer; Radiology; Molecular imaging; Prostate cancer; Fluorodeoxyglucose; Cancer treatment; Medical physics; Internal medicine","score_opus":0.01006620525191059,"score_gpt":0.2800884320993827,"score_spread":0.2700222268474721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388784547","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023450842,0.0059416587,0.00021834411,0.05402827,0.9384875,0.00000998812,0.000036910595,0.00004802164,0.0012056964],"genre_scores_gemma":[0.0002830162,0.003579275,0.00017382034,0.02947949,0.961505,0.000012678646,0.000020330835,0.000023844916,0.004922552],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937844,0.0016831314,0.00069139444,0.0006240512,0.0028579147,0.00035904886],"domain_scores_gemma":[0.9486743,0.028146029,0.002075852,0.0010871076,0.015016957,0.004999705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011769781,0.0027700618,0.0032966374,0.0025568642,0.0022852914,0.0073418464,0.0029359176,0.019319132,0.011609228],"category_scores_gemma":[0.03992694,0.0011464625,0.0028810687,0.0010934711,0.0028515498,0.005053231,0.0016042503,0.032575797,0.00865188],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003650426,0.000010601869,0.000031964264,0.00014207944,0.000022278417,0.00008552995,0.0000069825114,0.0000371486,0.000039568506,0.0004971193,0.99129957,0.007790763],"study_design_scores_gemma":[0.00010354846,0.000037048605,0.00037735156,0.0005313981,0.00009063971,0.00033519926,0.000038989532,0.00034329,0.0001255192,0.0035851318,0.9943954,0.00003657851],"about_ca_topic_score_codex":0.002478242,"about_ca_topic_score_gemma":0.0072497595,"teacher_disagreement_score":0.019319132,"about_ca_system_score_codex":0.003283295,"about_ca_system_score_gemma":0.0034840435,"threshold_uncertainty_score":0.06224531},"labels":[],"label_agreement":null},{"id":"W4388792763","doi":"10.1016/j.euo.2023.10.029","title":"Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds","year":2023,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Meta-analysis; Prostate cancer; Prostate; Diagnostic accuracy; Cancer detection; Clinical Practice; Oncology; Medical physics; Cancer; Radiology; Pathology; Internal medicine","score_opus":0.146282979589173,"score_gpt":0.4195829427805316,"score_spread":0.27329996319135863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388792763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005057816,0.9927712,0.0009608388,0.00024383192,0.00013164438,0.00017376232,0.0004600012,0.000023889665,0.00017706834],"genre_scores_gemma":[0.31390366,0.67583686,0.0053062816,0.0013529108,0.0005607831,0.0012954625,0.0014024357,0.000051989762,0.0002895984],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9792981,0.010253573,0.0053545116,0.002362468,0.002255801,0.00047558354],"domain_scores_gemma":[0.9374778,0.05062544,0.0070206337,0.0016122805,0.0028995904,0.00036419978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024523634,0.0030212612,0.017833054,0.00853783,0.00074987614,0.0037496306,0.002400318,0.0025727358,0.0022694643],"category_scores_gemma":[0.06634197,0.0015455664,0.046813443,0.00812096,0.0010385836,0.002190266,0.0016621866,0.0020304702,0.00025768485],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021132047,0.000026751588,0.012671763,0.23746113,0.73318064,0.00011647608,0.000068092595,0.00057597656,0.00020450458,0.0001433246,0.00050284644,0.012935254],"study_design_scores_gemma":[0.00030099833,0.00012801154,0.0043519833,0.015657539,0.9781516,0.00008795411,0.000024069775,0.000253474,0.000113090195,0.00020096278,0.00070975104,0.000020512436],"about_ca_topic_score_codex":0.0063569285,"about_ca_topic_score_gemma":0.009691323,"teacher_disagreement_score":0.024523634,"about_ca_system_score_codex":0.0027676984,"about_ca_system_score_gemma":0.003577614,"threshold_uncertainty_score":0.12969488},"labels":[],"label_agreement":null},{"id":"W4389506762","doi":"10.1016/j.euo.2023.11.015","title":"Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Titan (rocket family); Post-hoc analysis; Hazard ratio; Androgen deprivation therapy; Prostate-specific antigen; Oncology; Internal medicine; Proportional hazards model; Urology; Cancer; Confidence interval","score_opus":0.03240159015732779,"score_gpt":0.33411530116144855,"score_spread":0.30171371100412075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389506762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990877,0.00012654556,0.00012612762,0.000036543377,0.00003808846,0.000028259412,0.00022389481,0.0000051101615,0.00032766128],"genre_scores_gemma":[0.99848336,0.000039459435,0.00014996185,0.000038895716,0.00002634196,0.00006042048,0.0003304692,0.000003893199,0.0008672164],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986557,0.00058565306,0.000073677256,0.0002426903,0.00012206412,0.00032021035],"domain_scores_gemma":[0.99839455,0.00094009016,0.00019532088,0.000121023666,0.0001010061,0.00024801414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016299016,0.0004860524,0.0013843463,0.00023996536,0.00027213152,0.00077940064,0.0005534265,0.0003414075,0.0039403955],"category_scores_gemma":[0.002408434,0.00018850497,0.0025219005,0.00031056016,0.00042291245,0.00084367755,0.00057056284,0.0012463287,0.00018469755],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47642308,0.004717033,0.46436107,0.0004101987,0.009515202,0.00041061436,0.00061471044,0.002413653,0.006332072,0.00047352695,0.0020298138,0.032298986],"study_design_scores_gemma":[0.0064397743,0.089042515,0.8853429,0.000030078001,0.004405998,0.0002558494,0.00093953626,0.008464681,0.0022421377,0.00043313918,0.0023353351,0.00006808061],"about_ca_topic_score_codex":0.002242517,"about_ca_topic_score_gemma":0.0037954925,"teacher_disagreement_score":0.0039403955,"about_ca_system_score_codex":0.0005556247,"about_ca_system_score_gemma":0.0011088866,"threshold_uncertainty_score":0.013181984},"labels":[],"label_agreement":null},{"id":"W4389664194","doi":"10.1016/j.euo.2023.11.016","title":"Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; London Health Sciences Centre; Western University; Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; University of Calgary; Université Laval; Centre Hospitalier de l’Université de Montréal; McMaster University; Alberta Health Services; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; University Health Network; Dalhousie University; University of Manitoba; Juravinski Cancer Centre; McGill University Health Centre","funders":"McGill University","keywords":"Medicine; Renal cell carcinoma; Systemic therapy; Oncology; Internal medicine; Intensive care medicine; Pathology; Cancer","score_opus":0.04354414202864189,"score_gpt":0.3461018557140005,"score_spread":0.3025577136853586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389664194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627966,0.00037322144,0.00018577518,0.00014735729,0.000013024298,0.000016376327,0.0019155492,0.00000841984,0.0010606012],"genre_scores_gemma":[0.99840146,0.00008620631,0.000097417455,0.00003183331,0.000011677608,0.000011956999,0.0012801999,0.0000021200408,0.0000771462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993777,0.00022566167,0.00007785097,0.00014034481,0.00007352592,0.00010491771],"domain_scores_gemma":[0.99723095,0.00057821395,0.0013759015,0.000094840056,0.00026933654,0.00045075026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007465136,0.00017227858,0.00039030515,0.00063121517,0.00031063895,0.0010545177,0.0002850482,0.00044660282,0.0014364539],"category_scores_gemma":[0.0047034123,0.00007716965,0.0005546245,0.0008949182,0.00034560444,0.0007824633,0.0006586092,0.0004877644,0.00029528266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008679752,0.00007740064,0.9918954,0.000038798524,0.00012878429,0.00013056582,0.00011608169,0.00041971396,0.00014049542,0.000063500476,0.00050484674,0.005616396],"study_design_scores_gemma":[0.00003180394,0.00052527076,0.99526525,0.000022639362,0.00008940909,0.00066678127,0.00048099723,0.0016180681,0.00012482586,0.00014829845,0.0010080322,0.000018656978],"about_ca_topic_score_codex":0.002031978,"about_ca_topic_score_gemma":0.0027842342,"teacher_disagreement_score":0.002031978,"about_ca_system_score_codex":0.00061651395,"about_ca_system_score_gemma":0.00034781036,"threshold_uncertainty_score":0.004805386},"labels":[],"label_agreement":null},{"id":"W4390147069","doi":"10.1016/j.euo.2023.11.024","title":"Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Medicine; Testosterone (patch); Prostate cancer; Discontinuation; Urology; Internal medicine; Adverse effect; Androgen; Endocrinology; Hormone; Cancer","score_opus":0.06108210601142114,"score_gpt":0.3852625919943143,"score_spread":0.3241804859828932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390147069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922748,0.0049518817,0.0002758835,0.00039036912,0.00010117239,0.00026051415,0.0005880398,0.00010026671,0.0010569746],"genre_scores_gemma":[0.99338657,0.0022364915,0.00058796303,0.0005027223,0.00016602411,0.00022527657,0.00090152957,0.000048259724,0.0019452306],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994649,0.00031132475,0.000014748208,0.00006269988,0.000051186744,0.00009501989],"domain_scores_gemma":[0.99929285,0.00021848174,0.00017268238,0.000050234794,0.000023935016,0.00024172197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015099612,0.0010872978,0.0021520385,0.00034998386,0.0003456807,0.0010516278,0.00069846463,0.00080002256,0.0038288604],"category_scores_gemma":[0.0010568881,0.00036549504,0.0021013273,0.00036050173,0.0011435508,0.0008624516,0.0003479626,0.0024737264,0.00054666115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91500795,0.013301407,0.0027300667,0.0005196268,0.0014732071,0.000056377103,0.00018433988,0.0013754179,0.0067493096,0.00019370641,0.0014878233,0.056920737],"study_design_scores_gemma":[0.5291598,0.43672797,0.025757562,0.00007347965,0.0014144507,0.00020823175,0.00026573025,0.0012545137,0.0020592473,0.00046040508,0.0025461717,0.00007236756],"about_ca_topic_score_codex":0.0018931023,"about_ca_topic_score_gemma":0.004296643,"teacher_disagreement_score":0.0038288604,"about_ca_system_score_codex":0.00066879415,"about_ca_system_score_gemma":0.0010273145,"threshold_uncertainty_score":0.0128088},"labels":[],"label_agreement":null},{"id":"W4390238410","doi":"10.1016/j.euo.2023.11.018","title":"A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer","year":2023,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Cancer Research UK","keywords":"Medicine; Prostate cancer; External beam radiotherapy; Brachytherapy; Prostatectomy; Androgen deprivation therapy; Hazard ratio; Radiation therapy; Oncology; Internal medicine; Meta-analysis; Urology; Randomized controlled trial; Systematic review; Cancer; Surgery; Confidence interval; MEDLINE","score_opus":0.03625900258292838,"score_gpt":0.3562044579438824,"score_spread":0.31994545536095403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390238410","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027196016,0.99567705,0.00019243674,0.00020158506,0.00013395179,0.00054132927,0.0002891748,0.000011154322,0.00023377719],"genre_scores_gemma":[0.043342683,0.95269,0.0012728324,0.000730967,0.00013577072,0.0013865072,0.00023779241,0.000010671222,0.00019279546],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9866803,0.0062430943,0.004267974,0.0008077485,0.0017470653,0.0002537877],"domain_scores_gemma":[0.97632366,0.015273943,0.0055823377,0.00038954848,0.0021437902,0.00028662264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0108654965,0.0018696303,0.0139687685,0.007928942,0.00068476656,0.002580147,0.0020169772,0.002277231,0.0038694828],"category_scores_gemma":[0.04000022,0.0011781787,0.011518237,0.008212839,0.0012056552,0.0019867981,0.0012734951,0.0013093014,0.00028501995],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005327832,0.000015427107,0.0004465947,0.9574313,0.02794825,0.000087580076,0.00009397763,0.00009554555,0.00019129248,0.0000749045,0.0004603506,0.012622097],"study_design_scores_gemma":[0.0013001544,0.0007538507,0.0049922285,0.65895635,0.3242046,0.0004434799,0.00020786226,0.00016273525,0.0002987185,0.00022224094,0.008409123,0.00004864903],"about_ca_topic_score_codex":0.007834811,"about_ca_topic_score_gemma":0.022943027,"teacher_disagreement_score":0.0139687685,"about_ca_system_score_codex":0.0047814925,"about_ca_system_score_gemma":0.010406236,"threshold_uncertainty_score":0.05746293},"labels":[],"label_agreement":null},{"id":"W4390589225","doi":"10.1016/j.euo.2023.12.005","title":"Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Rectal examination; Prostate cancer; Prostate-specific antigen; Confidence interval; Meta-analysis; Internal medicine; Prospective cohort study; Prostate cancer screening; Oncology; Prostate; Gynecology; Clinical endpoint; Cancer; Randomized controlled trial","score_opus":0.11174096733802175,"score_gpt":0.3616802524531709,"score_spread":0.24993928511514918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390589225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004969587,0.99312216,0.00057228433,0.00020502256,0.00014936476,0.00028098244,0.0004556971,0.00002686514,0.00021803088],"genre_scores_gemma":[0.2337826,0.7581866,0.0031935093,0.001195777,0.00046352067,0.0016873237,0.0010895147,0.00005381466,0.000347302],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98319846,0.009197136,0.0038934168,0.0016608521,0.0016251721,0.00042505082],"domain_scores_gemma":[0.9571279,0.034778066,0.0045648715,0.0009828383,0.002164288,0.00038194374],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.021372333,0.0032827132,0.021996303,0.0070810304,0.0007769864,0.00406272,0.0028908178,0.0029505808,0.0030926894],"category_scores_gemma":[0.056861456,0.0017575877,0.0488428,0.007708315,0.0010110163,0.0021186108,0.0015990218,0.0023494668,0.00030527238],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020912902,0.000025375513,0.004166749,0.2650064,0.7207356,0.000085889376,0.000058727514,0.0005234454,0.00013770512,0.00009177916,0.0004153432,0.0066617667],"study_design_scores_gemma":[0.00035931185,0.00012917913,0.002008739,0.013405699,0.9831162,0.000050820243,0.000019286816,0.00014521519,0.00006738672,0.000099246936,0.00058381306,0.000015088569],"about_ca_topic_score_codex":0.00869904,"about_ca_topic_score_gemma":0.01627188,"teacher_disagreement_score":0.9780037,"about_ca_system_score_codex":0.0033631155,"about_ca_system_score_gemma":0.004306585,"threshold_uncertainty_score":0.11302906},"labels":[],"label_agreement":null},{"id":"W4391235019","doi":"10.1016/j.euo.2024.01.006","title":"Propensity-matched Analysis of Open Versus Robotic Primary Retroperitoneal Lymph Node Dissection for Clinical Stage II Testicular Cancer","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Retroperitoneal lymph node dissection; Testicular cancer; Surgery; Perioperative; Interquartile range; Propensity score matching; Confidence interval; Internal medicine; Chemotherapy","score_opus":0.1065948100420579,"score_gpt":0.4281949242288868,"score_spread":0.3216001141868289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391235019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965486,0.0006715046,0.0016513207,0.00003617243,0.000078319405,0.00007681813,0.00035236223,0.000010036936,0.0005750063],"genre_scores_gemma":[0.99889815,0.0000933199,0.00035880218,0.000044719858,0.000033300264,0.000031481635,0.00030279192,0.0000044857456,0.00023288684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998054,0.00083753356,0.00020559631,0.0004901247,0.00019398364,0.00021876766],"domain_scores_gemma":[0.99759513,0.0010558817,0.0006249685,0.0004679668,0.00009665343,0.00015937812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019063951,0.00030502217,0.0008745439,0.00026757465,0.00021721798,0.0006894778,0.00060179806,0.00039946835,0.0025718564],"category_scores_gemma":[0.0054519786,0.00032786644,0.0017943376,0.00051182276,0.0003647204,0.0005090267,0.00045287132,0.00052888854,0.00025696994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27155432,0.0012409716,0.606998,0.00091244007,0.01506925,0.0006409088,0.00050429435,0.008178472,0.010017796,0.0015923227,0.003310372,0.07998081],"study_design_scores_gemma":[0.011355663,0.022763712,0.91762847,0.00011382708,0.008274883,0.0009987789,0.0006865621,0.027182285,0.0023419848,0.003728577,0.0048148814,0.00011038529],"about_ca_topic_score_codex":0.00093404815,"about_ca_topic_score_gemma":0.0018135995,"teacher_disagreement_score":0.0025718564,"about_ca_system_score_codex":0.0004267028,"about_ca_system_score_gemma":0.00051983504,"threshold_uncertainty_score":0.010082126},"labels":[],"label_agreement":null},{"id":"W4391426559","doi":"10.1016/j.euo.2024.01.004","title":"External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"AI in cancer detection","field":"Computer Science","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; Foundation Medicine; University of California, San Francisco; EMD Serono; Astellas Pharma; Endocyte; Advanced Accelerator Applications; NRG Oncology; Varian Medical Systems; Sanofi; Invitae; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Hazard ratio; Confidence interval; Oncology; Internal medicine; Randomized controlled trial; Clinical trial; Proportional hazards model; Histopathology; Pathology","score_opus":0.041464742584998965,"score_gpt":0.33211571387983935,"score_spread":0.2906509712948404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391426559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9472907,0.0022016135,0.023490973,0.0023012115,0.00042170435,0.003035248,0.008250383,0.001391004,0.011617232],"genre_scores_gemma":[0.96248776,0.00033088177,0.019716876,0.0012983988,0.0000991441,0.0031627072,0.009372521,0.00017093698,0.0033608167],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99431795,0.0044789067,0.00014297134,0.00053722225,0.00038958192,0.00013332776],"domain_scores_gemma":[0.9951073,0.0025816013,0.00054809503,0.00094774476,0.00051180733,0.00030357373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012442579,0.0009211549,0.000713828,0.00030303927,0.0002889685,0.0014718937,0.001246622,0.001194825,0.003730563],"category_scores_gemma":[0.014988712,0.00036475054,0.0012112845,0.0004221725,0.0010170339,0.00072931213,0.0010316554,0.0014724447,0.0018840582],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27457243,0.010099104,0.10533018,0.0027151422,0.008107157,0.0004528894,0.00087582157,0.1380416,0.031042993,0.006148245,0.050750118,0.37186426],"study_design_scores_gemma":[0.117228016,0.11741675,0.17870913,0.0011430408,0.012356967,0.0016043321,0.00053244916,0.38153926,0.05202428,0.018463813,0.11862493,0.00035712172],"about_ca_topic_score_codex":0.0017791968,"about_ca_topic_score_gemma":0.002092401,"teacher_disagreement_score":0.012442579,"about_ca_system_score_codex":0.0009170718,"about_ca_system_score_gemma":0.001847522,"threshold_uncertainty_score":0.06580341},"labels":[],"label_agreement":null},{"id":"W4391579712","doi":"10.1016/j.euo.2024.01.014","title":"Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Université de Sherbrooke; University of Toronto; Western University; Princess Margaret Cancer Centre; University of Calgary; Queen's University; McMaster University; University of British Columbia; McGill University Health Centre; University of Ottawa; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Bladder cancer; Lymphovascular invasion; Cystectomy; Cohort; Hazard ratio; Oncology; Internal medicine; Chemotherapy; Cisplatin; Gemcitabine; Radiation therapy; Neoadjuvant therapy; Cancer; Stage (stratigraphy); Subgroup analysis; Urology; Confidence interval; Breast cancer","score_opus":0.02563735697349227,"score_gpt":0.31314711485307073,"score_spread":0.28750975787957844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391579712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99177426,0.0022030682,0.0043315603,0.00029140382,0.000058695365,0.000087506894,0.0004962941,0.000022463173,0.00073478266],"genre_scores_gemma":[0.99822277,0.00023905704,0.00073072664,0.00006325936,0.000023760931,0.000030508241,0.00041773877,0.000014531388,0.00025758188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789536,0.0013364378,0.00012481032,0.0003682459,0.00013695998,0.000138193],"domain_scores_gemma":[0.995,0.0035976705,0.0007142169,0.00030123082,0.00020172405,0.00018524908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038978374,0.00073688553,0.0013311064,0.00046895636,0.00021938556,0.0009700564,0.0007541541,0.0007630268,0.0022760818],"category_scores_gemma":[0.011810951,0.0004097069,0.0049538445,0.00041963172,0.00052102207,0.0010200444,0.0008195521,0.0010747506,0.00017372095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20781592,0.0021126315,0.42775962,0.00242467,0.047468144,0.00075052556,0.00037659876,0.1555248,0.004802766,0.0027997124,0.002795045,0.14536963],"study_design_scores_gemma":[0.008356693,0.023187986,0.51200086,0.0003608019,0.06970358,0.000991259,0.0006270829,0.36928907,0.0026317341,0.0070032445,0.005551571,0.00029601104],"about_ca_topic_score_codex":0.0031051743,"about_ca_topic_score_gemma":0.0029485167,"teacher_disagreement_score":0.0038978374,"about_ca_system_score_codex":0.00081299775,"about_ca_system_score_gemma":0.0007387115,"threshold_uncertainty_score":0.020613968},"labels":[],"label_agreement":null},{"id":"W4393902181","doi":"10.1016/j.euo.2024.03.010","title":"Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Movember Foundation","keywords":"Androgen deprivation therapy; Medicine; Prostate cancer; Oncology; Castration; Metastasis; Internal medicine; Cancer therapy; Cancer; Hormone","score_opus":0.06196786233524793,"score_gpt":0.3735454185204336,"score_spread":0.3115775561851857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393902181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99893314,0.00050015573,0.00007492173,0.000028202623,0.0000073016718,0.000010572303,0.00025062903,0.0000026730104,0.00019248234],"genre_scores_gemma":[0.9995086,0.00007151583,0.0000377495,0.00002041763,0.000009531206,0.0000056244357,0.0002957294,0.0000019282736,0.00004888499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982849,0.0008936887,0.00014071747,0.0002551921,0.00018267856,0.00024290069],"domain_scores_gemma":[0.9972427,0.0008896484,0.0010698079,0.0002091629,0.00016916137,0.00041955555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013295196,0.00027229762,0.00062057487,0.00072538207,0.00042086336,0.00095822697,0.00049720187,0.00040716826,0.0009119914],"category_scores_gemma":[0.0029883985,0.00017851267,0.0013107219,0.0012672872,0.0004036081,0.0004914824,0.0007580359,0.0004600655,0.000079611265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012309562,0.0003449944,0.9760749,0.00007535166,0.0013975187,0.00010687642,0.00009797033,0.0007653108,0.0011267926,0.000057116988,0.00020565341,0.0074379807],"study_design_scores_gemma":[0.000119235105,0.0011916178,0.99714404,0.000007705995,0.00034916808,0.00011280234,0.00019246312,0.0004354041,0.00018262559,0.000033226097,0.00022033666,0.00001129235],"about_ca_topic_score_codex":0.0062186546,"about_ca_topic_score_gemma":0.012056125,"teacher_disagreement_score":0.0062186546,"about_ca_system_score_codex":0.0010816812,"about_ca_system_score_gemma":0.0010080669,"threshold_uncertainty_score":0.012364864},"labels":[],"label_agreement":null},{"id":"W4393947130","doi":"10.1016/j.euo.2024.03.007","title":"A Systematic Review and Meta-analysis of the Impact of Local Therapies on Local Event Suppression in Metastatic Hormone-sensitive Prostate Cancer","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Androgen deprivation therapy; Docetaxel; Systemic therapy; Randomized controlled trial; Incidence (geometry); Context (archaeology); Meta-analysis; Hormone therapy; Cancer; Breast cancer","score_opus":0.06297612795242534,"score_gpt":0.40676260869719383,"score_spread":0.3437864807447685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393947130","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045198062,0.9935556,0.0004193483,0.0001842026,0.00014639318,0.00033333857,0.00054613454,0.000021322978,0.0002738738],"genre_scores_gemma":[0.17167336,0.8219916,0.002283827,0.0010223066,0.00025501207,0.0015839254,0.00087654917,0.000026808648,0.00028664546],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9872251,0.0066005546,0.0034403244,0.001142804,0.0012354708,0.00035570172],"domain_scores_gemma":[0.97636056,0.017092433,0.0040329676,0.00062692515,0.0016012064,0.00028593044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015965503,0.0027482037,0.020878922,0.006755137,0.0006856508,0.003300491,0.0022372801,0.0023277847,0.0034422793],"category_scores_gemma":[0.04173908,0.0013727805,0.033379413,0.008263849,0.0008337772,0.0018057551,0.0013779687,0.0017631962,0.00031447154],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017576956,0.000022082158,0.0025538988,0.5100368,0.47473648,0.00014032667,0.00007046063,0.00047124465,0.00020867298,0.00011967823,0.0005664362,0.00931613],"study_design_scores_gemma":[0.00064477936,0.00018569468,0.0030866507,0.038458727,0.95577055,0.00008296563,0.000033780765,0.00014054851,0.000100676036,0.00014892241,0.0013276887,0.000019035797],"about_ca_topic_score_codex":0.009015102,"about_ca_topic_score_gemma":0.019149281,"teacher_disagreement_score":0.020878922,"about_ca_system_score_codex":0.003265836,"about_ca_system_score_gemma":0.005024682,"threshold_uncertainty_score":0.08443469},"labels":[],"label_agreement":null},{"id":"W4394015334","doi":"10.1016/j.euo.2024.03.006","title":"Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Tolerability; Prostate cancer; Placebo; Adverse effect; Abiraterone; Internal medicine; Oncology; Enzalutamide; Prednisone; Common Terminology Criteria for Adverse Events; Cancer; Pathology","score_opus":0.03318067851103599,"score_gpt":0.32747253788979147,"score_spread":0.29429185937875546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394015334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742802,0.018981444,0.0005083767,0.0010055426,0.00015765126,0.0011484597,0.0017726112,0.000076565964,0.0020692425],"genre_scores_gemma":[0.98841476,0.005309774,0.0008229945,0.0009687046,0.0003370458,0.0009878826,0.002217349,0.000020380716,0.0009211987],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99891126,0.00076935027,0.000048832015,0.00007368557,0.000101064354,0.00009574276],"domain_scores_gemma":[0.99781525,0.0006605758,0.0007630574,0.00012332374,0.00018042474,0.0004573533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028429853,0.0008592006,0.0013801983,0.0002582146,0.00023149233,0.0009020151,0.00058621727,0.0007159017,0.0047873184],"category_scores_gemma":[0.0024814573,0.00027159447,0.0020329452,0.0004921148,0.0005730456,0.00070637226,0.00037478041,0.0018744548,0.0006818482],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85920477,0.008767365,0.00665422,0.0023776775,0.0029293117,0.00023655625,0.0002116468,0.0012397409,0.006671243,0.00012048396,0.0037274214,0.10785945],"study_design_scores_gemma":[0.7616961,0.20703202,0.022775397,0.0003055446,0.0014779337,0.0004107613,0.00010097916,0.000603943,0.0011411257,0.00028321877,0.0041262726,0.000046679896],"about_ca_topic_score_codex":0.0005010494,"about_ca_topic_score_gemma":0.0014337247,"teacher_disagreement_score":0.0047873184,"about_ca_system_score_codex":0.0007286817,"about_ca_system_score_gemma":0.0011952998,"threshold_uncertainty_score":0.016015172},"labels":[],"label_agreement":null},{"id":"W4394936185","doi":"10.1016/j.euo.2024.03.015","title":"Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; NRG Oncology","keywords":"Medicine; Bladder cancer; Oncology; Internal medicine; Infiltration (HVAC); Cancer","score_opus":0.0150333448679207,"score_gpt":0.2704961794348791,"score_spread":0.2554628345669584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394936185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990018,0.00024396923,0.00004335558,0.000019075082,0.000005234309,0.0000037044422,0.0003824506,0.0000036304573,0.0002969365],"genre_scores_gemma":[0.99917185,0.00003603174,0.00002387251,0.0000131416,0.000012817675,0.000004054676,0.00054555264,0.0000030650085,0.00018953677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995503,0.00012839495,0.00003474692,0.00010142087,0.000062184816,0.00012285965],"domain_scores_gemma":[0.9989518,0.0002258968,0.0003794986,0.00010416896,0.000093545445,0.0002449504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000492264,0.00027412517,0.00060310867,0.0006114872,0.0002314334,0.0005924541,0.00038821556,0.0004240094,0.0018713395],"category_scores_gemma":[0.0014045695,0.00015315325,0.0008782215,0.00075810496,0.00023574146,0.00039555767,0.0005141488,0.00047809602,0.00024798102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024208569,0.00007317295,0.992773,0.000018295941,0.00027362024,0.00007189842,0.000040351253,0.0001761971,0.0014684054,0.000020393109,0.00019353516,0.0024703399],"study_design_scores_gemma":[0.000030577678,0.00035446938,0.9985977,0.0000030188235,0.00011136294,0.00013950947,0.00008411408,0.0002405077,0.0001836003,0.000020781132,0.00023071986,0.0000035351563],"about_ca_topic_score_codex":0.0017552627,"about_ca_topic_score_gemma":0.0027156323,"teacher_disagreement_score":0.0018713395,"about_ca_system_score_codex":0.00027940105,"about_ca_system_score_gemma":0.00029449715,"threshold_uncertainty_score":0.006260276},"labels":[],"label_agreement":null},{"id":"W4395084982","doi":"10.1016/j.euo.2024.04.004","title":"The State of Intermediate Clinical Endpoints as Surrogates for Overall Survival in Prostate Cancer in 2024","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"European Association of Urology; Pfizer","keywords":"Medicine; Prostate cancer; Cancer; Oncology; Prostate; Internal medicine; Intensive care medicine","score_opus":0.09682521397665769,"score_gpt":0.4804949331967629,"score_spread":0.3836697192201052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395084982","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008850254,0.9993605,0.00011503115,0.00019543829,0.0000488496,0.000007572785,0.000026482281,0.0000011664966,0.00015645025],"genre_scores_gemma":[0.0033500683,0.9955087,0.0004425558,0.0004392714,0.000089825604,0.000042222684,0.00006175467,0.0000032042283,0.00006229043],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99225616,0.0046508876,0.0013072578,0.00057641766,0.001098774,0.00011048754],"domain_scores_gemma":[0.9663993,0.029881794,0.0018959207,0.00043780456,0.0012763983,0.00010881352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01940711,0.00084259576,0.004479766,0.0026053255,0.00023644739,0.0028694512,0.0013119052,0.0013721419,0.0017373477],"category_scores_gemma":[0.031945996,0.00049912144,0.0038008704,0.00387945,0.0009248767,0.0018723052,0.0010790675,0.002437514,0.0004342998],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052778254,0.000035707653,0.0009062029,0.2467092,0.00565574,0.000054952896,0.00019043619,0.00078157126,0.00030187107,0.0091789765,0.0058026914,0.7298548],"study_design_scores_gemma":[0.00044165828,0.0009668173,0.008719682,0.45992252,0.023815734,0.00075906626,0.00039346088,0.0006941733,0.00094675383,0.018494794,0.4846703,0.00017514487],"about_ca_topic_score_codex":0.0021066042,"about_ca_topic_score_gemma":0.0033859243,"teacher_disagreement_score":0.01940711,"about_ca_system_score_codex":0.0016428361,"about_ca_system_score_gemma":0.003607826,"threshold_uncertainty_score":0.1026358},"labels":[],"label_agreement":null},{"id":"W4396580817","doi":"10.1016/j.euo.2024.04.006","title":"Association Between GLP1R Agonists and Prostate, Kidney, and Bladder Cancers","year":2024,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"American Urological Association; UroGen Pharma; Bladder Cancer Advocacy Network","keywords":"Medicine; Internal medicine; Prostate; Oncology; Urology; Endocrinology; Cancer","score_opus":0.012779636498212742,"score_gpt":0.2633122084156718,"score_spread":0.2505325719174591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396580817","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044513936,0.0017028009,0.000078655095,0.9767022,0.009354114,0.0000115342755,0.00015059055,0.000015791715,0.0075328792],"genre_scores_gemma":[0.049749408,0.003127849,0.00032796102,0.8643603,0.07055789,0.00004194507,0.0001443387,0.000019263356,0.011671005],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9990238,0.00037694324,0.00013144746,0.00008748243,0.00023543075,0.00014481608],"domain_scores_gemma":[0.9959914,0.0024046851,0.00030584217,0.00011082004,0.0005461997,0.0006410981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015176472,0.0002503495,0.00064835907,0.00049688964,0.0018573208,0.0010794429,0.00045772156,0.0128267845,0.004407353],"category_scores_gemma":[0.009178564,0.00025491964,0.0007652048,0.0005106163,0.00071756775,0.0008522109,0.00048296203,0.009043745,0.0015009965],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036755938,0.00017468254,0.025402348,0.00012382641,0.00008582344,0.009509384,0.00019896096,0.00015728813,0.0005517125,0.0024023226,0.93063337,0.030392786],"study_design_scores_gemma":[0.00089471525,0.0005860407,0.056424864,0.0011436917,0.0003574575,0.02964555,0.0020458375,0.0025756904,0.00079623895,0.015551321,0.8898222,0.00015647901],"about_ca_topic_score_codex":0.010329299,"about_ca_topic_score_gemma":0.018370189,"teacher_disagreement_score":0.0128267845,"about_ca_system_score_codex":0.0017483133,"about_ca_system_score_gemma":0.0021822979,"threshold_uncertainty_score":0.02053839},"labels":[],"label_agreement":null},{"id":"W4396851239","doi":"10.1016/j.euo.2024.04.016","title":"Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Regret; Medicine; Prostate cancer; Cancer; Clinical decision making; Oncology; Prostate; Intensive care medicine; Gynecology; Internal medicine; Computer science","score_opus":0.019947117813326087,"score_gpt":0.3648454804820636,"score_spread":0.3448983626687375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396851239","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004138453,0.9941459,0.00023156367,0.00039103566,0.00006593129,0.00033655672,0.0004000827,0.0000066880234,0.00028383386],"genre_scores_gemma":[0.08656297,0.90970886,0.0012685262,0.0007728642,0.00015719062,0.00089419546,0.0004930546,0.00000896018,0.0001334179],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98328537,0.007626112,0.0051649204,0.0011100108,0.0023766314,0.00043686415],"domain_scores_gemma":[0.9051315,0.07490412,0.014591315,0.00084224663,0.004037704,0.00049298466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016298043,0.0015602814,0.006939555,0.00881812,0.0007880522,0.0037238733,0.001599066,0.0021538702,0.0037752178],"category_scores_gemma":[0.08816119,0.0011538013,0.013639414,0.009678193,0.0009230988,0.0022602773,0.0014760323,0.001655684,0.0002570111],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047395486,0.00004960564,0.008906966,0.90819967,0.043754976,0.0001591212,0.00034627723,0.00028089224,0.0000756939,0.00032427814,0.0010772656,0.03635133],"study_design_scores_gemma":[0.00035401192,0.00029416726,0.016808897,0.73671275,0.23494509,0.0005369188,0.0005160133,0.00038102356,0.00017270408,0.00068065256,0.00851418,0.00008360668],"about_ca_topic_score_codex":0.009321213,"about_ca_topic_score_gemma":0.022308405,"teacher_disagreement_score":0.016298043,"about_ca_system_score_codex":0.004382994,"about_ca_system_score_gemma":0.013550703,"threshold_uncertainty_score":0.08619332},"labels":[],"label_agreement":null},{"id":"W4399119977","doi":"10.1016/j.euo.2024.05.008","title":"Patient-reported Outcome Measures and Experience Measures After Active Surveillance Versus Radiation Therapy Versus Radical Prostatectomy for Prostate Cancer: A Systematic Review of Prospective Comparative Studies","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Radiation therapy; Prospective cohort study; Urology; Prostate; Cancer; Oncology; Internal medicine","score_opus":0.16056889472391286,"score_gpt":0.4397345203007834,"score_spread":0.2791656255768705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399119977","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020359324,0.9966286,0.00016463308,0.00011801228,0.000070744296,0.00043106958,0.0004116848,0.0000043369123,0.00013502847],"genre_scores_gemma":[0.06923228,0.9243924,0.0017901218,0.0007318066,0.0001562873,0.0028496361,0.00070273096,0.000009805382,0.00013484889],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9736878,0.011468409,0.009328954,0.0017711425,0.0033798332,0.00036381622],"domain_scores_gemma":[0.92685646,0.05371226,0.014577055,0.0008456489,0.003622263,0.0003862767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024112962,0.0015709148,0.01095766,0.0069383723,0.00059442443,0.0028981115,0.0017293278,0.0018262863,0.0033309923],"category_scores_gemma":[0.085112154,0.0008410272,0.017412739,0.008988045,0.0011092674,0.0020805201,0.0014202915,0.0016058894,0.00016751133],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085542374,0.000032561093,0.0015198219,0.9351568,0.042220425,0.000050513245,0.00013930432,0.00011229266,0.00007814063,0.00013329183,0.00033857164,0.019362837],"study_design_scores_gemma":[0.0014017138,0.0010723791,0.012084484,0.6189314,0.35755196,0.00030572258,0.00041085956,0.00015947087,0.00028543905,0.00041572246,0.007301335,0.000079550366],"about_ca_topic_score_codex":0.0043936735,"about_ca_topic_score_gemma":0.011728257,"teacher_disagreement_score":0.024112962,"about_ca_system_score_codex":0.0036959033,"about_ca_system_score_gemma":0.0072980775,"threshold_uncertainty_score":0.127523},"labels":[],"label_agreement":null},{"id":"W4399199106","doi":"10.1016/j.euo.2024.05.007","title":"Prostate Magnetic Resonance Imaging Using the Prostate Imaging for Recurrence Reporting (PI-RR) Scoring System to Detect Recurrent Prostate Cancer: A Systematic Review and Meta-analysis","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sinai Health System; Women's College Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Magnetic resonance imaging; Meta-analysis; Prostate; Radiology; Oncology; Cancer; Internal medicine","score_opus":0.0962896154507982,"score_gpt":0.39811055240029514,"score_spread":0.30182093694949697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399199106","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034015486,0.9954644,0.0002888096,0.00008277154,0.00009834257,0.0000996031,0.00042104162,0.000014138329,0.0001293409],"genre_scores_gemma":[0.099841505,0.8960543,0.0016778351,0.0007485788,0.00015884991,0.00030219613,0.00081460207,0.000027838258,0.00037424],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99683434,0.000981004,0.0011388699,0.00050567056,0.0003943183,0.00014578014],"domain_scores_gemma":[0.99617153,0.0024904546,0.0007951231,0.00013307929,0.0003344965,0.000075192664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044475077,0.0024146228,0.0129857855,0.004696497,0.0004835102,0.002113127,0.0016373309,0.001627628,0.003474679],"category_scores_gemma":[0.010758686,0.0011226385,0.027977575,0.006088766,0.00053745694,0.0015572136,0.0013874493,0.0018792957,0.00035311663],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015158209,0.000041802516,0.0063180267,0.35500526,0.6131619,0.0001096123,0.00008673032,0.000515431,0.00036439372,0.0001295632,0.001133587,0.021617962],"study_design_scores_gemma":[0.0005446496,0.00013770944,0.0054202196,0.01622357,0.9754769,0.0000992852,0.00005662082,0.00014792776,0.00009396477,0.00013644688,0.0016259985,0.00003658554],"about_ca_topic_score_codex":0.010339461,"about_ca_topic_score_gemma":0.032523893,"teacher_disagreement_score":0.0129857855,"about_ca_system_score_codex":0.0016724875,"about_ca_system_score_gemma":0.0024643606,"threshold_uncertainty_score":0.023520947},"labels":[],"label_agreement":null},{"id":"W4399597402","doi":"10.1016/j.euo.2024.05.011","title":"Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institutes of Health; Movember Foundation; National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Castration; Cancer; Prostate; Hormone","score_opus":0.021770141579877285,"score_gpt":0.3371124047456912,"score_spread":0.31534226316581393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399597402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992126,0.0002129018,0.000095728814,0.000007886255,9.786485e-7,0.0000046775167,0.00030532654,0.0000029623309,0.0001569046],"genre_scores_gemma":[0.99968517,0.000030432951,0.000063785614,0.000004141204,0.0000017282151,0.0000029043242,0.00015877563,0.0000013357643,0.000051584666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997683,0.000042024123,0.000016095524,0.000089774236,0.00003100281,0.000052767246],"domain_scores_gemma":[0.9991579,0.00011509078,0.0004962019,0.000054785676,0.00003804521,0.00013798254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023981647,0.00020927282,0.00020099765,0.0011040305,0.00025146498,0.00038527223,0.00025151606,0.00026215357,0.0014252947],"category_scores_gemma":[0.00073822873,0.00013000009,0.00027145803,0.0007604575,0.00029832998,0.0001693179,0.00039708495,0.0002731023,0.0001045083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031518715,0.000019142506,0.992282,0.00001306448,0.000053448068,0.00016760899,0.0000415904,0.00013970188,0.0045576845,0.000029498591,0.00003257999,0.0023485338],"study_design_scores_gemma":[0.00000303371,0.0000836257,0.9985902,0.0000017385349,0.000018891129,0.00057976984,0.00004225313,0.00013318754,0.00041569347,0.000024577988,0.00010519527,0.0000018526139],"about_ca_topic_score_codex":0.0016598729,"about_ca_topic_score_gemma":0.0024043587,"teacher_disagreement_score":0.0016598729,"about_ca_system_score_codex":0.00020888688,"about_ca_system_score_gemma":0.00018087125,"threshold_uncertainty_score":0.0047680736},"labels":[],"label_agreement":null},{"id":"W4400019582","doi":"10.1016/j.euo.2024.05.013","title":"Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Sunnybrook Hospital; Jewish General Hospital","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Prostate cancer; Prednisone; Internal medicine; Pembrolizumab; Clinical endpoint; Oncology; Interquartile range; Cohort; Urology; Cancer; Clinical trial; Surgery; Androgen deprivation therapy","score_opus":0.017376358492093395,"score_gpt":0.2946632417206965,"score_spread":0.2772868832286031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400019582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989777,0.0028103595,0.00019471107,0.00036841893,0.00006131087,0.0005405093,0.005032101,0.000026691336,0.0011887708],"genre_scores_gemma":[0.9886606,0.0013645731,0.00045429845,0.0007027068,0.00010936138,0.0002983495,0.0074581937,0.000012942752,0.0009389537],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99936205,0.0001970184,0.00006644816,0.00015415222,0.00010255539,0.00011770072],"domain_scores_gemma":[0.99878174,0.00012917184,0.00030438945,0.00013785143,0.00014149459,0.0005053758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014706799,0.0005879183,0.0009111072,0.00024422441,0.00048574954,0.0009272829,0.0005609636,0.0005119057,0.0023072087],"category_scores_gemma":[0.0013598476,0.0003057142,0.0017820752,0.00046352658,0.0003586552,0.00057142106,0.0005093422,0.0012407606,0.0005098126],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51450866,0.019190436,0.30770478,0.0014308216,0.0070238286,0.000569906,0.00096141605,0.0016034477,0.015368089,0.00028814274,0.016865,0.11448552],"study_design_scores_gemma":[0.16906632,0.13217603,0.66118646,0.00039283966,0.0070445975,0.0016528539,0.00090331107,0.0018742753,0.0040363525,0.00041423738,0.02110089,0.00015195695],"about_ca_topic_score_codex":0.008244125,"about_ca_topic_score_gemma":0.013452907,"teacher_disagreement_score":0.008244125,"about_ca_system_score_codex":0.0014240369,"about_ca_system_score_gemma":0.0020596716,"threshold_uncertainty_score":0.01639229},"labels":[],"label_agreement":null},{"id":"W4400443896","doi":"10.1016/j.euo.2024.06.012","title":"Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the Kidney","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Juravinski Cancer Centre; McGill University Health Centre; Ottawa Hospital; McMaster University; London Health Sciences Centre","funders":"","keywords":"Medicine; Radiosurgery; Ablative case; Renal cell carcinoma; Renal function; Internal medicine; Oncology; Kidney; Kidney cancer; Radiation therapy; Clear cell renal cell carcinoma; Term (time); Radiology","score_opus":0.018680012198882545,"score_gpt":0.2707078697871421,"score_spread":0.2520278575882596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400443896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99849904,0.0004999155,0.00004461489,0.000117262316,0.0000099870595,0.00000579823,0.00027316881,0.000002309392,0.00054785126],"genre_scores_gemma":[0.9992205,0.00021041083,0.000018961931,0.000048761773,0.000021616042,0.0000033252686,0.0003974419,0.0000011072401,0.00007787325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995427,0.000076192024,0.000043397515,0.00007843719,0.00012753996,0.00013180605],"domain_scores_gemma":[0.9986883,0.00017596543,0.00052885344,0.000044800392,0.00018130927,0.00038077062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005454604,0.00015036411,0.0004290033,0.00049523043,0.0005712972,0.0008414192,0.00029241253,0.00029400788,0.0005300766],"category_scores_gemma":[0.0016265869,0.000091944865,0.00066378334,0.0011861104,0.00033765848,0.00048277635,0.0006133915,0.00051618397,0.00008136059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013917885,0.00006195155,0.99564797,0.000015282942,0.00009964134,0.0003543881,0.00011576137,0.000087991386,0.00013179652,0.00001628848,0.00021992363,0.003109805],"study_design_scores_gemma":[0.000005734134,0.000083575105,0.9990553,0.0000045973848,0.00008103754,0.00031320303,0.00017069902,0.00005510959,0.00004168969,0.000015519283,0.00016848971,0.000004961893],"about_ca_topic_score_codex":0.010483362,"about_ca_topic_score_gemma":0.015869062,"teacher_disagreement_score":0.010483362,"about_ca_system_score_codex":0.0009539888,"about_ca_system_score_gemma":0.00093993,"threshold_uncertainty_score":0.020844698},"labels":[],"label_agreement":null},{"id":"W4400613267","doi":"10.1016/j.euo.2024.05.016","title":"Effect of Radical Prostatectomy on Survival for Men with High-risk Nonmetastatic Prostate Cancer Features Selected According to STAMPEDE Criteria: An EMPaCT Study","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Vlaamse regering; Fonds Wetenschappelijk Onderzoek","keywords":"Medicine; Prostate cancer; Prostatectomy; Oncology; Urology; Gynecology; Internal medicine; Cancer","score_opus":0.013337358796774782,"score_gpt":0.34969508765784457,"score_spread":0.3363577288610698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400613267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978278,0.0013806182,0.000022607052,0.00008957906,0.000030022115,0.0000076291412,0.00022714685,0.0000034025593,0.00041123765],"genre_scores_gemma":[0.9989255,0.00041149577,0.00002256283,0.000057239296,0.000051881863,0.000005742922,0.00027872578,0.0000018714012,0.00024491476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99954826,0.00015647338,0.000029872755,0.00009347874,0.00006882745,0.000102978716],"domain_scores_gemma":[0.998698,0.0004417165,0.0002985203,0.00008931717,0.000040981588,0.00043156976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082071265,0.00033750304,0.00064092566,0.0003899403,0.00033192354,0.00046557083,0.00037573223,0.0005665897,0.0013732368],"category_scores_gemma":[0.001582452,0.00013756803,0.0015305068,0.0003127416,0.00039282272,0.00042439238,0.0004820762,0.00062813715,0.00010383956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11177684,0.002923679,0.8336802,0.0002679032,0.0023922436,0.00031316208,0.00022433753,0.0017554902,0.0020426488,0.00019561284,0.001447578,0.04298028],"study_design_scores_gemma":[0.001049696,0.00877575,0.9883923,0.000017647884,0.00057496136,0.00014248464,0.00012264894,0.00037641963,0.00012778112,0.00006910237,0.00033245742,0.000018756913],"about_ca_topic_score_codex":0.0039543817,"about_ca_topic_score_gemma":0.0069655697,"teacher_disagreement_score":0.0039543817,"about_ca_system_score_codex":0.00049050146,"about_ca_system_score_gemma":0.0006241362,"threshold_uncertainty_score":0.007862747},"labels":[],"label_agreement":null},{"id":"W4400720534","doi":"10.1016/j.euo.2024.07.003","title":"Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of British Columbia; Health Sciences Centre; BC Cancer Agency; University of Toronto","funders":"Movember Foundation","keywords":"SAFER; Medicine; Prostate cancer; Medical physics; Cancer; Internal medicine; Computer security; Computer science","score_opus":0.12654041648727882,"score_gpt":0.4275346217680749,"score_spread":0.30099420528079607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400720534","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15921336,0.08210736,0.007804333,0.72434264,0.0038272084,0.00025851204,0.0041344278,0.0003303888,0.017981706],"genre_scores_gemma":[0.84590864,0.07210314,0.012176424,0.059457872,0.0040086955,0.00037884424,0.0044431686,0.00023174257,0.0012914806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98414236,0.01025979,0.0020185823,0.0012175973,0.0016708875,0.0006908604],"domain_scores_gemma":[0.8879581,0.05762807,0.015421679,0.014115834,0.01784167,0.0070345295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06277027,0.00041805278,0.0009900263,0.0020121022,0.00074671715,0.0048804358,0.0021748152,0.0022063334,0.004273817],"category_scores_gemma":[0.08458533,0.00038837275,0.001056562,0.0050752843,0.0024336837,0.007846588,0.0034994322,0.0039120894,0.00048519118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005427041,0.0002075248,0.5417152,0.0018559078,0.000360253,0.00046635987,0.0037341963,0.0012364403,0.00018093559,0.015014061,0.08970307,0.34498346],"study_design_scores_gemma":[0.00043360458,0.0010989646,0.61542577,0.019260338,0.0009349862,0.0022564789,0.021264283,0.004039279,0.0007103909,0.030127209,0.30406743,0.00038128722],"about_ca_topic_score_codex":0.013602525,"about_ca_topic_score_gemma":0.012697129,"teacher_disagreement_score":0.06277027,"about_ca_system_score_codex":0.00200568,"about_ca_system_score_gemma":0.008114298,"threshold_uncertainty_score":0.33196485},"labels":[],"label_agreement":null},{"id":"W4401180930","doi":"10.1016/j.euo.2024.07.006","title":"De-escalation of Monitoring in Active Surveillance for Prostate Cancer: Results from the GAP3 Consortium","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Movember Foundation","keywords":"Medicine; Prostate cancer; De-escalation; Active monitoring; Oncology; Gynecology; Internal medicine; Cancer","score_opus":0.029248663105080203,"score_gpt":0.3298719499419391,"score_spread":0.3006232868368589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401180930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95697695,0.010005606,0.001191425,0.0054614353,0.0002486962,0.0006932978,0.016776968,0.00019855189,0.008447086],"genre_scores_gemma":[0.95911807,0.0031785804,0.0030736441,0.0044122287,0.00027410183,0.0008896908,0.027652312,0.000103757106,0.0012977552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99491197,0.0026668739,0.0002570073,0.0005432524,0.0009801622,0.00064076425],"domain_scores_gemma":[0.9877077,0.004593746,0.0022261261,0.0009149906,0.0019480207,0.0026093414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013778684,0.0004646786,0.00080646895,0.00060772256,0.00046285387,0.0016293515,0.0011316377,0.0011528044,0.001597247],"category_scores_gemma":[0.013969261,0.00016053174,0.0015233938,0.0012754726,0.00043398238,0.00089044985,0.0026341258,0.0008963072,0.00033201024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07149887,0.0048047975,0.4711728,0.002307583,0.0027211404,0.00018555281,0.0012601938,0.0062418045,0.0016948862,0.0013149041,0.050813127,0.38598442],"study_design_scores_gemma":[0.009385017,0.008726691,0.931925,0.0011324269,0.0027483697,0.0004158422,0.0014124281,0.0047322125,0.0016267262,0.0013503922,0.036429424,0.000115478404],"about_ca_topic_score_codex":0.020122323,"about_ca_topic_score_gemma":0.015188257,"teacher_disagreement_score":0.020122323,"about_ca_system_score_codex":0.002477912,"about_ca_system_score_gemma":0.007954989,"threshold_uncertainty_score":0.07286954},"labels":[],"label_agreement":null},{"id":"W4402087631","doi":"10.1016/j.euo.2024.08.001","title":"Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG)","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; European Association of Urology","keywords":"Medicine; Bladder cancer; Urology; Cancer; Oncology; Internal medicine","score_opus":0.06929239183369176,"score_gpt":0.4047866575280217,"score_spread":0.33549426569432994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402087631","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001389792,0.9993492,0.000040785686,0.0001387448,0.00008589659,0.000013744724,0.00006105788,0.000002600049,0.00016911518],"genre_scores_gemma":[0.0011774343,0.998071,0.00013194815,0.00040052185,0.000039167775,0.000016896483,0.00007338014,0.0000012887265,0.000088378816],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9995222,0.00014167445,0.00012275118,0.00007275152,0.000105863954,0.00003483114],"domain_scores_gemma":[0.9991922,0.00044763277,0.00020150922,0.000015762225,0.00010613464,0.00003676951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017008367,0.00077533664,0.00302076,0.0020412237,0.00018844908,0.00085430406,0.0010757897,0.0008040564,0.0035341543],"category_scores_gemma":[0.0021140552,0.00027677073,0.0027466174,0.0020923095,0.0002940289,0.0007388231,0.0007241309,0.0012615264,0.0004241182],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006848423,0.00006631638,0.00047202906,0.26526898,0.003231508,0.000104807295,0.00008993716,0.0005190411,0.0010660362,0.0009966468,0.022650583,0.7048493],"study_design_scores_gemma":[0.0016009469,0.0011788385,0.007855261,0.21829097,0.033631634,0.0010909173,0.00021885512,0.00029799825,0.0008337506,0.001598169,0.7333135,0.000089061214],"about_ca_topic_score_codex":0.0028052493,"about_ca_topic_score_gemma":0.0085790865,"teacher_disagreement_score":0.0035341543,"about_ca_system_score_codex":0.0008387339,"about_ca_system_score_gemma":0.001994275,"threshold_uncertainty_score":0.0118229985},"labels":[],"label_agreement":null},{"id":"W4402883766","doi":"10.1016/j.euo.2024.09.010","title":"Lights and Shadows of Bacillus Calmette-Guérin (BCG)-exposed and BCG-unresponsive Definitions: A Practical Overview","year":2024,"lang":"en","type":"editorial","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"European Association of Urology","keywords":"Medicine; Bacillus (shape); BCG vaccine; Tuberculosis; Microbiology; Pathology; Biology","score_opus":0.061467679491246124,"score_gpt":0.3512845803886108,"score_spread":0.28981690089736467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402883766","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000032764856,0.05713021,0.0002107214,0.04213474,0.89973855,0.000013488117,0.000036378966,0.000028269487,0.0006748196],"genre_scores_gemma":[0.00033294293,0.022564841,0.0001658075,0.03952974,0.9348287,0.000022021393,0.000028678996,0.000029130011,0.0024980868],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99200505,0.0028089413,0.0017191096,0.00087574683,0.0021684868,0.00042272732],"domain_scores_gemma":[0.963229,0.024667894,0.0020407818,0.00053023075,0.0071137045,0.0024183674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0125626,0.0045132297,0.005130089,0.005336418,0.0030558011,0.009180876,0.004827078,0.021860916,0.0044635357],"category_scores_gemma":[0.033797354,0.001824818,0.003757846,0.0024806159,0.005598708,0.008469724,0.0027960953,0.036375932,0.0048962804],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054796903,0.000016228998,0.00003871113,0.0006025338,0.000039157585,0.00016798502,0.00004378446,0.000032881635,0.000045078315,0.0009562257,0.9883152,0.009687354],"study_design_scores_gemma":[0.00009340023,0.000054793236,0.00035177957,0.001784011,0.00009876138,0.0007156186,0.0001504757,0.00012227499,0.000072286115,0.001961888,0.9945478,0.000046887253],"about_ca_topic_score_codex":0.003764831,"about_ca_topic_score_gemma":0.010210321,"teacher_disagreement_score":0.021860916,"about_ca_system_score_codex":0.0065054866,"about_ca_system_score_gemma":0.0047693364,"threshold_uncertainty_score":0.0664382},"labels":[],"label_agreement":null},{"id":"W4402947065","doi":"10.1016/j.euo.2024.09.009","title":"Room for improvement when approaching RCC in the solitary kidney: surgery is not the only choice","year":2024,"lang":"en","type":"editorial","venue":"European Urology Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Sunnybrook Health Science Centre; Western University","funders":"Pharmaceuticals Bayer; Varian Medical Systems","keywords":"Medicine; Kidney; General surgery; Surgery; Medical physics; Internal medicine","score_opus":0.04625114927445017,"score_gpt":0.35284315541850464,"score_spread":0.30659200614405446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402947065","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023626757,0.005793814,0.000103577426,0.046695333,0.9466192,0.000010704111,0.00002264777,0.000041002542,0.0006900136],"genre_scores_gemma":[0.00017467303,0.0029241561,0.000058506856,0.021526882,0.9738482,0.000009940631,0.00000993393,0.000015067589,0.0014324853],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99283195,0.0015478351,0.000980891,0.0009305149,0.0031876047,0.00052110385],"domain_scores_gemma":[0.95633566,0.023379633,0.0025024433,0.00072985893,0.010554139,0.0064983102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009837019,0.0043063075,0.0064434637,0.0037356687,0.0042951256,0.009613832,0.004894717,0.03481037,0.009266612],"category_scores_gemma":[0.044201784,0.0021130927,0.003970048,0.0018564395,0.0039816573,0.0073504,0.0021792392,0.051603515,0.009119021],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004209613,0.000011764727,0.000031132797,0.00027445986,0.00003772868,0.00014587842,0.000013395107,0.000029796072,0.000037088248,0.00023019823,0.9944186,0.0047278204],"study_design_scores_gemma":[0.00021100834,0.00008181834,0.000520228,0.0016139483,0.00020842953,0.000935314,0.00012443902,0.00028547904,0.00013239379,0.0024778296,0.99333584,0.00007334778],"about_ca_topic_score_codex":0.002686323,"about_ca_topic_score_gemma":0.008563778,"teacher_disagreement_score":0.03481037,"about_ca_system_score_codex":0.004920853,"about_ca_system_score_gemma":0.0044935457,"threshold_uncertainty_score":0.05202371},"labels":[],"label_agreement":null},{"id":"W4403213466","doi":"10.1016/j.euo.2024.09.013","title":"Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Abiraterone; Prostate cancer; Abiraterone acetate; Olaparib; Asymptomatic; Placebo; Internal medicine; Oncology; Urology; Cancer; Androgen deprivation therapy; Pathology","score_opus":0.06115839959823703,"score_gpt":0.3709653573860134,"score_spread":0.30980695778777634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403213466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827435,0.013188715,0.00032281168,0.00048090954,0.00020078903,0.00085335167,0.0009841225,0.000055212506,0.0011706164],"genre_scores_gemma":[0.9948376,0.0023656178,0.00037728364,0.00031981894,0.00021256071,0.0005344474,0.0007794391,0.000008678081,0.0005644817],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987878,0.0007686114,0.000102038466,0.00012292822,0.00010846825,0.00011012365],"domain_scores_gemma":[0.99836594,0.00054612826,0.00054541987,0.000095072224,0.00008182531,0.00036548876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026467494,0.0010989336,0.0025379814,0.0004002442,0.00026801607,0.0011757778,0.000690944,0.0008361246,0.0030270363],"category_scores_gemma":[0.0024334441,0.000370331,0.0033153852,0.0004065603,0.00067060196,0.0006418062,0.0003840053,0.002167033,0.00046882362],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97012055,0.0018133563,0.0022066836,0.000536733,0.0024282297,0.000040330095,0.000054741122,0.00040771984,0.0023867725,0.000038201066,0.00041637465,0.019550296],"study_design_scores_gemma":[0.8008533,0.17395249,0.016511561,0.00012146603,0.0047393944,0.00020378952,0.00006943456,0.0007597297,0.0012771055,0.00032849947,0.0011422937,0.00004097182],"about_ca_topic_score_codex":0.00050457346,"about_ca_topic_score_gemma":0.001734336,"teacher_disagreement_score":0.0030270363,"about_ca_system_score_codex":0.0007491444,"about_ca_system_score_gemma":0.0009909931,"threshold_uncertainty_score":0.013997495},"labels":[],"label_agreement":null},{"id":"W4403731062","doi":"10.1016/j.euo.2024.10.008","title":"Oncological Outcomes of Active Surveillance versus Surgery or Ablation for Patients with Small Renal Masses: A Systematic Review and Quantitative Analysis","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"Agencja Badań Medycznych; European Association of Urology","keywords":"Medicine; Ablation; Renal mass; Radiology; Medical physics; Internal medicine; Kidney; Nephrectomy","score_opus":0.13097529584533918,"score_gpt":0.3802293122406022,"score_spread":0.249254016395263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403731062","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0071268044,0.98825186,0.00049404247,0.0002965062,0.00009421064,0.00095385965,0.0024227018,0.000016067692,0.00034397648],"genre_scores_gemma":[0.1658989,0.82292485,0.0027603616,0.0010821061,0.00018042664,0.0048704552,0.001987505,0.000027172755,0.0002681034],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9838598,0.005176426,0.007239894,0.0012639364,0.0021165276,0.00034344953],"domain_scores_gemma":[0.9443606,0.039679542,0.011384255,0.00078688416,0.0033536393,0.0004349924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01502075,0.0013888625,0.011848374,0.013430359,0.0006378353,0.0027846433,0.0017058329,0.0014530247,0.0031162584],"category_scores_gemma":[0.054962274,0.0008426789,0.0152783,0.012965766,0.0009987002,0.002135338,0.0016417737,0.0010549267,0.00019295138],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005769974,0.000017589333,0.0032143747,0.9221358,0.061041858,0.0000621697,0.00017293192,0.00010738488,0.00011665459,0.00013121548,0.0004978295,0.011925227],"study_design_scores_gemma":[0.00077256764,0.00043659314,0.015366041,0.49058035,0.48434776,0.00030492226,0.00038968993,0.00020606714,0.00019022569,0.00043886152,0.006894201,0.00007263968],"about_ca_topic_score_codex":0.005025547,"about_ca_topic_score_gemma":0.015171747,"teacher_disagreement_score":0.01502075,"about_ca_system_score_codex":0.0032273938,"about_ca_system_score_gemma":0.0061773937,"threshold_uncertainty_score":0.07943821},"labels":[],"label_agreement":null},{"id":"W4404316580","doi":"10.1016/j.euo.2024.10.017","title":"Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"National Cancer Institute; Division of Cancer Prevention, National Cancer Institute; National Institutes of Health; Pfizer; Bristol-Myers Squibb","keywords":"Subtyping; Medicine; Oncology; Internal medicine; Prostate cancer; Prostate; Biopsy; Pathology; Cancer","score_opus":0.03929479077338504,"score_gpt":0.35905274845038837,"score_spread":0.3197579576770033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404316580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9567862,0.03180713,0.0016479277,0.0015978197,0.00028855895,0.00052827684,0.004865313,0.00012477391,0.0023538922],"genre_scores_gemma":[0.9831739,0.0050121136,0.0020340432,0.0010403475,0.00026986236,0.00023840355,0.007236362,0.00008033994,0.0009145886],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9957437,0.0030687486,0.00017121084,0.0004808417,0.00036240238,0.00017311772],"domain_scores_gemma":[0.9959074,0.0021031045,0.000846187,0.00039766525,0.00033246807,0.00041313784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009601681,0.0015757063,0.00395447,0.00068891986,0.0003424754,0.0017939337,0.0010341253,0.0010932867,0.001846453],"category_scores_gemma":[0.007958809,0.00046519932,0.0046026614,0.0009967695,0.0005370288,0.0016620363,0.0007995349,0.0021310293,0.0004383944],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5626459,0.002912067,0.14209774,0.0031686064,0.060623344,0.00013036349,0.0003014265,0.010825483,0.0069606677,0.000477298,0.01333038,0.19652674],"study_design_scores_gemma":[0.21798964,0.100239575,0.44168594,0.0012797271,0.17413937,0.0013939512,0.0006349655,0.031066729,0.0039076866,0.005333971,0.021852745,0.00047576998],"about_ca_topic_score_codex":0.0018682185,"about_ca_topic_score_gemma":0.0070742783,"teacher_disagreement_score":0.009601681,"about_ca_system_score_codex":0.00079912465,"about_ca_system_score_gemma":0.0009886647,"threshold_uncertainty_score":0.050779164},"labels":[],"label_agreement":null},{"id":"W4404868817","doi":"10.1016/j.euo.2024.11.007","title":"Frailty in Older Adults with Prostate Cancer","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Gerontology; Cancer; Oncology; Internal medicine","score_opus":0.037113717786421585,"score_gpt":0.36195392486886746,"score_spread":0.3248402070824459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404868817","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000103606486,0.99957854,0.000013313763,0.00008322371,0.000055405064,0.0000028247998,0.000010242058,0.0000014098114,0.00015147934],"genre_scores_gemma":[0.00109773,0.9986111,0.0000327641,0.00009513502,0.000058530553,0.000005693493,0.000020888288,3.5837232e-7,0.00007773912],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997241,0.00006888527,0.000059399008,0.00003253214,0.000090200636,0.000024938216],"domain_scores_gemma":[0.9993573,0.00035297556,0.00014793364,0.000009251921,0.00009844848,0.000034115485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069679756,0.0008065711,0.0017729248,0.0020862124,0.000255731,0.00087182946,0.0006929487,0.00092782016,0.0027983445],"category_scores_gemma":[0.0020517763,0.00021147725,0.0012759216,0.0015726022,0.0002662366,0.0007178478,0.00078580744,0.001005801,0.0004469638],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000116354284,0.00004275115,0.0007697769,0.07914832,0.00060540764,0.000098989214,0.00009397699,0.00016742811,0.0001670455,0.0008043619,0.016189162,0.90179646],"study_design_scores_gemma":[0.00019660371,0.0004977842,0.023134092,0.2614951,0.005234245,0.0041213054,0.0004233032,0.00036568794,0.0003354981,0.0034778453,0.70062196,0.000096581025],"about_ca_topic_score_codex":0.003148533,"about_ca_topic_score_gemma":0.0063338024,"teacher_disagreement_score":0.003148533,"about_ca_system_score_codex":0.00051210995,"about_ca_system_score_gemma":0.0012107983,"threshold_uncertainty_score":0.009361386},"labels":[],"label_agreement":null},{"id":"W4405465549","doi":"10.1016/j.euo.2024.12.005","title":"Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Docetaxel; Gemcitabine; Bladder cancer; Bacillus (shape); Urology; Oncology; Internal medicine; Cancer; Microbiology","score_opus":0.01886197048488084,"score_gpt":0.2837807346246937,"score_spread":0.26491876413981286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405465549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960001,0.0029782122,0.000055775872,0.0001333932,0.00007479256,0.000031364325,0.00014193634,0.000005377817,0.0005790784],"genre_scores_gemma":[0.9988324,0.00049734407,0.000043290227,0.00011647679,0.000042757532,0.000019917177,0.00020386555,0.0000021948745,0.00024175164],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99964166,0.00011851919,0.00003559576,0.00006790813,0.00003393297,0.00010225395],"domain_scores_gemma":[0.9994265,0.00015973939,0.00015009634,0.000034222223,0.00003548967,0.0001939768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004837531,0.00031253268,0.0011761693,0.00023038257,0.00019828495,0.0006435166,0.0002936787,0.00047583797,0.0014811921],"category_scores_gemma":[0.001470014,0.00020870093,0.0016982211,0.00033125622,0.00034341376,0.0006234391,0.00027148315,0.0011644514,0.00017854621],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6870028,0.0076204925,0.13666092,0.00073383085,0.004511979,0.0003874837,0.00029436446,0.0062813,0.0058385893,0.00027636244,0.0019752174,0.14841671],"study_design_scores_gemma":[0.056097426,0.34408373,0.57350516,0.00030517223,0.008763764,0.00074763177,0.00051813666,0.0071501024,0.003735481,0.000772285,0.0042114533,0.0001096489],"about_ca_topic_score_codex":0.002097612,"about_ca_topic_score_gemma":0.005251735,"teacher_disagreement_score":0.002097612,"about_ca_system_score_codex":0.0010014585,"about_ca_system_score_gemma":0.00066332554,"threshold_uncertainty_score":0.007266164},"labels":[],"label_agreement":null},{"id":"W4405945558","doi":"10.1016/j.euo.2024.12.011","title":"Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Alberta; BC Cancer Agency; Alberta Health Services; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Carcinoma; Internal medicine; Cancer research","score_opus":0.04675184849823367,"score_gpt":0.31053943928657235,"score_spread":0.2637875907883387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405945558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93582094,0.0025161514,0.00089191063,0.0004406385,0.00003288497,0.00016395838,0.058683027,0.000036804737,0.0014136491],"genre_scores_gemma":[0.95528036,0.00050461263,0.0005208979,0.00014727013,0.000043285778,0.0002041111,0.043080416,0.000018009228,0.00020110367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952401,0.0013742984,0.0008340292,0.0012745578,0.00087789126,0.00039907705],"domain_scores_gemma":[0.98613757,0.0041306196,0.006480113,0.0010769641,0.0012953578,0.0008794436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005387863,0.00044212386,0.0012190713,0.003355127,0.00039541326,0.0012842433,0.0014215789,0.00055304135,0.0014612519],"category_scores_gemma":[0.01124393,0.00032354752,0.0026797773,0.006028448,0.000260344,0.00086062716,0.0014817219,0.0011873607,0.00020145102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011216609,0.00006155176,0.989218,0.00019486035,0.002525678,0.0000754473,0.00007553982,0.0011516684,0.00005354711,0.000140621,0.0025922402,0.0027891048],"study_design_scores_gemma":[0.00023448376,0.00016358649,0.9914259,0.00009810216,0.0014426197,0.0003177043,0.00021594303,0.0042006862,0.0000913318,0.0001066869,0.0016706195,0.000032411986],"about_ca_topic_score_codex":0.034492664,"about_ca_topic_score_gemma":0.030577647,"teacher_disagreement_score":0.034492664,"about_ca_system_score_codex":0.0018281065,"about_ca_system_score_gemma":0.0015536257,"threshold_uncertainty_score":0.06858379},"labels":[],"label_agreement":null},{"id":"W4406136944","doi":"10.1016/j.euo.2024.12.009","title":"Benefit and Harms of Radical Nephroureterectomy as Part of a Multimodal Treatment Strategy for Upper Tract Urothelial Carcinoma Patients Presenting with Clinical Evidence of Regional Lymph Node Metastasis: A Systematic Review and Meta-analysis by the European Association of Urology Guidelines","year":2025,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Urothelial carcinoma; Lymph node metastasis; Multimodal therapy; Lymph node; Metastasis; Oncology; General surgery; Urology; Internal medicine; Cancer; Bladder cancer","score_opus":0.16649947699337558,"score_gpt":0.42395589411950907,"score_spread":0.2574564171261335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406136944","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040612207,0.99468863,0.00024359331,0.00014810218,0.00012007917,0.00008609107,0.0003917422,0.000010422331,0.00025012833],"genre_scores_gemma":[0.15034884,0.8456004,0.0012144676,0.0012757538,0.00024338323,0.00024830806,0.00060839334,0.000019249937,0.0004411655],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99766785,0.001094358,0.0005331223,0.00033366744,0.00026902882,0.0001019431],"domain_scores_gemma":[0.9958242,0.0031178496,0.00069488335,0.00009569442,0.0001871156,0.00008023005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035246275,0.0013013887,0.007900378,0.0020229858,0.00028012684,0.001312652,0.0010350208,0.0014455967,0.003859926],"category_scores_gemma":[0.009465958,0.00086183427,0.019159768,0.0020437585,0.0005130429,0.0009937187,0.0010322684,0.0020255472,0.0002605556],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005626736,0.00005400381,0.004115326,0.45737478,0.4817016,0.000108308865,0.000108865475,0.00076859526,0.00038184575,0.00025008168,0.0015510282,0.047958694],"study_design_scores_gemma":[0.0025218767,0.00053659244,0.007792237,0.039404195,0.9436863,0.00013233488,0.000077217635,0.00021201576,0.00015057139,0.00045425718,0.0049888087,0.000043485696],"about_ca_topic_score_codex":0.0057325833,"about_ca_topic_score_gemma":0.019200541,"teacher_disagreement_score":0.007900378,"about_ca_system_score_codex":0.001519823,"about_ca_system_score_gemma":0.0013705421,"threshold_uncertainty_score":0.01864028},"labels":[],"label_agreement":null},{"id":"W4406885123","doi":"10.1016/j.euo.2024.12.013","title":"A Systematic Review and Meta-analysis of the Clinical Impact of Prophylactic Quinolones with Adjuvant Bacillus Calmette-Guérin Instillation for Non–muscle-invasive Bladder Cancer","year":2025,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Bladder cancer; Adjuvant; Meta-analysis; Bacillus (shape); Oncology; Urology; Cancer; Internal medicine; Surgery; Microbiology","score_opus":0.11001338861337835,"score_gpt":0.43894441216388796,"score_spread":0.3289310235505096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406885123","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055741933,0.9932921,0.00023728622,0.00011275283,0.00014605514,0.0001330215,0.00027735115,0.000012479594,0.00021476272],"genre_scores_gemma":[0.17708535,0.81910294,0.001311666,0.0010020618,0.00020937916,0.0003126042,0.00054654,0.000021539041,0.00040795584],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959006,0.0017477887,0.0012504059,0.000477874,0.00044129745,0.0001820734],"domain_scores_gemma":[0.99432015,0.0038224275,0.0011526368,0.00017452905,0.0004063762,0.00012398894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005567089,0.00202622,0.0126554305,0.0025512497,0.00045923432,0.0021195756,0.0015681022,0.0017216459,0.003675452],"category_scores_gemma":[0.014251884,0.0010342706,0.025019955,0.0038007859,0.0006040032,0.0012241201,0.0012186291,0.001852502,0.00030472947],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067524253,0.000060834802,0.0025779179,0.38832983,0.5791274,0.00015285294,0.00008268421,0.00050402497,0.00043715214,0.00011434516,0.00077281427,0.02108776],"study_design_scores_gemma":[0.0015571616,0.00039213602,0.0031259367,0.015548801,0.9770055,0.000080316764,0.000038193728,0.000105068866,0.000102482765,0.00012442314,0.0018956439,0.000024443705],"about_ca_topic_score_codex":0.0075413147,"about_ca_topic_score_gemma":0.020348227,"teacher_disagreement_score":0.0126554305,"about_ca_system_score_codex":0.0018391956,"about_ca_system_score_gemma":0.0026934363,"threshold_uncertainty_score":0.029441953},"labels":[],"label_agreement":null},{"id":"W4407090068","doi":"10.1016/j.euo.2024.12.015","title":"Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials","year":2025,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Fraction (chemistry); Meta-analysis; Radiation therapy; Prostate; Oncology; Prospective cohort study; Cancer; Internal medicine","score_opus":0.20613283951657208,"score_gpt":0.4449259458388961,"score_spread":0.23879310632232403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407090068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09825348,0.88778645,0.0073431632,0.0009915865,0.00085982063,0.00070597365,0.002323691,0.00026433644,0.0014714877],"genre_scores_gemma":[0.92832714,0.062306475,0.0040564616,0.0013592641,0.00032096074,0.0009865393,0.0017428107,0.00012311255,0.00077735237],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97993577,0.014403303,0.002251291,0.002058456,0.0009841318,0.0003669467],"domain_scores_gemma":[0.9791646,0.016146557,0.0024671918,0.0012931123,0.0006208164,0.00030766512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027465302,0.0032951368,0.013678725,0.0032202732,0.0005197629,0.003126719,0.002552086,0.0023908562,0.0038475154],"category_scores_gemma":[0.03172894,0.0013235159,0.055240806,0.0031932767,0.00072894426,0.001994107,0.0014779711,0.0027196463,0.00037269434],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007712482,0.000017969049,0.0045959638,0.01201373,0.9719149,0.000064276835,0.000024936731,0.00084316806,0.00015746767,0.00006442873,0.0002218783,0.002368792],"study_design_scores_gemma":[0.0019142883,0.00032554197,0.0032423632,0.0009004379,0.9922044,0.00006019366,0.000019002942,0.00051540404,0.00009574714,0.00024425675,0.00046247622,0.000015942675],"about_ca_topic_score_codex":0.0041152984,"about_ca_topic_score_gemma":0.0050626444,"teacher_disagreement_score":0.027465302,"about_ca_system_score_codex":0.0014694234,"about_ca_system_score_gemma":0.00094450655,"threshold_uncertainty_score":0.14525211},"labels":[],"label_agreement":null},{"id":"W4408476470","doi":"10.1016/j.euo.2025.02.008","title":"Treatment of Metastatic Renal Cell Carcinoma: Lack of Consensus Urges the Need for a Well-organized Multidisciplinary Team","year":2025,"lang":"en","type":"editorial","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Multidisciplinary approach; Multidisciplinary team; Intensive care medicine; Oncology; MEDLINE; Internal medicine; Nursing","score_opus":0.035304713824297264,"score_gpt":0.32354127302980945,"score_spread":0.28823655920551217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408476470","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026923724,0.007574285,0.000121760895,0.06362496,0.9277572,0.000014239153,0.000025436182,0.000033012908,0.00082213065],"genre_scores_gemma":[0.00031626204,0.0054531973,0.00011881755,0.03282923,0.95952547,0.000012881598,0.000018538323,0.00001872123,0.0017068316],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99053496,0.00279386,0.00145493,0.00079478725,0.0039393273,0.00048224907],"domain_scores_gemma":[0.9436372,0.029990626,0.0030964473,0.0009202059,0.016045623,0.0063099544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014105746,0.0030643402,0.0048231324,0.0037987137,0.003752325,0.009355334,0.0044829273,0.026529897,0.006723152],"category_scores_gemma":[0.045355987,0.0013574441,0.0034097477,0.0017974534,0.0033565224,0.0064337235,0.0019521296,0.03325006,0.0065692235],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033497057,0.000014535278,0.00003996674,0.00041292363,0.00004647179,0.00014117039,0.000015906056,0.000033967368,0.000027336635,0.00030900948,0.99216825,0.0067569837],"study_design_scores_gemma":[0.00018172525,0.00007439144,0.00057407917,0.0028105536,0.00021963021,0.0007287102,0.00012146207,0.00032515166,0.0001069119,0.0022351514,0.9925707,0.00005142223],"about_ca_topic_score_codex":0.0028791474,"about_ca_topic_score_gemma":0.008850931,"teacher_disagreement_score":0.026529897,"about_ca_system_score_codex":0.0044714506,"about_ca_system_score_gemma":0.005496774,"threshold_uncertainty_score":0.074599266},"labels":[],"label_agreement":null},{"id":"W4409833020","doi":"10.1016/j.euo.2025.03.011","title":"Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body Radiotherapy","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; BC Cancer Agency; CancerCare Manitoba; Sunnybrook Health Science Centre","funders":"Prostate Cancer Canada","keywords":"Medicine; Ablative case; Prostate; Radiosurgery; Radiation therapy; Term (time); Oncology; Medical physics; Internal medicine; Radiology; Cancer","score_opus":0.042587242600463045,"score_gpt":0.38245616294540197,"score_spread":0.33986892034493893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409833020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98952943,0.0060073617,0.00024391462,0.00080614316,0.00022066195,0.0008139673,0.00047812762,0.000032356496,0.001868029],"genre_scores_gemma":[0.992148,0.0017645947,0.00056024606,0.0010098388,0.0004439989,0.0014907452,0.00095599954,0.00001684845,0.0016097116],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99837214,0.0011581256,0.000068658206,0.00016007767,0.00012022284,0.00012078781],"domain_scores_gemma":[0.99822265,0.0004380011,0.000816539,0.00015428824,0.000085913496,0.0002825726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034424919,0.00089649844,0.0012500511,0.0002852513,0.00030391593,0.0009409411,0.0007301926,0.0015106803,0.0038561253],"category_scores_gemma":[0.0035738,0.0003147841,0.001947808,0.0003559454,0.0007516644,0.00091630494,0.00050493405,0.0029163626,0.00044913817],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9454648,0.0059588663,0.004215652,0.0006964488,0.0016748966,0.00005968797,0.00011010811,0.0006711785,0.0019167673,0.00016293672,0.0016722337,0.03739659],"study_design_scores_gemma":[0.7579183,0.20931473,0.025719684,0.00016558038,0.0020212876,0.00022271779,0.000057000987,0.001041236,0.00082874525,0.0005026711,0.0021645857,0.000043312488],"about_ca_topic_score_codex":0.00038447292,"about_ca_topic_score_gemma":0.0006774495,"teacher_disagreement_score":0.0038561253,"about_ca_system_score_codex":0.0004976329,"about_ca_system_score_gemma":0.0005793789,"threshold_uncertainty_score":0.018205881},"labels":[],"label_agreement":null},{"id":"W4410014449","doi":"10.1016/j.euo.2025.03.001","title":"Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Pharmaceuticals Bayer","keywords":"Medicine; Prostate cancer; Oncology; Prostate-specific antigen; Internal medicine; Prostate; Cancer; Clinical trial; Hormone","score_opus":0.030688283063919717,"score_gpt":0.33577459456679093,"score_spread":0.3050863115028712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410014449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9080283,0.07780377,0.0033665842,0.0023499923,0.00017244251,0.00044468223,0.0035897493,0.000060932944,0.0041836267],"genre_scores_gemma":[0.99026847,0.0054484652,0.0011959375,0.00046800677,0.00010862048,0.00022452704,0.0019224673,0.000019759049,0.00034375445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98470926,0.012167649,0.0009865519,0.00095774943,0.0008275204,0.00035121682],"domain_scores_gemma":[0.9581867,0.028345037,0.008483146,0.002891124,0.0012214723,0.000872584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.031702433,0.000514776,0.0018060583,0.00040893,0.00022984373,0.0011873987,0.00075915025,0.00068331644,0.0022684173],"category_scores_gemma":[0.033626396,0.00024945292,0.0048060245,0.0010403626,0.00070883735,0.0012803412,0.0009178328,0.0019458465,0.00023993036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2581697,0.0017394919,0.34742415,0.011340354,0.063744254,0.00043863623,0.0010294459,0.021062396,0.002924028,0.005193213,0.007989893,0.27894443],"study_design_scores_gemma":[0.038757585,0.071775295,0.7461821,0.005542156,0.054248385,0.0013490615,0.0008611092,0.023400178,0.0022225142,0.017501125,0.03775194,0.0004085612],"about_ca_topic_score_codex":0.0005903744,"about_ca_topic_score_gemma":0.0015449602,"teacher_disagreement_score":0.031702433,"about_ca_system_score_codex":0.0006041825,"about_ca_system_score_gemma":0.0011480056,"threshold_uncertainty_score":0.16766047},"labels":[],"label_agreement":null},{"id":"W4410038448","doi":"10.1016/j.euo.2025.02.007","title":"Variation in Prostate Magnetic Resonance Imaging Performance: Data from the Prostate Biopsy Collaborative Group","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Prostate; Magnetic resonance imaging; Prostate biopsy; Prostate cancer; Radiology; Internal medicine","score_opus":0.015590260090161713,"score_gpt":0.2857436566102127,"score_spread":0.270153396520051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410038448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972821,0.0016443554,0.00071816426,0.00033138468,0.00003204842,0.000040842824,0.022138845,0.00004485471,0.0022285841],"genre_scores_gemma":[0.98533916,0.00026036068,0.0002549679,0.00010184084,0.000022821925,0.000026313206,0.013770184,0.00002640526,0.00019808064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914727,0.0032495945,0.0008480389,0.0017475014,0.0020799248,0.00060221856],"domain_scores_gemma":[0.982157,0.0048537706,0.006161669,0.0025210169,0.0030952408,0.0012113494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006214724,0.00038821984,0.0008795925,0.002092484,0.0004958454,0.0010832374,0.0013755116,0.0009992322,0.0008920421],"category_scores_gemma":[0.016705494,0.00028521565,0.0010296573,0.006231149,0.0003876311,0.0006785218,0.0015633561,0.0005551838,0.00027294015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027333334,0.00002235581,0.994307,0.000029705743,0.00044634423,0.000027453283,0.00013186753,0.00027308505,0.00007511522,0.000049452636,0.0018006202,0.0025636859],"study_design_scores_gemma":[0.000011403295,0.000025781454,0.99912196,0.0000068253294,0.000052465915,0.000063929096,0.00007020454,0.00013685631,0.00002611615,0.000019563486,0.00045800422,0.0000069040325],"about_ca_topic_score_codex":0.047778774,"about_ca_topic_score_gemma":0.04897609,"teacher_disagreement_score":0.047778774,"about_ca_system_score_codex":0.0010670831,"about_ca_system_score_gemma":0.0010567226,"threshold_uncertainty_score":0.09500134},"labels":[],"label_agreement":null},{"id":"W4410038451","doi":"10.1016/j.euo.2025.04.004","title":"Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Merck; Pfizer; Merck Healthcare KGaA","keywords":"Medicine; Urothelial carcinoma; Metastatic Urothelial Carcinoma; Avelumab; Javelin; Oncology; Toxicity; Internal medicine; Urology; Bladder cancer; Immunotherapy; Cancer; Pembrolizumab","score_opus":0.06087568181395224,"score_gpt":0.3749091265974353,"score_spread":0.31403344478348305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410038451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910706,0.0063556633,0.00018479116,0.00028197234,0.00009192278,0.000058802365,0.001313151,0.0000229566,0.00062009844],"genre_scores_gemma":[0.99519664,0.0015502296,0.00019226392,0.0002656283,0.00010242592,0.00008160672,0.0017967483,0.000010923232,0.0008034808],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991036,0.0005094405,0.000045002933,0.00015088542,0.00006022317,0.00013073784],"domain_scores_gemma":[0.9984321,0.0004734171,0.0005124034,0.00020799723,0.00006133534,0.00031272805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025961169,0.0009304539,0.0019153155,0.00025338528,0.00026040385,0.0011390788,0.00075782463,0.0007505131,0.0016710081],"category_scores_gemma":[0.0022965653,0.00033305262,0.0031162275,0.00047188794,0.0006109314,0.0010910487,0.0005443126,0.0022943998,0.00028414303],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88976395,0.001838183,0.04302898,0.0013814314,0.01918727,0.00013495657,0.00012500907,0.0029730184,0.004448539,0.00036676953,0.003114685,0.03363716],"study_design_scores_gemma":[0.42368817,0.11674033,0.4013207,0.0004498924,0.036435686,0.0006551563,0.00037399438,0.0082342075,0.0029892286,0.0016025476,0.0072865095,0.000223651],"about_ca_topic_score_codex":0.0012108877,"about_ca_topic_score_gemma":0.0024413897,"teacher_disagreement_score":0.0025961169,"about_ca_system_score_codex":0.00073561876,"about_ca_system_score_gemma":0.000578281,"threshold_uncertainty_score":0.0137296915},"labels":[],"label_agreement":null},{"id":"W4410085374","doi":"10.1016/j.euo.2025.04.012","title":"Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Research and Development; Johnson and Johnson","keywords":"Abiraterone acetate; Medicine; Prednisone; Prostate cancer; Abiraterone; Oncology; Castration; Internal medicine; Urology; Cancer; Androgen deprivation therapy; Hormone; Androgen receptor","score_opus":0.08226572202178561,"score_gpt":0.40670531651909064,"score_spread":0.32443959449730503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410085374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9678965,0.01825774,0.0016766691,0.0014424633,0.00043834632,0.0019187693,0.0043970607,0.00015139903,0.0038211502],"genre_scores_gemma":[0.98598236,0.0033470618,0.0017204257,0.0007557729,0.0003936263,0.0013895246,0.0046402616,0.000033495395,0.001737425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99830294,0.0012919446,0.000064774096,0.00012818852,0.00011698532,0.00009520912],"domain_scores_gemma":[0.9981071,0.0006018049,0.0006277425,0.00022553063,0.00010453109,0.00033317346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005468839,0.0009046795,0.0015600111,0.00026809942,0.00024090617,0.0011117179,0.0006362076,0.00066997594,0.0044400375],"category_scores_gemma":[0.0039618714,0.00030769614,0.0035188126,0.00037727755,0.0004294149,0.0007272969,0.0004806508,0.0021450387,0.0005395385],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94143575,0.0024077063,0.006001775,0.0008659109,0.006397267,0.00005631345,0.000052766507,0.001954356,0.0025398165,0.00023633313,0.0026117256,0.035440348],"study_design_scores_gemma":[0.8362289,0.1019017,0.037758827,0.00032004344,0.011829921,0.00042904398,0.00006526396,0.0026659723,0.0016238422,0.0015621231,0.005555548,0.000058678248],"about_ca_topic_score_codex":0.00040232105,"about_ca_topic_score_gemma":0.0012272501,"teacher_disagreement_score":0.005468839,"about_ca_system_score_codex":0.0005417502,"about_ca_system_score_gemma":0.0014898167,"threshold_uncertainty_score":0.028922379},"labels":[],"label_agreement":null},{"id":"W4410116981","doi":"10.1016/j.euo.2025.03.017","title":"Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université de Saint-Boniface; CancerCare Manitoba; St. Boniface Hospital; London Health Sciences Centre; Princess Margaret Cancer Centre; University Health Network; Western University; Sunnybrook Health Science Centre; McGill University Health Centre; Juravinski Cancer Centre","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; Prostate cancer; Radiation therapy; Randomized controlled trial; Clinical trial; Quality of life (healthcare); Medical physics; Oncology; Prostate; Internal medicine; Cancer; Nursing","score_opus":0.11764613250169513,"score_gpt":0.49173306586966686,"score_spread":0.3740869333679717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410116981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99547654,0.0011536292,0.00034169297,0.00047685194,0.0001122876,0.0007719272,0.00062044436,0.00005975926,0.0009868299],"genre_scores_gemma":[0.9953928,0.0003871434,0.0008654036,0.00051243475,0.00009897868,0.0010573324,0.00085763907,0.00001361321,0.000814736],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99913174,0.0005476102,0.00003024798,0.0001067012,0.00006504896,0.00011873039],"domain_scores_gemma":[0.9991804,0.00017965307,0.00019745674,0.000057504578,0.000034378016,0.0003504906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001635972,0.0012359733,0.0015058474,0.00039064928,0.0005493179,0.00075510406,0.0007733735,0.0010757006,0.0036423702],"category_scores_gemma":[0.001482596,0.00038896815,0.0023350548,0.00035547387,0.0012229257,0.0007595008,0.0007538096,0.0029096843,0.00037958878],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9721773,0.007357583,0.0027173269,0.00023262629,0.001200916,0.00002700349,0.00005368601,0.00083580666,0.0026485934,0.00010942893,0.00060971436,0.012029987],"study_design_scores_gemma":[0.8351926,0.14403266,0.016818255,0.000036926318,0.0011885188,0.000053243417,0.000052081607,0.0010627276,0.0006491679,0.00030024807,0.0005851894,0.000028347784],"about_ca_topic_score_codex":0.0013208343,"about_ca_topic_score_gemma":0.0027033172,"teacher_disagreement_score":0.0036423702,"about_ca_system_score_codex":0.0006886432,"about_ca_system_score_gemma":0.0011314421,"threshold_uncertainty_score":0.0121849775},"labels":[],"label_agreement":null},{"id":"W4410338114","doi":"10.1016/j.euo.2025.02.015","title":"Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health","funders":"Bayer; Astellas Pharma US","keywords":"Medicine; Docetaxel; Pembrolizumab; Prostate cancer; Prednisone; Oncology; Internal medicine; Abiraterone; Enzalutamide; Cancer; Immunotherapy","score_opus":0.017536134480207105,"score_gpt":0.3190061985177405,"score_spread":0.3014700640375334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410338114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990798,0.006778346,0.00034339275,0.0002821228,0.000034001718,0.00018252712,0.0008190844,0.0000116605925,0.00075084856],"genre_scores_gemma":[0.9975514,0.00073324144,0.000308623,0.00012874661,0.000046343255,0.00017131519,0.00090579677,0.0000022295246,0.00015234036],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99742943,0.00167574,0.00015381582,0.00028929915,0.0003002835,0.00015141336],"domain_scores_gemma":[0.997488,0.00076041964,0.001283396,0.00010827132,0.0001145185,0.000245413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051602107,0.000537068,0.0010387265,0.00033889106,0.00019100794,0.00081406673,0.0004729234,0.00050080847,0.0019358506],"category_scores_gemma":[0.0035125483,0.00025144318,0.0022737256,0.00068194314,0.0002872019,0.0007033086,0.0006197852,0.0011492436,0.00018645817],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5895169,0.0054611233,0.22116128,0.0029226006,0.012493318,0.00026010253,0.00025627157,0.0053897784,0.0056846766,0.000341518,0.0027133178,0.15379906],"study_design_scores_gemma":[0.08445146,0.14339747,0.74429685,0.00044276187,0.010512881,0.0008328953,0.00020850918,0.0071329246,0.002767197,0.0006136187,0.0052420557,0.00010130575],"about_ca_topic_score_codex":0.00044608887,"about_ca_topic_score_gemma":0.00087592873,"teacher_disagreement_score":0.0051602107,"about_ca_system_score_codex":0.00058470113,"about_ca_system_score_gemma":0.00058771746,"threshold_uncertainty_score":0.027290165},"labels":[],"label_agreement":null},{"id":"W4410573706","doi":"10.1016/j.euo.2025.04.010","title":"Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non–muscle-invasive Bladder Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"European Association of Urology","keywords":"Medicine; Bladder cancer; Oncology; Cancer; Internal medicine; Intensive care medicine","score_opus":0.011843675398855743,"score_gpt":0.28240497704873446,"score_spread":0.27056130164987874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410573706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5765436,0.1295543,0.11667316,0.12383526,0.0032855582,0.0023607924,0.004317774,0.0007022549,0.042727288],"genre_scores_gemma":[0.86974996,0.019299284,0.087596536,0.012196398,0.0018325277,0.0014157996,0.004793248,0.00011535912,0.0030008256],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976044,0.0010071805,0.0005051371,0.00030809242,0.00024670537,0.00032852334],"domain_scores_gemma":[0.9921745,0.0030778893,0.0014095388,0.0002843274,0.0019519548,0.0011018704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006329165,0.00060378393,0.0011648057,0.0015973116,0.0010282148,0.0034677032,0.0017809896,0.0016507729,0.0017845902],"category_scores_gemma":[0.023630155,0.0002818661,0.0013306526,0.00090331206,0.00028678135,0.0027013496,0.0023928096,0.003290772,0.00059057504],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012288621,0.00121212,0.48884702,0.0013293352,0.0004306444,0.00062526175,0.0019060033,0.0055779163,0.0015558639,0.0069257314,0.022948101,0.4674132],"study_design_scores_gemma":[0.00064265943,0.0038003866,0.7476148,0.01974441,0.0035510936,0.002292627,0.017152358,0.033800293,0.0048322324,0.040948056,0.12529193,0.00032919462],"about_ca_topic_score_codex":0.008784447,"about_ca_topic_score_gemma":0.01390096,"teacher_disagreement_score":0.008784447,"about_ca_system_score_codex":0.0019191488,"about_ca_system_score_gemma":0.006030858,"threshold_uncertainty_score":0.03347224},"labels":[],"label_agreement":null},{"id":"W4410873763","doi":"10.1016/j.euo.2025.05.006","title":"Influence of Concomitant Androgen Deprivation Therapy and Its Duration for Salvage Radiation After Radical Prostatectomy: A Systematic Review and Network Meta-analysis According to Published Data","year":2025,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostatectomy; Medicine; Androgen deprivation therapy; Concomitant; Meta-analysis; Urology; Radiation therapy; Androgen; Duration (music); Prostate cancer; Oncology; Internal medicine; Hormone; Cancer","score_opus":0.095004380636919,"score_gpt":0.37583951501623175,"score_spread":0.28083513437931273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410873763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007162521,0.99006677,0.00069821934,0.00022218916,0.0001344672,0.00024511438,0.0011051823,0.000025666304,0.00033989054],"genre_scores_gemma":[0.37142652,0.6187887,0.0032848483,0.0016271494,0.00036734896,0.0016931443,0.0022818758,0.000086710184,0.0004436436],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98599863,0.007078117,0.003694019,0.0017944016,0.0010888672,0.00034594492],"domain_scores_gemma":[0.9747747,0.019335527,0.003705945,0.000834689,0.0011119345,0.00023716463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016241567,0.0026026098,0.015806874,0.005798182,0.0005828956,0.0032205181,0.002181918,0.0020416074,0.0033638058],"category_scores_gemma":[0.03559284,0.0013613902,0.046797935,0.007247491,0.00081366976,0.001854187,0.0015182637,0.001687508,0.00030956927],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017296801,0.000015820322,0.005542913,0.19201073,0.79342335,0.000079711295,0.000049798542,0.00052603765,0.00017444584,0.000098958044,0.00038038034,0.0059681535],"study_design_scores_gemma":[0.00042266145,0.000096129515,0.0031652243,0.008959651,0.9861136,0.000054811724,0.00002014496,0.00013630444,0.00006326643,0.00014465748,0.0008100439,0.000013451445],"about_ca_topic_score_codex":0.0077569755,"about_ca_topic_score_gemma":0.014485761,"teacher_disagreement_score":0.016241567,"about_ca_system_score_codex":0.0022678906,"about_ca_system_score_gemma":0.0029209377,"threshold_uncertainty_score":0.085894644},"labels":[],"label_agreement":null},{"id":"W4410879240","doi":"10.1016/j.euo.2025.05.008","title":"The Burden of Genitourinary Malignancies in Southeast Asia from 1990 to 2021","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Prostate Cancer Foundation","keywords":"Medicine; Genitourinary system; Southeast asia; Oncology; Intensive care medicine; Internal medicine; Ancient history","score_opus":0.01420437330433892,"score_gpt":0.2891482787989355,"score_spread":0.2749439054945966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410879240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9106798,0.020405885,0.00055714115,0.0093559,0.00046769393,0.000043953798,0.047754787,0.000075247204,0.010659557],"genre_scores_gemma":[0.9698317,0.012797766,0.00030922284,0.0011879683,0.0001667526,0.000035363813,0.013265422,0.000011153205,0.0023945784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99972385,0.000045332366,0.000046044137,0.000032867993,0.00005351814,0.00009837824],"domain_scores_gemma":[0.99933016,0.000036250953,0.00035682452,0.000016094793,0.00015692427,0.00010380977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043228333,0.00031669316,0.00020264488,0.00088105066,0.0003066562,0.00082832575,0.000415164,0.00054867717,0.0026049935],"category_scores_gemma":[0.0013683776,0.00016911734,0.00076042704,0.0020854839,0.0002482739,0.0008938518,0.00095041934,0.0006203912,0.00043664812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017940627,0.000041385134,0.9609414,0.00042099986,0.00016016122,0.00047916963,0.0007505628,0.0009285598,0.00045029153,0.0006353387,0.009705108,0.025307693],"study_design_scores_gemma":[0.0000069185176,0.000050161234,0.9850022,0.00027500573,0.00007280287,0.0005396097,0.0014993298,0.00052254373,0.00009955727,0.00018828617,0.011733685,0.000009769913],"about_ca_topic_score_codex":0.100699455,"about_ca_topic_score_gemma":0.14446166,"teacher_disagreement_score":0.100699455,"about_ca_system_score_codex":0.0014341903,"about_ca_system_score_gemma":0.00265101,"threshold_uncertainty_score":0.20022666},"labels":[],"label_agreement":null},{"id":"W4411094435","doi":"10.1016/j.euo.2025.05.012","title":"Quality Indicators for Renal Cancer Care: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality (philosophy); Intensive care medicine; Kidney cancer; Cancer; Internal medicine","score_opus":0.06814733408136993,"score_gpt":0.42249111102646647,"score_spread":0.35434377694509656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411094435","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009187406,0.9961259,0.00044380786,0.0004565452,0.000143924,0.001097846,0.00054187473,0.000021744327,0.00024963694],"genre_scores_gemma":[0.027576892,0.9647239,0.0030039477,0.0006216935,0.00014666015,0.0033235454,0.0005211871,0.000011889917,0.00007042054],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.962482,0.015270929,0.012250689,0.0018072067,0.0074660727,0.0007231292],"domain_scores_gemma":[0.90544885,0.06328055,0.02140145,0.001135129,0.007935348,0.0007985818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03461417,0.002142408,0.012673574,0.018165035,0.0011579506,0.004159486,0.0028036318,0.0021037704,0.0049664117],"category_scores_gemma":[0.121978104,0.0012948101,0.014872323,0.020848151,0.0013751404,0.004300935,0.0027291141,0.002612885,0.0002839126],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023359248,0.00002871638,0.0015155318,0.9466892,0.010405157,0.000034273136,0.00015840607,0.0001857413,0.00004048122,0.0003252086,0.0014750538,0.03890856],"study_design_scores_gemma":[0.0005974496,0.0002132262,0.0064974967,0.91492224,0.06618363,0.00016089878,0.00023124482,0.000284144,0.00010164953,0.00056624063,0.010184331,0.000057446003],"about_ca_topic_score_codex":0.0094039645,"about_ca_topic_score_gemma":0.017668191,"teacher_disagreement_score":0.03461417,"about_ca_system_score_codex":0.009843203,"about_ca_system_score_gemma":0.022430887,"threshold_uncertainty_score":0.18305945},"labels":[],"label_agreement":null},{"id":"W4411192142","doi":"10.1016/j.euo.2025.05.013","title":"Long Noncoding RNAs Identify a Subgroup of Patients with Low-grade Non–muscle-invasive Bladder Cancer with Less Favorable Outcomes","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; University of British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Oncology; Cancer; Long non-coding RNA; Subgroup analysis; Internal medicine; Bioinformatics; RNA; Gene; Genetics; Biology","score_opus":0.009344993534375973,"score_gpt":0.2855987190947529,"score_spread":0.2762537255603769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411192142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991048,0.00014166607,0.00031380844,0.00003573343,0.0000031233678,0.0000038572416,0.00018141569,0.000008119173,0.00020751682],"genre_scores_gemma":[0.9991867,0.0000324162,0.0001710611,0.00003846495,0.000006546101,0.0000041880985,0.00040408823,0.0000054985503,0.000151065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998267,0.000036133148,0.000021433145,0.00005489057,0.000021156871,0.000039600724],"domain_scores_gemma":[0.99959713,0.000104284176,0.00015459205,0.000039874838,0.00004148328,0.00006272337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024793702,0.00015876922,0.000282097,0.00062953506,0.00030216743,0.0006058256,0.00014690215,0.0003005046,0.0013310069],"category_scores_gemma":[0.00088850566,0.00008004907,0.0002344347,0.00045022997,0.00018408167,0.00019120947,0.00024215039,0.0002411445,0.0002578746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043433884,0.000031773136,0.97226465,0.00002791291,0.00009218427,0.00022166074,0.00014769309,0.00025191915,0.018002676,0.00008206338,0.00027632387,0.008166899],"study_design_scores_gemma":[0.000009886941,0.00008702754,0.99532855,0.000007847379,0.00006533545,0.00069964945,0.00025756602,0.001171642,0.0014401997,0.00022273097,0.0007017012,0.000007883368],"about_ca_topic_score_codex":0.0010005382,"about_ca_topic_score_gemma":0.0020487625,"teacher_disagreement_score":0.0013310069,"about_ca_system_score_codex":0.00013537265,"about_ca_system_score_gemma":0.00017020981,"threshold_uncertainty_score":0.004452646},"labels":[],"label_agreement":null},{"id":"W4411638092","doi":"10.1016/j.euo.2025.05.028","title":"Radiation Therapy in the Management of Muscle-invasive Bladder Cancer with Carcinoma in Situ: Still a No Go?","year":2025,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System","funders":"","keywords":"Medicine; Bladder cancer; Radiation therapy; Carcinoma in situ; Cancer therapy; Cancer; Oncology; General surgery; Internal medicine","score_opus":0.035201486465901315,"score_gpt":0.3372665991929558,"score_spread":0.3020651127270545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411638092","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038999537,0.9996574,0.000018667035,0.00009454118,0.0000560774,0.0000014471607,0.0000050840467,0.0000011396339,0.00012671582],"genre_scores_gemma":[0.00035210862,0.9992805,0.000049207858,0.00015194759,0.00006365851,0.00000204278,0.00000937021,5.017265e-7,0.0000906441],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997397,0.00008702114,0.000046291607,0.000039439285,0.000065340115,0.000022274722],"domain_scores_gemma":[0.9995003,0.0003006247,0.00009618343,0.000009085354,0.00007286032,0.000020920072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091832964,0.0006774072,0.0025333865,0.0013896994,0.00019213074,0.0009823631,0.0011172855,0.0010286494,0.0036996033],"category_scores_gemma":[0.0011748368,0.0002832699,0.0011417532,0.0017244214,0.00042250287,0.0009976442,0.0005212794,0.0016504712,0.00088525267],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001942092,0.000053201802,0.00018533516,0.053540777,0.00046955643,0.0001229085,0.00005536329,0.0004001476,0.0006145795,0.001343467,0.01878267,0.92423785],"study_design_scores_gemma":[0.00027133143,0.0004908316,0.0033163715,0.07538505,0.0028943717,0.0020445266,0.00021926285,0.0002908436,0.00045419403,0.0023174048,0.9122472,0.000068672125],"about_ca_topic_score_codex":0.0024536056,"about_ca_topic_score_gemma":0.0060024033,"teacher_disagreement_score":0.0036996033,"about_ca_system_score_codex":0.00059398834,"about_ca_system_score_gemma":0.0011124192,"threshold_uncertainty_score":0.012376368},"labels":[],"label_agreement":null},{"id":"W4411638096","doi":"10.1016/j.euo.2025.04.025","title":"PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Manchester Biomedical Research Centre; Merck Sharp and Dohme; Institute of Cancer Research; Prostate Cancer UK; Cancer Research UK; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Movember Foundation","keywords":"Medicine; Pembrolizumab; Prostate cancer; Open label; Oncology; Internal medicine; Castration; Clinical trial; Immune system; Immunotherapy; Cancer; Immunology; Hormone","score_opus":0.07294500427301906,"score_gpt":0.3603880609852758,"score_spread":0.2874430567122568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411638096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99053967,0.0011588621,0.0006401228,0.0005329282,0.00008044094,0.0035065666,0.0012171853,0.000092266644,0.0022320095],"genre_scores_gemma":[0.98667693,0.0006829464,0.0029313592,0.00055791566,0.00012533132,0.003444668,0.0016914204,0.000034185574,0.0038552524],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991166,0.00057084643,0.000029015115,0.0001279809,0.00007629098,0.00007919642],"domain_scores_gemma":[0.999318,0.00017733504,0.00020105984,0.00005070163,0.000041833333,0.00021112828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026807624,0.0014657184,0.0010055217,0.00045937177,0.00028773551,0.0006221282,0.0008014185,0.0010270601,0.0062677697],"category_scores_gemma":[0.0016468979,0.00040426353,0.0008388742,0.00023021965,0.0008355559,0.0007804876,0.00048640743,0.00186439,0.0007310076],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8654421,0.026389336,0.0055848868,0.0009452829,0.0009318026,0.00031160915,0.0002764701,0.003061229,0.034809723,0.00068531564,0.0028767404,0.058685556],"study_design_scores_gemma":[0.78661513,0.19674727,0.008148472,0.000038887825,0.00023504398,0.0002643066,0.000032568405,0.0015230217,0.003794199,0.00032492972,0.0022523124,0.000023814016],"about_ca_topic_score_codex":0.0003143936,"about_ca_topic_score_gemma":0.0008822456,"teacher_disagreement_score":0.0062677697,"about_ca_system_score_codex":0.00073230756,"about_ca_system_score_gemma":0.0010842434,"threshold_uncertainty_score":0.020967722},"labels":[],"label_agreement":null},{"id":"W4412492574","doi":"10.1016/j.euo.2025.04.008","title":"Years of Life Lost in Metastatic and Locally Advanced Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Prostate; Internal medicine","score_opus":0.012057575497284784,"score_gpt":0.3004577217629125,"score_spread":0.2884001462656277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412492574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894372,0.00447848,0.000095408104,0.00041674476,0.000092556525,0.0000072005832,0.0018125379,0.0000073765086,0.003652384],"genre_scores_gemma":[0.9979907,0.0005394422,0.000016499675,0.000053316387,0.000021434917,0.0000029978844,0.00071713433,0.0000021285286,0.00065621414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995011,0.00015441749,0.000044564153,0.000055142544,0.00006499269,0.00017976473],"domain_scores_gemma":[0.99850625,0.00030376096,0.00047016697,0.000037590456,0.000112430695,0.00056967896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006965253,0.0002484408,0.0004285868,0.0011669252,0.000537739,0.0009698337,0.00052075426,0.00074030843,0.003807765],"category_scores_gemma":[0.0039566737,0.00014095564,0.001153676,0.0010870027,0.00036369215,0.0009505257,0.0012694498,0.0010600181,0.00040720188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001074737,0.00015534999,0.98396033,0.000109888824,0.00031066898,0.00045265185,0.00037809875,0.0010551737,0.00009655573,0.0002764278,0.0011847107,0.010945489],"study_design_scores_gemma":[0.000012712008,0.00031102542,0.9957112,0.00006985887,0.00009380988,0.0008164323,0.000956561,0.00040528012,0.000026287824,0.00033398948,0.001246184,0.000016562359],"about_ca_topic_score_codex":0.00833365,"about_ca_topic_score_gemma":0.009256449,"teacher_disagreement_score":0.00833365,"about_ca_system_score_codex":0.0008376817,"about_ca_system_score_gemma":0.0004647769,"threshold_uncertainty_score":0.01657027},"labels":[],"label_agreement":null},{"id":"W4412492827","doi":"10.1016/j.euo.2025.04.009","title":"Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health; Movember Foundation; Sanofi; Veracyte; U.S. Department of Defense","keywords":"Docetaxel; Medicine; Prostate cancer; Oncology; Internal medicine; Hazard ratio; Radiation therapy; Metastasis; Chemotherapy; Cancer; Confidence interval","score_opus":0.01989595292806918,"score_gpt":0.3533734733597566,"score_spread":0.33347752043168744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412492827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966196,0.0013767147,0.00020138563,0.0002861945,0.000031013264,0.0002756206,0.0006057368,0.000023174534,0.0005805099],"genre_scores_gemma":[0.9964784,0.00046737568,0.0005965416,0.0003175184,0.000038539267,0.00031712072,0.0012866892,0.00000713091,0.00049069634],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99950504,0.0002947904,0.000024033452,0.00008352705,0.00005288089,0.00003966197],"domain_scores_gemma":[0.9995658,0.00010612775,0.00017265823,0.000037253638,0.00003242126,0.00008572295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015100864,0.00048090305,0.0006952699,0.00020935126,0.00021820773,0.0006168787,0.00029628968,0.0004259536,0.001770325],"category_scores_gemma":[0.0012244432,0.0001625996,0.0007675805,0.0003126957,0.00032529625,0.00025275024,0.00018050584,0.00071525533,0.00023557947],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6157213,0.007719546,0.1372902,0.0010738992,0.0032979096,0.00014372251,0.0002633472,0.0047292258,0.05639716,0.0003832381,0.0050766105,0.1679038],"study_design_scores_gemma":[0.166417,0.19745862,0.5900755,0.00021912713,0.007175723,0.000742392,0.00024384442,0.008146621,0.016129553,0.001471623,0.011821428,0.000098630444],"about_ca_topic_score_codex":0.0005653102,"about_ca_topic_score_gemma":0.0018781681,"teacher_disagreement_score":0.001770325,"about_ca_system_score_codex":0.00062698097,"about_ca_system_score_gemma":0.0006810134,"threshold_uncertainty_score":0.007986188},"labels":[],"label_agreement":null},{"id":"W4412521995","doi":"10.1016/j.euo.2025.06.009","title":"Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Princess Margaret Cancer Centre; Mount Sinai Hospital; Ottawa Hospital; University of British Columbia","funders":"Prostate Cancer Foundation","keywords":"Medicine; Radiation therapy; Prostate cancer; Hazard ratio; Cumulative incidence; Prostatectomy; Androgen deprivation therapy; Interquartile range; Internal medicine; Relative risk; Randomized controlled trial; Docetaxel; Oncology; Surgery; Confidence interval; Cancer; Urology; Cohort","score_opus":0.026251544192120835,"score_gpt":0.3216585503992758,"score_spread":0.295407006207155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412521995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9385629,0.036963377,0.0029445107,0.0037834146,0.0009825052,0.00029079188,0.0009685296,0.00007222357,0.015431716],"genre_scores_gemma":[0.99230474,0.0035677291,0.00091341085,0.0010664144,0.00029090006,0.000059227164,0.00051711744,0.000019714496,0.0012607877],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99936336,0.00018818253,0.000065639164,0.00014882618,0.00007528368,0.00015868637],"domain_scores_gemma":[0.9996288,0.00009080428,0.00006724181,0.000020519547,0.000029368994,0.00016330142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007102668,0.000251804,0.0008689413,0.0004679755,0.00039519224,0.0008189763,0.0005204044,0.00055057806,0.00588171],"category_scores_gemma":[0.0016412055,0.00011811253,0.0012469657,0.00043537194,0.00025079577,0.0005830995,0.00044191699,0.00073972554,0.00047129902],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060715,0.0047705253,0.12758842,0.0022039593,0.002625063,0.0010360066,0.0005045074,0.016492393,0.008581055,0.0055237934,0.0081745135,0.7617847],"study_design_scores_gemma":[0.006904551,0.06180706,0.82781965,0.0022508788,0.006918743,0.008448841,0.002027489,0.020372596,0.007644034,0.0134127615,0.042166647,0.00022673851],"about_ca_topic_score_codex":0.0025390428,"about_ca_topic_score_gemma":0.008576139,"teacher_disagreement_score":0.00588171,"about_ca_system_score_codex":0.0009571991,"about_ca_system_score_gemma":0.0016466555,"threshold_uncertainty_score":0.019676208},"labels":[],"label_agreement":null},{"id":"W4413408517","doi":"10.1016/j.euo.2025.06.010","title":"A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pharmaceuticals Bayer","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Prostate-specific antigen; Oncology; Internal medicine; Clinical trial; Hormone therapy; Prostate; Androgen; Hormone; Cancer; Breast cancer","score_opus":0.044188780447867254,"score_gpt":0.37906314171303823,"score_spread":0.334874361265171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413408517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620986,0.0016237175,0.00014829841,0.00032401638,0.00011537525,0.000052573665,0.00036235235,0.000019717023,0.0011439647],"genre_scores_gemma":[0.99747676,0.00045002968,0.00018903,0.00036796703,0.00009172217,0.000030359352,0.000702468,0.0000070699543,0.0006846569],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995596,0.0002462564,0.000022043596,0.000059264417,0.00004039806,0.00007240007],"domain_scores_gemma":[0.999106,0.00026843153,0.00024733366,0.00007283561,0.000035252117,0.00027009452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014698774,0.00043621607,0.0007760307,0.00012485322,0.00018637747,0.0008332466,0.0003072069,0.0004897908,0.0026721747],"category_scores_gemma":[0.0014742468,0.00017054692,0.00090969197,0.00023756234,0.00046917214,0.0006104678,0.0003530946,0.0019445636,0.0002810468],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72500366,0.008832372,0.103893995,0.00093919877,0.0045452258,0.00017603755,0.00020105655,0.0031874918,0.026183609,0.00058858306,0.00518324,0.12126557],"study_design_scores_gemma":[0.13100441,0.23165245,0.61431736,0.00016647007,0.003582799,0.00073902175,0.000265351,0.003248113,0.004330204,0.0019387767,0.008640605,0.00011442673],"about_ca_topic_score_codex":0.00033784154,"about_ca_topic_score_gemma":0.0011677631,"teacher_disagreement_score":0.0026721747,"about_ca_system_score_codex":0.00025963556,"about_ca_system_score_gemma":0.00044073586,"threshold_uncertainty_score":0.008939266},"labels":[],"label_agreement":null},{"id":"W4413734039","doi":"10.1016/j.euo.2025.07.011","title":"Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma—An Observational Prospective Multicentre Diagnostic Test Cohort Study","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre","funders":"NIHR Cambridge Biomedical Research Centre; Medical Research Council; Lunds Universitet; European Commission; Horizon 2020; National Institute for Health and Care Research; Cancer Research UK; Scottish Government","keywords":"Medicine; Renal cell carcinoma; Observational study; Internal medicine; Urine; Prospective cohort study; Cohort study; Oncology; Cohort","score_opus":0.02074644367003278,"score_gpt":0.2816981245404117,"score_spread":0.26095168087037895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413734039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987355,0.00017867862,0.00017232735,0.000037523503,0.000008289504,0.000037042017,0.00069890096,0.0000038820717,0.00012779696],"genre_scores_gemma":[0.9986749,0.00004512344,0.00016052758,0.000035615976,0.000011316979,0.000034907356,0.0009728235,0.000002943069,0.000061794584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837047,0.00053147966,0.00016513692,0.00040099563,0.0003234439,0.00020845163],"domain_scores_gemma":[0.9958982,0.00044004718,0.0019983412,0.000526239,0.00042364432,0.00071366073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028562027,0.0005512131,0.00057211105,0.0008553308,0.0006763435,0.0011362946,0.0010590844,0.00081504625,0.0007984259],"category_scores_gemma":[0.0055946293,0.00059001916,0.0011446849,0.0013043123,0.0004459639,0.0007395085,0.00090588146,0.00093778624,0.00028986804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033060435,0.000051527015,0.9988918,0.00000808959,0.000073358584,0.000048217677,0.000045091638,0.00002922852,0.00009049321,0.00000934075,0.000092803304,0.0003295137],"study_design_scores_gemma":[0.000054294997,0.00028373435,0.9984561,0.000007707338,0.00008629008,0.00028349852,0.00008934512,0.0005170339,0.000056096662,0.000020797297,0.00013685618,0.000008203724],"about_ca_topic_score_codex":0.008869607,"about_ca_topic_score_gemma":0.007783172,"teacher_disagreement_score":0.008869607,"about_ca_system_score_codex":0.0007110887,"about_ca_system_score_gemma":0.0007691801,"threshold_uncertainty_score":0.017636001},"labels":[],"label_agreement":null},{"id":"W4414422734","doi":"10.1016/j.euo.2025.07.007","title":"Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"McMaster University; Movember Foundation; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; Foundation for the National Institutes of Health; U.S. Department of Defense","keywords":"Androgen deprivation therapy; Prostate cancer; Predictive testing; Personalized medicine; Personalization; Precision medicine; Androgen","score_opus":0.03536143272135039,"score_gpt":0.35896742767318646,"score_spread":0.32360599495183606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414422734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704057,0.0013374889,0.00025377533,0.00013408152,0.000016112144,0.000009479541,0.00039614542,0.000009438685,0.0008028708],"genre_scores_gemma":[0.9994986,0.00008021917,0.00007309035,0.00002371055,0.0000141369665,0.0000031363074,0.0002025959,0.0000014907131,0.000102929414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997613,0.00007776693,0.000024866187,0.00005508215,0.000037487396,0.000043478507],"domain_scores_gemma":[0.99864036,0.0006118087,0.00037663674,0.00006175057,0.000077645374,0.00023176403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004571697,0.00014859033,0.00027364833,0.00043513504,0.000108103464,0.00033584397,0.00013793858,0.00026827917,0.0018317803],"category_scores_gemma":[0.0024608334,0.000057443114,0.0002751461,0.00041736354,0.00014819512,0.00021594179,0.00016635304,0.00032867418,0.00015366434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018404067,0.00007287385,0.9803258,0.000023459477,0.00014160888,0.00010064977,0.000019862047,0.00060151843,0.0026922382,0.000061190265,0.00019377138,0.013926641],"study_design_scores_gemma":[0.00002905846,0.00045260208,0.9968659,0.000006503946,0.00013174977,0.00024024429,0.000034296885,0.0010201642,0.0006146354,0.000101665995,0.00049889943,0.0000042605375],"about_ca_topic_score_codex":0.001065128,"about_ca_topic_score_gemma":0.0014742196,"teacher_disagreement_score":0.0018317803,"about_ca_system_score_codex":0.00021286382,"about_ca_system_score_gemma":0.00017300915,"threshold_uncertainty_score":0.006127894},"labels":[],"label_agreement":null},{"id":"W4414517593","doi":"10.1016/j.euo.2025.08.004","title":"MicroRNA as a Liquid Biomarker to Detect Malignancy in Small Testicular Masses","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; St. Michael's Hospital; University Health Network; University of British Columbia; Princess Margaret Cancer Centre","funders":"University of Toronto; Fundação para a Ciência e a Tecnologia; Princess Margaret Cancer Foundation","keywords":"Malignancy; microRNA; Biomarker; Diagnostic biomarker; Testicular cancer","score_opus":0.018829348508647026,"score_gpt":0.3074765358319598,"score_spread":0.28864718732331274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414517593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8675664,0.066600196,0.03942338,0.004142503,0.0020102,0.00038641677,0.0023630229,0.0018819781,0.015625875],"genre_scores_gemma":[0.9532082,0.0067297276,0.029828794,0.0022161873,0.00073997467,0.00032614093,0.0013316649,0.00017263067,0.0054467143],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99894625,0.00034736044,0.000071687275,0.00018172522,0.0003642084,0.00008889709],"domain_scores_gemma":[0.9991393,0.00036522478,0.00016878836,0.000038217197,0.00019415088,0.000094256735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013254838,0.00068561384,0.0009705446,0.0018899956,0.00050350255,0.0022463335,0.00044100927,0.0013082891,0.0017527029],"category_scores_gemma":[0.0026543883,0.00043779865,0.00053629634,0.0011956197,0.00066102867,0.0009339889,0.0005757098,0.0010996514,0.00094537495],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005449755,0.00075346464,0.26058063,0.0013994895,0.00082713086,0.002724623,0.00053898245,0.0024711657,0.42456406,0.002752253,0.010122393,0.28781605],"study_design_scores_gemma":[0.00059238705,0.008373543,0.18580025,0.00084101764,0.0023426546,0.015130373,0.001192434,0.07539454,0.63164103,0.005991016,0.072371446,0.00032935574],"about_ca_topic_score_codex":0.000526782,"about_ca_topic_score_gemma":0.00091643113,"teacher_disagreement_score":0.0022463335,"about_ca_system_score_codex":0.0005314309,"about_ca_system_score_gemma":0.00066011393,"threshold_uncertainty_score":0.0070099235},"labels":[],"label_agreement":null},{"id":"W4414564476","doi":"10.1016/j.euo.2025.07.014","title":"Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; University Health Network; Prostate Cancer Canada; McGill University Health Centre; Hôtel-Dieu de Québec; Centre Hospitalier de l’Université de Montréal; Université Laval; Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Prostate cancer; Biomarker; Disease; Androgen; Prostate; Tumor progression; PCA3; Androgen receptor","score_opus":0.018948851700828263,"score_gpt":0.29512109710868834,"score_spread":0.27617224540786006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414564476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944465,0.0013036412,0.0002388446,0.00026795897,0.000019974235,0.000010343203,0.0022420199,0.000017319508,0.001453415],"genre_scores_gemma":[0.9978168,0.00027463716,0.000115935676,0.000055122116,0.000017052811,0.0000049691816,0.0013665591,0.0000098367755,0.00033906742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999403,0.00008902972,0.000021579286,0.00012343568,0.00013248777,0.00023043407],"domain_scores_gemma":[0.99869746,0.00015619921,0.00040032863,0.00017340669,0.0002672433,0.00030534412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010257458,0.0004252031,0.00041792312,0.0010428777,0.0008729376,0.0013047942,0.0008091053,0.00042419138,0.0015718918],"category_scores_gemma":[0.0023532216,0.00023002898,0.00057082006,0.0020629547,0.0006875048,0.000379564,0.0010735143,0.0007366342,0.00020104846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029260418,0.000011461914,0.99314415,0.0000121155845,0.00015352892,0.000064473796,0.00011008356,0.0001691339,0.0007944943,0.0001466823,0.0007399762,0.004361245],"study_design_scores_gemma":[0.000009050409,0.000023852454,0.99808204,0.0000074006757,0.000093405906,0.00012306166,0.00023469325,0.0002801719,0.00013918553,0.00012684692,0.0008717039,0.000008642511],"about_ca_topic_score_codex":0.18664236,"about_ca_topic_score_gemma":0.31902176,"teacher_disagreement_score":0.18664236,"about_ca_system_score_codex":0.00168282,"about_ca_system_score_gemma":0.0024760726,"threshold_uncertainty_score":0.37111193},"labels":[],"label_agreement":null},{"id":"W4414695231","doi":"10.1016/j.euo.2025.07.006","title":"Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Terry Fox Research Institute","keywords":"Cabazitaxel; Enzalutamide; Abiraterone; Prostate cancer; Phases of clinical research; PTEN; Clinical endpoint; Circulating tumor cell","score_opus":0.06026926909396508,"score_gpt":0.4007988400723302,"score_spread":0.3405295709783651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414695231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954477,0.0020647151,0.00019350917,0.00027129427,0.00010311221,0.0009864516,0.00030760583,0.00003389586,0.0005916523],"genre_scores_gemma":[0.99382126,0.0017826746,0.0008053901,0.0003693261,0.00022063608,0.0010472204,0.00051483803,0.000009982737,0.001428692],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995763,0.00022754986,0.000024884357,0.000056308094,0.00004565695,0.00006934646],"domain_scores_gemma":[0.9992716,0.00018054788,0.00018798193,0.000047964128,0.00004706617,0.00026489687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001600149,0.0011378386,0.0016746065,0.00042836362,0.00027098352,0.00077416905,0.00066610693,0.0009488645,0.002978047],"category_scores_gemma":[0.0010862558,0.00044909405,0.0011188634,0.00041758022,0.00079595245,0.00054185867,0.00020615774,0.0021492273,0.00050039764],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91458094,0.023497052,0.002757225,0.0006442739,0.0010097622,0.00009258418,0.00012893007,0.0010737013,0.01076483,0.00010039973,0.00073761976,0.044612575],"study_design_scores_gemma":[0.7428274,0.24706434,0.006540647,0.000041972104,0.0006003921,0.00011216122,0.000028820605,0.00074160553,0.0012041489,0.000085713036,0.0007330253,0.000019777872],"about_ca_topic_score_codex":0.0014027328,"about_ca_topic_score_gemma":0.004549233,"teacher_disagreement_score":0.002978047,"about_ca_system_score_codex":0.00087547774,"about_ca_system_score_gemma":0.0011349764,"threshold_uncertainty_score":0.009962618},"labels":[],"label_agreement":null},{"id":"W4415082452","doi":"10.1016/j.euo.2025.08.003","title":"Intermediate-risk Non–muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; North York General Hospital","funders":"","keywords":"Clinical trial; Bladder cancer; Research design; Clinical study design; MEDLINE; Clinical research; Standard of care","score_opus":0.09042560362667153,"score_gpt":0.38350139166491815,"score_spread":0.29307578803824663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415082452","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0098894285,0.22954758,0.23268306,0.38619077,0.01916964,0.07448174,0.016105328,0.0018283993,0.030104112],"genre_scores_gemma":[0.034937948,0.058058567,0.66286385,0.12399052,0.008631171,0.09661241,0.009778285,0.00094839215,0.0041788574],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.7826966,0.15739901,0.039336488,0.003926498,0.014458664,0.0021826965],"domain_scores_gemma":[0.65468293,0.23932375,0.036716368,0.014433797,0.046979796,0.007863383],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.282124,0.0030596051,0.009226559,0.0059831114,0.0023290894,0.009744531,0.0071254144,0.011762042,0.005232794],"category_scores_gemma":[0.36483192,0.002240302,0.012304233,0.005965758,0.0032451134,0.0059184176,0.0047496674,0.017163351,0.0040731947],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01287582,0.0012032953,0.017240537,0.031835258,0.007478464,0.00029849022,0.0013759079,0.00455932,0.0017438316,0.032067046,0.38528094,0.50404114],"study_design_scores_gemma":[0.040095367,0.0044248453,0.057240147,0.20444603,0.026175689,0.0011468176,0.0012526244,0.014762048,0.0043675005,0.13131535,0.51371276,0.0010608434],"about_ca_topic_score_codex":0.004949129,"about_ca_topic_score_gemma":0.010289763,"teacher_disagreement_score":0.282124,"about_ca_system_score_codex":0.004447288,"about_ca_system_score_gemma":0.018641138,"threshold_uncertainty_score":0.8852689},"labels":[],"label_agreement":null},{"id":"W4415899361","doi":"10.1016/j.euo.2025.10.010","title":"Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Abiraterone; Prostate cancer; Placebo; Olaparib; Prostate-specific antigen; Biomarker; Population","score_opus":0.09922039059211404,"score_gpt":0.41549668792859473,"score_spread":0.31627629733648066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415899361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99220955,0.0041373237,0.0003557178,0.00025929246,0.0000844696,0.00087863684,0.00094478036,0.00003899781,0.0010913055],"genre_scores_gemma":[0.9953745,0.0009754282,0.00065954315,0.00016527802,0.0001273414,0.00095575483,0.00077660196,0.000008459058,0.0009572599],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985246,0.0010144095,0.00007714468,0.00011976923,0.00015751748,0.00010662101],"domain_scores_gemma":[0.9977964,0.0010301037,0.0006232784,0.00011333631,0.00012671137,0.00031025126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028804154,0.0007479281,0.0017055116,0.00049945625,0.00015181457,0.000633843,0.00067171524,0.00070824986,0.004385983],"category_scores_gemma":[0.0033999602,0.00035219744,0.0016799681,0.000477197,0.00057408947,0.00068640267,0.0004387786,0.0017075138,0.00035066533],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9582794,0.0036366489,0.0020399184,0.0007426365,0.0012517725,0.0000616327,0.000051647137,0.00072573544,0.004479398,0.000060307964,0.0003591053,0.028311726],"study_design_scores_gemma":[0.5185128,0.4459143,0.024832904,0.0001267003,0.0026377463,0.00022320793,0.00007051361,0.0016268602,0.0038626504,0.00034331347,0.001811926,0.00003707152],"about_ca_topic_score_codex":0.00036256068,"about_ca_topic_score_gemma":0.00085720856,"teacher_disagreement_score":0.004385983,"about_ca_system_score_codex":0.0006364757,"about_ca_system_score_gemma":0.00087552186,"threshold_uncertainty_score":0.015233219},"labels":[],"label_agreement":null},{"id":"W4415899403","doi":"10.1016/j.euo.2025.10.001","title":"Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Bayer HealthCare; Bayer Corporation; Bayer","keywords":"Docetaxel; Subgroup analysis; Placebo; Prostate cancer; Clinical trial; Prostate","score_opus":0.019614739825982806,"score_gpt":0.3182689564540624,"score_spread":0.29865421662807956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415899403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884721,0.009475739,0.00020110878,0.00016959479,0.00010603268,0.0002586599,0.00072693237,0.000013778697,0.00057599624],"genre_scores_gemma":[0.99739575,0.0010025506,0.00016256225,0.0001702988,0.00012402564,0.00019827389,0.00075061,0.0000073680335,0.0001886275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978204,0.0011270348,0.00033089763,0.0003037956,0.0002315934,0.00018630964],"domain_scores_gemma":[0.9978635,0.0006905945,0.0007361955,0.00032032855,0.00013265548,0.00025674916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043153376,0.00096533773,0.0034292503,0.0005190223,0.00030180812,0.0009957739,0.0005728146,0.0007939795,0.001154902],"category_scores_gemma":[0.0037819706,0.00030372245,0.008103482,0.0006931389,0.0003345767,0.0006873329,0.0005566592,0.0011859789,0.000167761],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73861027,0.0010752337,0.15189,0.0016449655,0.06755316,0.00033806846,0.00023769635,0.0019438843,0.0042996616,0.00017086128,0.0016745452,0.030561648],"study_design_scores_gemma":[0.2445929,0.07246506,0.58492494,0.00047871497,0.08331148,0.0011197142,0.0005198647,0.005108434,0.0018372086,0.0013314992,0.004116224,0.00019395753],"about_ca_topic_score_codex":0.0008412239,"about_ca_topic_score_gemma":0.002128357,"teacher_disagreement_score":0.0043153376,"about_ca_system_score_codex":0.0006076608,"about_ca_system_score_gemma":0.00073618325,"threshold_uncertainty_score":0.022821903},"labels":[],"label_agreement":null},{"id":"W4415901316","doi":"10.1016/j.euo.2025.09.018","title":"Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"University of Texas MD Anderson Cancer Center; National Institutes of Health","keywords":"Epigenomics; Renal cell carcinoma; Chromophobe cell; Renal oncocytoma; Clear cell; Oncocytoma","score_opus":0.028362661116922934,"score_gpt":0.2982851752699084,"score_spread":0.26992251415298546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415901316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909533,0.001370462,0.0021723185,0.00029172405,0.000029634304,0.000035526387,0.001663674,0.000058819744,0.0034246228],"genre_scores_gemma":[0.99695337,0.00023510084,0.00071367866,0.00012291443,0.000017170918,0.000017662402,0.0012051733,0.000013338818,0.00072163827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996257,0.000054472293,0.00003641728,0.00010120098,0.0000895469,0.00009271362],"domain_scores_gemma":[0.9995932,0.0001254042,0.000096310876,0.00004622898,0.00008379628,0.00005518929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004427282,0.0002072407,0.00027103082,0.0010743876,0.00027824336,0.00089137384,0.00021099728,0.00038024306,0.0020934278],"category_scores_gemma":[0.0012647905,0.0001061794,0.00018609565,0.00068530487,0.00029420556,0.00035570862,0.0004846894,0.00031004453,0.00034439916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063832704,0.00005988866,0.8799465,0.00010405527,0.00020112477,0.00036546311,0.00023987288,0.00038232966,0.08348577,0.00046819155,0.00079229125,0.033316143],"study_design_scores_gemma":[0.000013067719,0.00011906189,0.9801512,0.000019378831,0.00014277524,0.0012213093,0.00040940585,0.001260335,0.011429528,0.000621082,0.0046045645,0.000008371416],"about_ca_topic_score_codex":0.0011433891,"about_ca_topic_score_gemma":0.0032312465,"teacher_disagreement_score":0.0020934278,"about_ca_system_score_codex":0.00019162652,"about_ca_system_score_gemma":0.00026581786,"threshold_uncertainty_score":0.0070032477},"labels":[],"label_agreement":null},{"id":"W4416275632","doi":"10.1016/j.euo.2025.09.002","title":"A Systematic Review of Intracavitary Therapies for Upper Tract Urothelial Carcinoma","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Urothelial carcinoma; Urothelial cancer; Disease; Mitomycin C; MEDLINE; Carcinoma","score_opus":0.015169956557332038,"score_gpt":0.31247897854828194,"score_spread":0.2973090219909499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416275632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014468496,0.99740183,0.000086002794,0.0001318275,0.0000886961,0.00013421173,0.00044093246,0.000005596215,0.00026403938],"genre_scores_gemma":[0.044277985,0.9532885,0.00062021334,0.0009179517,0.0001229313,0.0002505537,0.0003460795,0.000009051986,0.00016674916],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99295914,0.0026941148,0.0028278232,0.0006049336,0.00073972374,0.000174288],"domain_scores_gemma":[0.98260134,0.011428938,0.0043606902,0.00030686217,0.0010908766,0.00021127371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050155907,0.0010314898,0.00784928,0.0057518603,0.00046582567,0.0018582906,0.0012903418,0.0013228649,0.0035660758],"category_scores_gemma":[0.02264072,0.0007849049,0.008894617,0.0067081605,0.00074215134,0.0013881954,0.0011857462,0.0012043094,0.00027377543],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005710724,0.000017222148,0.0016447481,0.92422307,0.0473963,0.000079362755,0.00014413026,0.00012708054,0.00029210228,0.000105170664,0.0012524022,0.024147402],"study_design_scores_gemma":[0.0012373993,0.00066775415,0.013170216,0.57009226,0.3915452,0.0004820092,0.00023319137,0.00011617508,0.0002223436,0.0002713682,0.021901673,0.000060444843],"about_ca_topic_score_codex":0.008859715,"about_ca_topic_score_gemma":0.033579003,"teacher_disagreement_score":0.008859715,"about_ca_system_score_codex":0.0025311955,"about_ca_system_score_gemma":0.005521483,"threshold_uncertainty_score":0.026525319},"labels":[],"label_agreement":null},{"id":"W4416405197","doi":"10.1016/j.euo.2025.09.010","title":"Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Abiraterone; Olaparib; Placebo; Prostate cancer; Clinical trial","score_opus":0.061145733419048894,"score_gpt":0.38868008007266386,"score_spread":0.32753434665361497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416405197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902445,0.005911866,0.00023339519,0.0003452983,0.00015200589,0.0006222293,0.0017398997,0.000026969985,0.00072369137],"genre_scores_gemma":[0.99466914,0.0013413925,0.00031606865,0.00041793103,0.00015967159,0.0008311523,0.0018193977,0.000005697977,0.00043946828],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99901867,0.0006013997,0.00005536326,0.00009217373,0.0001329146,0.00009949491],"domain_scores_gemma":[0.9984566,0.00034900903,0.0005436847,0.000080522725,0.00011464304,0.00045550364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028453304,0.00087764923,0.0019748923,0.0003389491,0.00034140144,0.00080559636,0.0005976896,0.0009062743,0.0019480332],"category_scores_gemma":[0.0019021562,0.0002988287,0.0028377373,0.00047112745,0.00041142723,0.00056199275,0.0003773121,0.0018619851,0.000287007],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93825924,0.0055010184,0.023548767,0.00061449816,0.003999144,0.00007891821,0.00008799002,0.00091818266,0.001800408,0.00006666846,0.001312823,0.023812292],"study_design_scores_gemma":[0.6676569,0.20775904,0.1140231,0.00015327655,0.0044640834,0.00021377347,0.0001247899,0.001450693,0.0013234218,0.00033786654,0.0024208166,0.00007226433],"about_ca_topic_score_codex":0.0006071225,"about_ca_topic_score_gemma":0.0012280863,"teacher_disagreement_score":0.0028453304,"about_ca_system_score_codex":0.0005484437,"about_ca_system_score_gemma":0.0010015424,"threshold_uncertainty_score":0.015047729},"labels":[],"label_agreement":null}]}